US20220169676A1 - Inhibitors of growth factor activation enzymes - Google Patents

Inhibitors of growth factor activation enzymes Download PDF

Info

Publication number
US20220169676A1
US20220169676A1 US17/475,290 US202117475290A US2022169676A1 US 20220169676 A1 US20220169676 A1 US 20220169676A1 US 202117475290 A US202117475290 A US 202117475290A US 2022169676 A1 US2022169676 A1 US 2022169676A1
Authority
US
United States
Prior art keywords
substituted
unsubstituted
compound
seq
kbt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US17/475,290
Inventor
James W. Janetka
Zhenfu Han
Peter Harris
Partha Karmakar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University in St Louis WUSTL filed Critical Washington University in St Louis WUSTL
Priority to US17/475,290 priority Critical patent/US20220169676A1/en
Assigned to WASHINGTON UNIVERSITY reassignment WASHINGTON UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KARMAKAR, PARTHA, HAN, ZHENFU, HARRIS, PETER, JANETKA, JAMES W.
Publication of US20220169676A1 publication Critical patent/US20220169676A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/126—Tetrapeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Definitions

  • the present invention generally relates to compounds that are useful for inhibiting one or more serine proteases including Hepatocyte Growth Factor Activator, matriptase, and hepsin.
  • the present invention also relates to various methods of using the inhibitor compounds including treating a malignancy, a pre-malignant condition, or cancer by administering an effective amount of the inhibitor to a subject in need thereof.
  • Proteases also known as proteinases, peptidases, or proteolytic enzymes, are enzymes that degrade proteins by hydrolyzing peptide bonds between amino acid residues. It is known that proteases regulate numerous physiological processes which enable or stimulate the growth and metastasis of tumor cells. This involves the proteolytic degradation of the extracellular matrix proteins surrounding the tumor cells, which enables the invasion of tumor cells metastasizing from the tumors into the surrounding tissue and the lymph system or the blood system. Proteases are also involved in the activation of growth factors that stimulate the proliferation of cancer cells, thus enabling tumors to grow.
  • proteolytic enzymes include matrix metalloproteases, membrane-bound metalloproteases, lysosomal cysteine proteases, and a large number of serine proteases such as urokinase, plasmin, elastase, thrombin, and cathepsin G.
  • serine proteases such as urokinase, plasmin, elastase, thrombin, and cathepsin G.
  • type II transmembrane serine proteases TTSPs
  • matriptase is a trypsin-like serine protease expressed by cells of epithelial origin and overexpressed in a wide variety of human cancers. Unlike most proteases, which are either secreted from or retained in the cell, matriptase, as a TTSP, is readily accessible on the cell surface and hence a good target for a variety of therapies, including vaccines, monoclonal antibodies and small molecule compounds. Inhibition of the enzyme results in concomitant inhibition of two crucial mediators of tumorigenesis, hepatocyte growth factor (HGF) and the urokinase-type plasminogen activator (uPA).
  • HGF hepatocyte growth factor
  • uPA urokinase-type plasminogen activator
  • Hepsin is another member of the type II transmembrane serine protease family. Hepsin is thought to play a role in cell growth and is known to be produced at a particularly high level in the liver as well as in human hepatoma cells, some cancer cells, and nerve cells. Hepatocyte Growth Factor Activator (HGFA) is a trypsin-like protease but is a plasma protease.
  • HGFA Hepatocyte Growth Factor Activator
  • Hepsin, matriptase and HGFA are differentially expressed and have upregulated function in numerous tumor types including multiple myeloma, breast, prostate, lung, liver, and pancreatic. These proteases cleave the single-chain zymogen precursors, pro-HGF (hepatocyte growth factor), and pro-MSP (macrophage stimulating protein) into active two-chain heterodimeric forms. Active HGF and MSP are activating ligands for the oncogenic receptor tyrosine kinases (RTKs), c-MET and RON, respectively.
  • RTKs oncogenic receptor tyrosine kinases
  • Matriptase inhibitors are of therapeutic importance, but development has been a challenging task. To date, a number of small molecule inhibitors and inhibitory antibodies have been reported. See, for example; Enyedy et al., J. Med. Chem. 2001, 44, 1349-1355; Steinmetzer et al., J. Med. Chem., 2006, 49: 4116-4126, and Farady et al., J Mol Biol, 2007, 369: 1041-1051. Also a series of peptide-based matriptase inhibitors was recently described by Marsault et al., ACS Med Chem. Lett., 2012, 3: 530-534.
  • hepsin and HFGA small molecule hepsin inhibitors were discovered through high-throughput screening (Chevillet, J. R., et al. Mol. Cancer Ther. 2008, 7, 3343) but the only reported HGFA inhibitors are the non-selective serine protease inhibitors, Nafamostat and Leupeptin (Shimomura, T., et al., Cytotechnology, 1992, 8, 219).
  • the present invention relates to compounds that are useful for inhibiting one or more serine proteases including Hepatocyte Growth Factor Activator, matriptase, hepsin, thrombin, and Factor Xa along with various methods of use.
  • the present invention is directed to compounds of Formula (I), as a single stereoisomer or as a mixture thereof:
  • R 1 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
  • B 1 is selected from the group consisting of:
  • C 1 is a group selected from the group consisting of:
  • W is CH, CH2, N, or NH
  • R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are each independently hydrogen, substituted or unsubstituted alkyl or cycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted aryl or heteroaryl, with the proviso that when R 2 is methyl, then R 3 cannot also be methyl and vice versa; and m is 0 to 5, or a pharmaceutically acceptable salt thereof.
  • the present invention also relates to compounds of Formula (II):
  • P 2 is a residue of an amino acid selected from the group consisting Leu, Phe, Met, Thr, Val, Tyr, Trp, Ser, Pro, His, Glu, Gln, Asp, Arg, Lys, Ile, Ala, Gly, Asn, hLeu, NptGly, L-Orn, L-Cha, Nle, hTyr, Nva, Orn, Cha, and an unnatural amino acid residue
  • P 3 is a residue of an amino acid selected from the group consisting Asp, Glu, Arg, Lys, Met, Trp, Leu, Gln, Phe, Tyr, His, hArg, D-Trp, L-Orn, D-Gln, L-Met(O), L-Nle(OBzl), Agp, hCha, hTyr, hPhe, D-Arg, Nle(OBzl), Orn, Met(O), and an unnatural amino acid residue
  • P 4 is a residue of an amino acid
  • the present invention further relates to pharmaceutical compositions comprising a therapeutically effective amount of at least one compound as described herein.
  • the present invention also relates to various methods of use including a method of inhibiting matriptase, hepsin, or HGFA comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of at least one compound as described herein.
  • Another method includes a method of inhibiting HGF/MET oncogenic signaling comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of at least one compound as described herein.
  • Other methods include a method of inhibiting carcinoma progression and a method of treating a malignancy, a pre-malignant condition, or cancer comprising administering to the subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of at least one compound as described herein.
  • the present invention relates to imaging compositions comprising a radiolabeled compound of Formula (I) or (II) as described herein and a method of detecting cancer comprising administering to a subject an imaging composition comprising the radiolabeled compound; employing a nuclear imaging technique for monitoring or visualizing a distribution of the radiolabeled compound within the body or within a portion thereof; and correlating the distribution of the radiolabeled compound to the existence of cancer.
  • the present invention relates to imaging compositions comprising a fluorescent compound of Formula (I) or (II) as described herein and a method of detecting cancer comprising administering to a subject an imaging composition comprising the fluorescent compound; employing an imaging technique for monitoring or visualizing a distribution of the fluorescent compound within the body of within a portion thereof; and correlating the distribution of the fluorescent compound to the existence of cancer.
  • FIG. 1 presents a plot of the results for the HGFA competition assay of inhibitor Ac-KQLR (SEQ ID NO: 1)-Kt.
  • FIG. 2 presents a plot of the results for the fluorescent inhibitor assay for inhibitor Boc-QLR-AMC and HGFA.
  • FIG. 3 presents a plot of the results for the fluorescent inhibitor assay for inhibitor Boc-QAR-AMC and hepsin.
  • FIG. 4 presents a plot of the results for the fluorescent inhibitor assay for inhibitor Boc-QAR-AMC and matriptase.
  • FIG. 5 presents a plot of the results of a dilution recovery experiments with Ac-KQLR (SEQ ID NO: 1)-Kt and HGFA.
  • FIG. 6 presents a plot of the results of a dilution recovery experiments with Ac-KQLR (SEQ ID NO: 1)-Kt and HGFA.
  • FIG. 7 shows the inhibition of HGFA-mediated scHGF (pro-HGF) cleavage by inhibitors.
  • Immunoblot of scHGF cleavage reactions Pro-HGF (30 ng) was cleaved with 1 nM HGFA in the presence of inhibitors (5-fold dilutions from 12.5 ⁇ M).
  • FIG. 8 shows the inhibition of HGFA-mediated scMSP (pro-MSP) cleavage by inhibitors.
  • Immunoblot of scMSP cleavage reactions Pro-MSP (50 ng) was cleaved with 10 nM HGFA in the presence of inhibitors (5-fold dilutions from 12.5 ⁇ M).
  • FIG. 9 shows MDA-MB-231 c-MET phosphorylation of cells treated with pro-HGF/HGFA reactions (3-fold dilutions of inhibitors starting at 100 ⁇ M).
  • FIG. 10 presents a plot of the results of a chromogenic kinetic enzyme assay for matriptase and selected inhibitor compounds.
  • FIG. 11 presents a plot of the results of a chromogenic kinetic enzyme assay for matriptase and selected inhibitor compounds.
  • FIG. 12 presents a plot of the results of a chromogenic kinetic enzyme assay for hepsin and selected inhibitor compounds.
  • FIG. 13 presents a plot of the results of a chromogenic kinetic enzyme assay for matriptase and selected inhibitor compounds.
  • FIG. 14 presents a plot of the results of a chromogenic kinetic enzyme assay for matriptase and selected inhibitor compounds.
  • FIG. 15 presents a plot of the results of a chromogenic kinetic enzyme assay for matriptase and selected inhibitor compounds.
  • FIG. 16 presents a plot of the results of a chromogenic kinetic enzyme assay for hepsin and selected inhibitor compounds.
  • FIG. 17 presents a plot of the results of a chromogenic kinetic enzyme assay for hepsin and selected inhibitor compounds.
  • FIG. 18 shows MDA-MB-231 vs T47D breast cancer cells following MSP stimulation.
  • FIG. 19 shows the inhibition of MRC-5 mediated/pro-HGF migration and invasion of triple negative human MDA-MB-231 breast cancer cells using selected inhibitor compounds.
  • FIG. 20 shows the MSP-MS profiling for HGFA substrate cleavage and specificity.
  • FIG. 21 shows iceLogo figures.
  • A. Shows frequency at which specific amino acids are present at each position.
  • the present invention generally relates to compounds that are useful for inhibiting one or more serine proteases, including Hepatocyte Growth Factor Activator, matriptase, hepsin, thrombin, and Factor Xa along with various methods of use.
  • the present invention also relates to various methods of using the inhibitor compounds including treating a malignancy, a pre-malignant condition, or cancer by administering an effective amount of the inhibitor to a subject in need thereof.
  • one class of compounds useful for inhibiting one or more of hepatocyte growth factor activator, matriptase, and hepsin includes benzamidine compounds of Formula (I), as a single stereoisomer or as a mixture thereof:
  • R 1 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
  • B 1 is selected from the group consisting of:
  • C 1 is a group selected from the group consisting of:
  • W is CH, CH 2 , N, or NH
  • R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are each independently hydrogen, substituted or unsubstituted alkyl or cycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted aryl or heteroaryl, with the proviso that when R 2 is methyl, then R 3 cannot also be methyl and vice versa; and m is 0 to 5, or a pharmaceutically acceptable salt of Formula (I).
  • R 1 is substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 3 -C 6 cycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl, or a substituted or unsubstituted nitrogen-containing aromatic ring.
  • the substituted C 1 -C 6 alkyl, substituted C 3 -C 6 cycloalkyl, substituted phenyl, substituted naphthyl, or substituted nitrogen-containing aromatic ring can comprise one or more substituents comprising halo, hydroxy, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halo-substituted C 1 -C 4 alkyl, or amino.
  • R 1 is an group selected from the group consisting of:
  • C 1 is a group selected from the group consisting of:
  • W is CH or N
  • R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are each independently hydrogen, substituted or unsubstituted alkyl or cycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted aryl or heteroaryl, with the proviso that when R 2 is methyl, then R 3 cannot also be methyl and vice versa; and m is 0 to 5, or a pharmaceutically acceptable salt thereof.
  • R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are each independently hydrogen, substituted or unsubstituted C 1 -C 10 alkyl or cycloalkyl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
  • R 2 is hydrogen;
  • R 3 is hydrogen, C 1 -C 6 alkyl, benzyl, or halo-substituted benzyl;
  • R 4 and R 5 are each independently hydrogen, C 1 -C 6 alkyl, halo- or alkoxy-substituted C 1 -C 6 alkyl, phenyl, phenethyl, benzyl, halo- or alkoxy-substituted benzyl; substituted or unsubstituted 3-benzothiophenyl, or substituted or unsubstituted 1-morpholinyl;
  • R 6 is hydrogen, C 1 -C 4 alkoxy; and/or
  • R 7 and R 8 are each independently hydrogen or C 1 -C 6 alkyl.
  • C 1 is
  • R 2 is hydrogen; and R 3 is hydrogen, C 1 -C 6 alkyl, benzyl, or halo-substituted benzyl.
  • the compound of Formula (I) is a selective inhibitor of hepsin.
  • P 2 is a residue of an amino acid selected from the group consisting Leu, Phe, Met, Thr, Val, Tyr, Trp, Ser, Pro, His, Glu, Gln, Asp, Arg, Lys, Ile, Ala, Gly, Asn, hLeu, NptGly, L-Om, L-Cha, Nle, hTyr, Nva, Orn, Cha, and an unnatural amino acid residue
  • P 3 is a residue of an amino acid selected from the group consisting Asp, Glu, Arg, Lys, Met, Trp, Leu, Gln, Phe, Tyr, His, hArg, D-Trp, L-Om, D-Gln, L-Met(O), L-Nle(OBzl), Agp, hCha, hTyr, hPhe, D-Arg, Nle(OBzl), Orn, Met(O), and an unnatural amino acid residue
  • P 4 is a residue of an amino acid
  • amino-acid residue As understood herein, when two or more amino acids combine to form a peptide (e.g., of Formula (II)), the elements of water are removed, and what remains of each amino acid is called an amino-acid residue.
  • polypeptide of Formula (II) include one or more of the following:
  • Y is H, acetyl, tert-butyloxycarbonyl, benzyloxymethyl acetyl, carboxybenzyl, fluroene, benzyl, —C(O)R 9 , —SOOR 9 , —COOR 9 , —C(O)NHR 9 , —(CH 2 ) x aryl-R 9 , heteroaryl-R 9 , -cycloalkyl-R 9 , or a fluorophore;
  • x is 0, 1, or 2;
  • R 9 is C 1 to C 12 alkyl, cycloalkyl, alkylaryl, or aryl;
  • P 2 is a residue of an amino acid selected from the group consisting Leu, Phe, Met, Thr, Val, Tyr, Trp, Ser, Pro, His, Glu, Gln, Asp, Arg, Lys, Ile, Ala, Gly, Asn, hLeu, NptGly
  • J 1 is C(O), SO 2 , CH 2 or heterocyclo;
  • K 1 is a D- or L-amino acid, wherein the C-terminus is —COOH, —C(O)NH 2 , —OH, —OR 10 , —NH 2 , —NR 11 R 12 , —H or heterocyclo;
  • R 10 is C 1 to C 12 alkyl, cycloalkyl, alkylaryl, or aryl;
  • R 11 and R 12 are each independently H, C 1 to C 12 alkyl, cycloalkyl, alkylaryl, aryl, or heterocyclo; and R 11 and R 12 together can form a ring; and/or Li is H, alkyl, cycloalkyl, alkylaryl, benzyl, substituted benzyl, 2- or 3- or 4-piperdinyl, 2- or 3- or 4-pyridinyl, alkyl, cycloalkyl, aryl, heterocyclo, or
  • P 1 , P 2 , P 3 , P 4 and P 5 can each independently be an unnatural amino acid residue.
  • the unnatural amino acids can be selected from the group listed in the following Table.
  • the unnatural amino acids can be the D- and/or L-isomers.
  • another class of compounds useful for inhibiting one or more of HGFA, matriptase, and hepsin includes cyclic peptides of Formula (II):
  • a compound useful for inhibiting HGFA includes a compound of Formula (II):
  • R 1 is Arg
  • R 2 is selected from the group consisting of Leu, Met, Phe, Tyr, Trp, hLeu, NptGly, Nle, hTyr, and Nva
  • P 3 is selected from the group consisting of His, Gln, Arg, Lys, Leu, Phe, Trp, Tyr, hArg, D-Trp, Agp, hCha, hTyr, hPhe, and D-Arg
  • P 4 is selected from the group consisting of Thr, Asn, Ser, Arg, Lys, Phe, Trp, His(Bom), Agp, Lys(2-Cl-Z), dhLeu, Ide, and Chg.
  • a compound useful for inhibiting matriptase includes a compound of Formula (II):
  • a compound useful for inhibiting hepsin includes a compound of Formula (II):
  • R 1 is Arg
  • R 2 is selected from the group consisting of Pro, Arg, Asn, Asp, Gln, Ile, Leu, Lys, Phe, Thr, Trp, Tyr, Orn, Cha, Nle, and Nva;
  • R 3 is selected from the group consisting of Leu, Trp, Phe, His, Gln, Lys, Arg, D-Gln, Agp, Nle (OBzl), Orn, Met(O), D-Trp, and D-Arg; and
  • R 4 is selected from the group consisting of Pro, Phe, Thr, Asn, Trp, Gln, Ser, Arg, Lys, Agp, DAB(Z), Nle (OBzl), Orn, Arg(NO 2 ), and His(Bom).
  • P 1 can be an amino acid residue of Arg.
  • P 2 can be an amino acid residue of Leu, Phe or Met.
  • P 3 can be an amino acid residue of Arg, Lys, Met, or Trp.
  • P 4 can be an amino acid residue of Arg, Lys, or Try.
  • the compound of Formula (II) is a selective inhibitor of HGFA.
  • Z is a benzothiazole of Formula (IV).
  • J 1 is C(O) and/or K 1 is an amino acid residue of Val.
  • Li is a substituted benzyl group.
  • exemplary substituted benzyl groups include, but are not limited to: 2-, 3-, and 4-carboxybenzyl and the C1-C5 esters thereof.
  • m is 1
  • n is 1
  • P 4 —P 3 —P 2 —P 1 of Formula (II) is a tetrapeptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, and mixtures thereof.
  • the compound of Formula (II) is a tetrapeptide selected from the group consisting of:
  • the compound of Formula (II) is a tripeptide selected from the group consisting of.
  • the compound of Formula (II) is a dipeptide selected from the group consisting of:
  • the compound of Formula (II) is a cyclic peptide of the following structure:
  • Y is a fluorophore.
  • the fluorophore can be selected from the group consisting of Cy3, Cy3.5, Cy5, Cy5.5, Cy7, and Cy7.5.
  • the compound of Formula (II) is selected from the group consisting of.
  • the compounds of Formulas (I) and (II) are useful for inhibiting one or more of matriptase, hepsin, and/or HGFA. Accordingly, the present invention is also directed to a method of inhibiting matriptase, hepsin, and/or HGFA comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (I) or (II). In certain, embodiments the compounds are highly selective for one of matriptase, hepsin, or HGFA.
  • the present invention is directed to various methods of using the inhibitor compounds to treat cancer in a subject (e.g., a human).
  • a subject e.g., a human
  • One method includes inhibiting HGF/MET oncogenic signaling by administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (I) or (II).
  • Another method includes inhibiting MPS/RON oncogene signaling by administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (I) or (II).
  • Yet another method including reversing resistance to a kinase inhibitor by blocking HGF and/or MPS production and/or activation by administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (I) or (II).
  • Another method includes inhibiting carcinoma progression comprising by administering to the subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (I) or (II).
  • a further method includes treating a malignancy, a pre-malignant condition, or cancer in a subject comprising administering to the subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (I) or (II).
  • the cancer can be selected from the group consisting of breast, ovarian, prostate, endometrial, colon, pancreatic, head and neck, gastric, renal, brain, liver, bladder, kidney, lung, esophageal, leukemia, multiple myeloma, lymphoma, and melanoma.
  • the malignancy and the pre-malignant condition can be a condition of the breast.
  • the pre-malignant condition can be selected from the group consisting of a typical ductal hyperplasia of the breast, actinic keratosis, leukoplakia, Barrett's epithelium (columnar metaplasia) of the esophagus, ulcerative colitis, adenomatous colorectal polyps, erythroplasia of Queyrat, Bowen's disease, bowenoid papulosis, vulvar intraepthelial neoplasia, and dysplastic changes to the cervix.
  • the cancer can also be metastasized.
  • the compounds of Formula (I) or (II) can also be administered in combination with an anticancer compound, radiation therapy, a compound that induces apoptosis, a surgical procedure, or any combination thereof.
  • a pharmaceutical composition comprising an inhibitor compound of Formula (I) or (II) is administered to the subject in need thereof.
  • the pharmaceutical composition can be administered by a routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, parenteral, topical, sublingual, or rectal means.
  • administration is selected from the group consisting of oral, intranasal, intraperitoneal, intravenous, intramuscular, intratumoral, rectal, and transdermal.
  • a therapeutically effective dose refers to that amount of active ingredient which provides the desired result.
  • the exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active ingredient or to maintain the desired effect. Factors which can be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions can be administered every 3 to 4 days, every week, or once every two weeks depending on the half-life and clearance rate of the particular formulation.
  • the normal dosage amount of the inhibitor can vary from about 0.05 to about 100 mg per kg body weight depending upon the route of administration.
  • Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. It will generally be administered so that a daily oral dose in the range, for example, from about 0.1 mg to about 75 mg, from about 0.5 mg to about 50 mg, or from about 1 mg to about 25 mg per kg body weight is given.
  • the active ingredient can be administered in a single dose per day, or alternatively, in divided does (e.g., twice per day, three time a day, four times a day, etc.). In general, lower doses can be administered when a parenteral route is employed.
  • a dose in the range for example, from about 0.05 mg to about 30 mg, from about 0.1 mg to about 25 mg, or from about 0.1 mg to about 20 mg per kg body weight can be used.
  • a pharmaceutical composition for oral administration can be formulated using pharmaceutically acceptable carriers known in the art in dosages suitable for oral administration.
  • Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the subject.
  • the composition is formulated for parenteral administration. Further details on techniques for formulation and administration can be found in the latest edition of REMINGTON'S PHARMACEUTICAL SCIENCES (Mack Publishing Co., Easton, Pa., which is incorporated herein by reference).
  • After pharmaceutical compositions have been prepared they can be placed in an appropriate container and labeled for treatment of an indicated condition. Such labeling would include amount, frequency, and method of administration.
  • the pharmaceutical composition can contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries that facilitate processing of the active compounds into preparations which can be used pharmaceutically.
  • suitable pharmaceutically acceptable carrier means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material, or formulation auxiliary of any type.
  • materials which can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil; and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; detergents such as TWEEN 80; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; artificial cerebral spinal fluid (CSF), and phosphate buffer solutions, as well as
  • an imaging composition in accordance with the present invention comprises a radiolabeled compound of Formula (I) or (II), wherein the labeled compound comprises a radioisotope selected from the group consisting of 11 C, 13 N, 15 O, 18 F, 75 Br, 124 I, 125 I, and 131 I.
  • Methods known in the art for radiolabeling the compounds of the present invention may be used.
  • Imaging methods in accordance with the present invention include a method of detecting cancer comprising:
  • the nuclear imaging technique is positron emission tomography (PET) or photon emission computed tomography (SPECT).
  • PET positron emission tomography
  • SPECT photon emission computed tomography
  • Imaging methods in accordance with the present invention include a method of detecting cancer comprising:
  • High-performance liquid chromatography was carried out on GILSON GX-281 using Waters C18 5 ⁇ M, 4.6*50 mm and Waters Prep C18 5 ⁇ M, 19*150 mm reverse phase columns, eluted with a gradient system of 5:95 to 95:5 acetonitrile:water with a buffer consisting of 0.05% TFA.
  • MS mass spectra
  • Tripeptide synthesis Tripeptide intermediates were synthesized on a 0.1 mmol scale using a CEM Liberty Microwave Peptide Synthesizer and Fmoc-amino acid-preloaded 2-Cl-trityl resins. Standard peptide coupling conditions were employed utilizing 5 equiv. of Fmoc-amino acid/4.5 equiv. HBTU/10 equiv. N,N-Diisopropylethylamine ( i Pr 2 NEt) in DMF was added and the mixture was heated at 75° C. for 5 minutes by microwave. Piperidine/DMF (20% v/v) was employed for the deprotection of the Fmoc protecting group using the microwave for 5 minutes.
  • Acetyl (Ac) capping of the tripeptides The tripeptide resin was suspended in 15 mL of 0.5 M Ac 2 O/DMF and 1 M i Pr 2 NEt/DMF. The mixture was shaken at room temperature for 1 hour. The resin was filtered and washed with DMF (10 mL ⁇ 4) followed by CH 2 Cl 2 (10 mL ⁇ 4).
  • the cyclic peptide is listed in Table 3.1 were synthesized in accordance with the general schemes 3A and 3B and cyclization schemes 3C, 3D, 3E, and 3F shown below and the procedures described below.
  • Example 2 The compounds prepared in Example 2 were subjected to a series of inhibitions studies. The compounds were first tested in an HGFA enzymatic assay using the fluorogenic substrate Boc-QLR-AMC with a recombinant form of the HGFA serine protease domain.
  • Boc-R(NO 2 )-AMC Under nitrogen atmosphere, pyridine (60 mL) was added into the round bottom flask containing Boc-R(NO 2 )—OH (4.653 g, 14.6 mmol) and 7-amino-4-methylcoumarin (3.829 g, 21.9 mmol). Diisopropylcarbodiimide (2.023 g, 16.0 mmol) was added and the mixture was stirred overnight. The mixture was filtered. The filtrate was concentrated then dried in vacuo. The resultant residue was purified by silica gel chromatography with dichloromethane/methanol combinations as eluent giving rise to Boc-R(NO 2 )-AMC (2.964 g) in 43% yield. MS (ESI): found [M+H] + , 477.4.
  • Boc-QL-OH Under nitrogen atmosphere, anhydrous DMF (10 mL) was added into the round bottom flask containing Boc-Q-OH (0.500 g, 2.0 mmol), H-L-OMe-HCl (0.406 g, 2.2 mmol), EDCI.HCl (0.467 g, 2.4 mmol), and HOBt (0.466 g, 3.1 mmol). N,N-diisopropylethylamine (0.787 g, 6.1 mmol) was added and the mixture was stirred overnight.
  • Boc-QLR(NO 2 )-AMC Under nitrogen atmosphere, anhydrous DMF (10 mL) was added into the round bottom flask containing Boc-QL-OH (0.603 g, 1.7 mmol), HCl.H 2 N—R(NO 2 )-AMC (0.406 g, 2.2 mmol), EDCI.HCl (0.322 g, 1.7 mmol), and HOBt (0.257 g, 1.7 mmol). N,N-diisopropylethylamine (0.904 g, 7.0 mmol) was added and the mixture was stirred overnight. The majority of DMF was removed in vacuo and to the resulting residue was added 20 mL of water.
  • Boc-QLR-AMC Into the solution of Boc-QLR(NO 2 )-AMC (0.250 g, 0.35 mmol) in MeOH (15 mL) was added Pd/C (10%) (0.111 g) followed by several drops of acetic acid. The mixture was stirred under hydrogen atmosphere for 21 hours. Additional Pd/C (10%) (0.184 g) was added with a few drops of acetic acid. The mixture was stirred for 24 hours, then filtered. The filtrate was concentrated. 1 ⁇ 5 of the resulting residue was purified by HPLC (C18, 15*150 mm column; eluent: acetonitrile/water (0.05% TFA)) to give the title compound (0.037 g) in 78% yield.
  • HGFA bacmids were obtained by transforming DH10Bac Escherichia coli cells.
  • purified bacmids were transfected into Sf9 insect cells. After 5 days in culture at 27° C., media was harvested from transfected Sf9 cells. This media was used to prepare baculovirus infected insect cells (BIICs). These BIIICs were used to infect High 5 insect cells. Four days post infection, media was harvested and recombinant protein prepared as follows. Media was chilled to 4° C. and spun at 4000 ⁇ g for 20 minutes (all subsequent steps were performed at 4° C.
  • Clarified media was passed first through a Whatman GF/B 1 um (#1821-047, GE Healthcare Life Sciences, Piscataway, N.J.) and then a 0.22 um PES membrane (#99955, TPP Techno Plastic Products AG, Trasadingen, Switzerland) and then concentrated using a Pall Centramate tangential flow system and Centramate T-series Cassette (#OS010T12, Pall Corporation, Port Washington, N.Y.). Concentrated media was then buffer exchanged in two steps, five volumes of 50 mM Na-phosphate, 500 mM NaCl, pH 6.2, followed by five volumes of 50 mM Na-phosphate, 500 mM NaCl, pH 7.5.
  • the concentrated and buffered exchanged insect cell media was again filtered as above and made 25 mM imidazole (#I202, Sigma-Aldrich, St. Louis, Mo.) and was mixed with nickel agarose beads (#H-321-25, Gold Biotechnology, Inc., St. Louis Mo.). After mixing this slurry for 12 hours, nickel agarose beads were allowed to settle by gravity and then loaded into a column. Beads were washed with buffer (25 mM Na-phosphate, 500 mM NaCl, 25 mM imidazole, pH 8) and the bound protein eluted using (25 mM Na-phosphate, 500 mM NaCl, 250 mM imidazole, pH 8).
  • Chromogenic Kinetic Enzyme InhibitorAssays of HGFA The inhibitors (0-50 ⁇ M final concentration in reaction) were diluted in DMSO (2% DMSO final concentration in reaction) and then mixed with recombinant HGFA (12.5 nM final concentration in reaction) in TNC buffer (25 mM Tris, 150 mM NaCl, 5 mM CaCl 2 ), 0.01% TRITON X-100, pH 8). After incubating for thirty minutes at 25° C., chromogenic substrate, Pefachrome FVIIa, (#093-01, Enzyme Research Laboratories, South Bend, Ind.)) was added to a final concentration of 250 ⁇ M in a final reaction volume of 40 microliters.
  • Thrombin and Factor Xa Chromogenic Kinetic Enzyme Assays of Thrombin and Factor Xa: Inhibitors (11-pt serial dilutions, 0-20 ⁇ M final concentration) were serially diluted in DMSO (2% DMSO final concentration) and then mixed with recombinant thrombin (0.15 nM final concentration) or Factor Xa (0.35 nM final concentration) in TNC buffer (25 mM Tris, 150 mM NaCl, 5 mM CaCl 2 ), 0.01% TRITON X-100, pH 8) using clear 384 well plates.
  • HGFA Competition Assay of inhibitor Ac-KQLR (SEQ ID NO: 1)-Kt (5) and substrate To determine whether the ketothiazoles are behaving as competitive inhibitors, different amounts of Ac-KQLR (SEQ ID NO: 1)-Kt (5) (0, 0.25, 0.5, and 1.0 ⁇ M) were mixed with Pefachrome serially diluted in TNC buffer. HGFA was added to 12.5 nM and changes in absorbance at 405 nm were measured over time in a Biotek Synergy 2 plate reader. From the plots of the mean reaction velocity versus substrate concentration and the Michaelis-Menten enzyme kinetics equation within GraphPad Prism version 6.04 for Windows, the reaction V max and subsequent K m for each concentration of inhibitor was determined as shown in the FIG. 1 .
  • the final substrate concentrations for all assays were at the K m for the respective enzymes. Changes in fluorescence (excitation at 380 nm and emission at 460 nm) were measured at room temperature over time in a Biotek Synergy 2 plate reader (Winnoski, Vt.).
  • Hepsin Activation Recombinant Hepsin (10 ⁇ g, 0.44 mg/mL as received from R&D Systems, Catalogue #4776-SE) was diluted to 2.4 ⁇ M in TNC buffer (25 mM Tris, 150 mM NaCl, 5 mM CaCl 2 ), 0.01% TRITON X-100, pH 8) and incubated at 37° C. After twenty-four hours, the hepsin was diluted in glycerol to 50%. This stock hepsin (1.2 ⁇ M) was stored in a ⁇ 20° C. freezer and diluted in TNC buffer for use in assays.
  • the pro-HGF and pro-MSP tetrapeptides 5 and 6 showed K i s of 53 nM and 81 nM, respectively. These results demonstrate that inhibitor 5 was competitive with substrate to the active-site. The majority of compounds evaluated are more selective for matriptase and hepsin; most pronounced with hepsin where some inhibitors having K i s ⁇ 1 nM. There are several compounds which are equipotent for HGFA compared to matriptase but leupeptin is 3-fold selective for HGFA over matriptase and only 3-fold favoring hepsin.
  • the pro-HGF peptide (5) is 200-fold more potent for hepsin and 50-fold for matriptase while the pro-MSP peptide (6) is only slightly more potent for matriptase and 70-fold potent for hepsin versus HGFA.
  • Biochemical Assay for Proteolysis of pro-HGF and pro-MSP by HGFA A biochemical assay was employed in order to demonstrate that inhibitors can block the proteolytic activation of the endogenous growth factors, pro-HGF and pro-MSP by HGFA in a dose-dependent manner.
  • HGFA a concentration response of HGFA using a fixed concentration of pro-HGF and pro-MSP. Since both the single chain inactive pro-HGF or pro-MSP and the active heterodimers have the same molecular weight, SDS gels were developed under reducing conditions.
  • inhibitors (0-12.5 ⁇ M final concentration in reaction) were diluted in DMSO (2% DMSO final concentration in reaction) and then mixed with recombinant HGFA (1.0 nM final concentration) in TNC buffer. After 30 minutes incubation at room temperature (25° C.), 25 ng of pro-HGF (R&D Systems, NKG011306A) was added. After 1 hour incubation at 37° C., reactions were stopped by adding SDS gel loading buffer containing DTT (reducing) and then run on 12% PAGE. Proteins were transferred to Millipore Immobilon-P membranes (Billerica, Mass.) and then immunoblotted at 4° C.
  • pro-MSP proteolysis assays the procedures were similar, except that the HGFA concentration was 75 nM, pro-MSP (R&D Systems ZN081306A) concentration was 50 ng per reaction, and 1:500 dilution of anti-MSP antibody (R&D Systems, AF352) was used for MSP detection during immunoblotting.
  • Lanes with pro-HGF ( FIG. 7 ) and pro-MSP ( FIG. 8 ) contain one band at 90 and 75 KDa, respectively, whereas activated HGF and MSP appear as two bands as the 60 KDa ⁇ -chain and 30 KDa ⁇ -chain in HGF and 50 KDa and 25 KDa for MSP (note: MSP Ab only recognizes the ⁇ -chain).
  • FIG. 4 we found that nafamostat and the three inhibitors 5, 5h, 5g all showed a dose-dependent inhibition of pro-HGF activation with similar EC50 values in direct correlation with those found from the HGFA enzyme assay.
  • c-MET Phosphorylation (Y1234/1235) in cells treated with HGFA processed pro-HGF and MSP: To show the inhibition provided by the tetrapeptide compounds would have effects on cell signaling through c-MET kinase, a phosphorylation assay using the invasive breast cancer cell line, MDA-MB-231 was developed. This cell line has high expression of c-MET and pro-HGFA but not pro-HGF.
  • MDA-MB-231 cells were maintained in RPMI medium (Sigma-Aldrich R8758, St. Louis, Mo.) containing 10% fetal bovine serum (Sigma F2442) and 1 ⁇ Penicillin/Streptomycin (Pen/Strep) antibiotics (Thermo Fisher SV30010).
  • RPMI medium containing 1 mM Sodium Pyruvate (Corning 25-000-ci), 10 mM HEPES (Corning 25-060-ci), 0.225% Glucose (Corning 25-037-ci), 1 ⁇ PenStrep).
  • HGFA Proteolysis reactions containing 1 nM HGFA, 50 ng pro-HGF and various amounts of inhibitors. After 15 minutes incubation, media was removed by aspiration and the remaining cells were washed twice with cold Dulbeccos Phosphate Buffered Saline (Life Technologies #14190-136).
  • Lysis Buffer 50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.25% Sodium Deoxcholate, pH 7.5
  • 1 mM sodium fluoride 1 mM sodium orthovanandate
  • 1 ⁇ Sigma (P8340) Inhibitor Cocktail 1 ⁇ Sigma (P8340) Inhibitor Cocktail
  • one Roche Complete Mini, EDTA-free Protease Inhibitor Cocktail tablet per 10 ml buffer and stored frozen. Lysate aliquots were mixed with reducing SDS gel loading buffer and run on 10% PAGE.
  • Immunoblots were performed as described previously, except primary antibodies, anti-phospho cMet (Cell Signaling, CS3077) and anti-total cMet (Cell Signaling, CS3127) were used and diluted in 5% BSA/TBST. Secondary antibodies, HRP-anti rabbit antibody (CS7074) and HRP-anti mouse (CS7076) were used, respectively. All antibodies were used at a 1:1000 dilution. Images were obtained and quantitated using BioRad ChemiDoc MP Imaging System. cMet phosphorylation signals were normalized using the total cMet signals and % inhibition calculated using the ratio of inhibited versus uninhibited HGFA Proteolytic reactions. Results were plotted in GraphPad Prism and a four parameter curve fit was used to determine the inhibitor EC 50 s.
  • polypeptide ketobenzothiazoles (kbt) listed in Table 5.1 were synthesized in accordance with the general scheme 5A shown below and the procedures described below.
  • Tripeptides were synthesized in 0.5 mmol scale through consecutive coupling of amino acid-preloaded 2-Cl-trityl resin with Fmoc protected amino acids followed by the deprotection of Fmoc group.
  • Fmoc-amino acid 5 equiv. Fmoc-amino acid/5 equiv. HBTU/10 equiv. i Pr 2 NEt was used and the mixture was shaken at room temperature overnight.
  • piperidine/DMF (20% v/v) was employed and the mixture was shaken from 1 to 4 hours at room temperature to ensure complete reaction.
  • Acetyl capping of the tripeptides The tripeptide resin was suspended in 30 mL of 0.5 M Ac 2 O/DMF and 1 M i Pr 2 NEt/DMF. The mixture was shaken at room temperature for 1 hour. The resin was filtered and washed with DMF (10 mL ⁇ 4) followed by CH 2 Cl 2 (10 mL ⁇ 4).
  • Boc-WF-OMe Boc-Trp-OH (1 g, 3.28 mmol) and HCl.Phe-OMe (0.708g, 3.28 mmol) was taken in dry dichloromethane (10 mL) under nitrogen atmosphere and the reaction mixture was cooled to 0° C. and N,N-diisopropylethylamine (1.7 mL, 9.84 mmol) and propylphosphonic anhydride (1.9 mL, 3.28 mmol, 50% solution in EtOAc) were added to the solution drop wise respectively. The reaction mixture was then stirred at 25° C. under nitrogen atmosphere for 1 hour and the completion of the reaction was confirmed by LC-MS monitoring.
  • Boc-WF-OH Boc-WF-OMe (0.130 g, 0.279 mmol) was taken in a 1:1 mixture of THF and water and LiOH.H 2 O (0.035g, 0.873 mmol) was added to it. The reaction mixture was stirred for 30 minutes at 25° C. and the completion of the reaction was confirmed by LCMS monitoring. On completion, the THF was evaporated under reduced pressure and the remaining water layer was cooled to 0° C. The water layer was then brought to pH 6.5 by slow addition of 0.5 M HCl solution in water. The crude product precipitates out on addition of HCl and it was isolated by filtration.
  • Boc-WFR(Mtr)-kbt Boc-WF-OH (35 mg, 0.077 mmol) and HATU (43.9 mg, 0.115 mmol) was taken in dry DMF under nitrogen atmosphere and the reaction mixture was cooled to 0° C. N,N-diisopropylethylamine (0.04 mL, 0.231 mmol) was then added drop wise to the reaction mixture and the reaction mixture was allowed to stir for 15 minutes followed by addition of HCl.Arg(Mtr)-kbt (41.75 mg, 0.077 mmol). The reaction mixture was stirred for 12 hours at 25° C. under nitrogen atmosphere and the completion of the reaction was confirmed by LC-MS monitoring.
  • H-WFR-kbt (1-13A1) Boc-WFR(Mtr)-kbt (85 mg, crude product from previous step) was taken in 5 mL TFA:thioanisole:H 2 O (95:2.5:2.5) and the reaction mixture was stirred for 6 hours at 25° C. The completion of the reaction was confirmed by LC-MS monitoring. On completion, the reaction mixture was concentrated under reduced pressure and triturated with diethyl ether to obtain the crude product as brown solid.
  • Boc-dWF-OMe The title compound was synthesized using the same procedure as Boc-WF-OMe starting with Boc-dTrp-OH. Yield: 90%. Chemical formula: C 23 H 33 N 3 O 5 , Exact Mass: 465.55, MS(ESI): found: [M+Na] + , 488.58.
  • Boc-dWF-OH The title compound was synthesized using the same procedure as Boc-WF-OH starting with Boc-dWF-OMe. Yield: 80%. Exact Mass: 451.21, MS(ESI): found: [M+H] + , 452.26.
  • Boc-dWFR(Mtr)-kbt The title compound was synthesized using the same procedure as Boc-WFR(Mtr)-kbt starting with Boc-dWF-OH. The crude product was directly taken to the next step. Chemical formula: C 48 H 56 N 8 O 8 S 2 , Exact Mass: 936.37, MS(ESI): found: [M+H] + , 937.17.
  • H-dWFR-kbt (1-18A1) The title compound was synthesized using the same procedure as H-WFR(Mtr)-kbt starting with Boc-dWF-OH. Yield: 25 mg (42% over two steps).
  • Boc-dWL-OMe The title compound was synthesized using the same procedure as Boc-WF-OMe starting with Boc-dTrp-OH and HCl.H-Leu-OMe. Yield: 92%. Chemical formula: C 23 H 33 N 3 O 5 , Exact Mass: 431.24, MS(ESI): found: [M+Na] + , 454.3.
  • Boc-dWL-OH The title compound was synthesized using the same procedure as Boc-WF-OH starting with Boc-dWF-OMe. Yield: 83%. Exact Mass: 417.23, MS(ESI): found: [M+H] + , 418.26.
  • Boc-dWLR(Mtr)kbt The title compound was synthesized using the same procedure as Boc-WFR(Mtr)-kbt starting with Boc-dWL-OH. The crude product was directly taken to the next step. Chemical formula: C 45 H 58 N 8 O 8 S 2 , Exact Mass: 902.38, MS(ESI): found: [M+H] + , 903.5.
  • H-dWLR-kbt (1-15A1) The title compound was synthesized using the same procedure as H-WFR(Mtr)-kbt starting with Boc-dWLR(Mtr)kbt. Yield: 22 mg (41% over two steps).
  • H-WLRkbt-COOH (1-56A1) The title compound was synthesized using the same procedure as WLR(Mtr)kbt starting with Boc-WLR(Mtr)kbt-COOH. Yield: 26 mg (44% over two steps).
  • H-dWLRkbt-COOH (1-56A1): The title compound was synthesized using the same procedure as dWLR(Mtr)kbt starting with Boc-dWLR(Mtr)kbt-COOH. Yield: 25 mg (42% over two steps).
  • Fmoc-H(Bom)WL-OMe The title compound was synthesized using same procedure described as Boc-WF-OMe starting from Fmoc-His(Bom)-OH and HCl.H-WL-OMe. The crude product was directly taken to the next step. Chemical formula: C 47 H 50 N 6 O 7 , Exact Mass: 810.5, MS(ESI): found: [M+H] + , 811.78.
  • Fmoc-H(Bom)WL-OH The title compound was synthesized using same procedure described as Boc-WF-OH starting from Fmoc-His(Bom)WL-OMe. Yield: 76%. Chemical formula: C 46 H 48 N 6 O 7 , Exact Mass: 796.35, MS(ESI): found: [M+H] + , 797.78.
  • Fmoc-H(Bom)WLR(Mtr)-Kbt The title compound was synthesized using same procedure described as Boc-WF-RKbt starting from Fmoc-His(Bom)WL-OH and HCl.H-Arg(Mtr)-Kbt. Yield: 65%. Exact Mass: 1281.514, MS(ESI): found: [M+H] + , 1262.7.
  • H(Bom)WLR-Kbt (1-54A1) The title compound was synthesized using same procedure described as H-WF-RKbt starting from Fmoc-His(Bom)WLR(Mtr)Kbt, followed by a treatment with 4M HCl solution. Yield: 20% over three steps.
  • H(Bom)dWLR-Kbt (1-58A1) The title compound was synthesized using same procedure described as H-WF-RKbt starting from Fmoc-dHis(Bom)WLR(Mtr)Kbt, followed by a treatment with 4M HCl solution. Yield: 36% over three steps.
  • Boc-LL-OMe The title compound was synthesized using the same procedure as Boc-dWL-OMe starting with Boc-Leu-OH and HCl.H-Leu-OMe.
  • Boc-LL-OH The title compound was synthesized using the same procedure as Boc-dWL-OH starting with Boc-LL-OMe. Exact Mass: 417.5 MS(ESI): found: [M+H] + 418.6
  • H-LLR-kbt V amide (7182). Synthesized in a similar manner to H-WFRkbt from Boc-LLR(Mtr)-Kbt V amide. Yield 4.6 mg. Chemical Formula: C 31 H 49 N 9 O 5 S, Exact Mass: 659.36, MS(ESI): found: [M+H] + , 660.6.
  • Boc-WL-OH The title compound was synthesized using the same procedure as Boc-dWL-OH starting with Boc-WL-OMe. Exact Mass: 417.2, MS(ESI): found: [M+H] + , 418.3.
  • H-WLR-kbt V amide (7181). Synthesized in a similar manner to H-dWLR-kbt from Boc-WLR(Mtr)-kbt V amide. Yield 4.5 mg. Chemical Formula: C 36 H 48 N 10 O 5 S, Exact Mass: 732.35, MS(ESI): found: [M+H] + , 733.6.
  • Boc-R(Mtr)L-OH The title compound was synthesized using the same procedure as Boc-dWL-OH starting with Boc-R(Mtr)L-OMe. Exact Mass: MS(ESI): 599.7 found: [M+H] + , 600.8.
  • Tripeptides were synthesized in 0.5 mmol scale through consecutive coupling of amino acid-preloaded 2-Cl-trityl resin with Fmoc protected amino acids followed by the deprotection of Fmoc group.
  • Fmoc-amino acid 5 equiv. Fmoc-amino acid/4.5 equiv. HBTU/10 equiv. i Pr 2 NEt was used and the mixture was shaken at room temperature overnight.
  • piperidine/DMF (20% v/v) was employed and the mixture was shaken for 4 hours at room temperature.
  • the mixture was stirred at room temperature for 10 minutes, then added into the reaction vial containing the resin. The mixture was shaken at room temperature overnight, then filtered. The resin was washed with DMF (20 mL ⁇ 4). To the resulting resin piperidine/DMF (20% v/v, 30 mL) was added. The mixture was shaken for 4 hours at room temperature, then filtered. The resin was washed with DMF (10 mL ⁇ 4).
  • Acetyl capping of the tripeptides The tripeptide resin was suspended in 30 mL of 0.5 M Ac 2 O/DMF and 1 M i Pr 2 NEt/DMF. The mixture was shaken at room temperature for 1 hour. The resin was filtered and washed with DMF (10 mL ⁇ 4) followed by CH 2 Cl 2 (10 mL ⁇ 4).
  • BocHN-Arg(Mtr) ketobenzothiazole At ⁇ 78° C., n-BuLi/Hex (2.5M) (14 mL, 35 mmol) was added dropwise into the solution of benzothiazole (4.87 g, 36 mmol) in THF (50 mL) over 15 minutes. After the mixture was stirred for additional half an hour, the solution of Boc-HN-Arg(Mtr) Weinreb amide (1.06 g, 2 mmol) in THF (15 mL) was added slowly over 50 min.
  • n-BuLi/Hex 2.5M
  • BocHN-Arg(Mtr) ketobenzothiazole-6-COOH At ⁇ 78° C., n BuLi/Hex (2.5M) (28.5 mL, 71.4 mmol) was added dropwise into the solution of 6-carboxybenzothiazole (6.57 g, 37 mmol) in THF (450 mL) over 25 minutes. After the mixture was stirred for additional half an hour, the solution of Boc-HN-Arg(Mtr) Weinreb amide (1.63 g, 3.08 mmol) in THF (60 mL) was added slowly over 20 minutes at ⁇ 78° C. After the addition then the mixture was stirred at ⁇ 24° C. to ⁇ 20° C. for 1.5 hours.
  • BocHN-Arg(Mtr) ketobenzothiazole-6-CONH-Val-amide Under nitrogen atmosphere, at 0° C. anhydrous DMF (5 mL) was added into the round bottom flask containing BocHN-Arg(Mtr) ketobenzothiazole-COOH (0.060 g, 0.093 mmol) and HATU (0.042 g, 0.11 mmol). After stirring for 10 minutes, L-valine amide hydrochloride (0.017 g, 0.11 mmol), then N,N-diisopropylethylamine (0.062 g, 0.55 mmol) were added. The mixture was stirred overnight while being warmed to room temperature naturally.
  • anhydrous DMF 13 mL was added into the round bottom flask containing Ac-S( t Bu)-K(Boc)-L-OH (0.3650 g, 0.67 mmol) and HATU (0.255 g, 0.67 mmol). The mixture was stirred for 10 minutes, then b (0.40 g, 0.56 mmol) and N,N-diisopropylethylamine (0.49 mL, 2.8 mmol) were added sequentially. The mixture was stirred overnight while being warmed to room temperature naturally. DMF was removed and to the resulting residue, water (20 mL) was added.
  • Cy5.5-KRLR (SEQ ID NO: 8)-OH (RSC-1177).
  • H-K(Boc)R(Pbf)L-2-Cl Trt resin (190 mg, 0.067 mmol), synthesized in a similar fashion to 7-AMINE)] was added 5 mL of DMF and 5 mL of DCM. After 30 min, the solvent was filtered and a solution of Cy5.5-NHS ester (71 mg, 0.10 mmol, Lumiprobe) in DMF (5 mL) and Hunig's Base (0.025 mL, 0.13 mmol) were added, then stirred overnight at room temperature. The solvent was filtered off and the resin washed thoroughly with DMF and DCM, then dried under vacuum.
  • Cy5.5-KRLR (SEQ ID NO: 8)-cmk (RSC-1179).
  • THF a cooled (ice bath) solution of Cy5.5-KRLR (SEQ ID NO: 8)-OH (15 mg, 0.011 mmol) in THF (1 mL) was added N-methylmorpholine (0.011 mmol) and isopropyl chloroformate (0.011 mL, 1M solution in toluene.
  • Cy5.5-KRLR (SEQ ID NO: 8)-kbt (RSC-1178). Synthesized in a similar manner to Ac-KQLR (SEQ ID NO: 1) kbt (3) from Cy5.5-KRLR (SEQ ID NO: 8)-OH. Chemical Formula: C 71 H 93 N 14 O 5 S+Cl ⁇ , Exact Mass: 1253.72, MS(ESI): found: [M] + , 1253.7.
  • Fluorescent inhibitor and chromogenic proteolytic assays were performed in general accordance with the procedures described in Example 4 for compounds prepared in Examples 5 and 6.
  • Ac-KQLR SEQ ID NO: 1-kbt (7) improves potency 2-fold and further substitution of the benzothiazole ring with Valine, Ac-KQLR (SEQ ID NO: 1)-kbt V amide (8) increases potency another 2-fold for HGFA (Ki 13 nM) but decreased matriptase activity >10-fold (Ki 7 nM) and >3-fold for hepsin (Ki 0.3 nM). This result demonstrates that these inhibitor compounds have improved selectivity for HGFA.
  • benzamidine inhibitors listed in Table 8.1 were synthesized in accordance with the general scheme 8A shown below and the procedures described below.
  • Phenylalanine naphthyl sulfonamides were synthesized in accordance with general scheme B and the procedures described below.
  • Reagents and conditions in Scheme A are as follows a) HATU, THF (or DMF), DIPEA; b) 4N HCl in 1,4-doxane; c) R 1 SO 2 Cl, DMAP, pyridine, THF; d) i. NH 2 OH—HCl, K2CO 3 (or DIPEA), EtOH; e) Ac 2 O, AcOH; f) Zn, AcOH.
  • Reagents and conditions in Scheme B are as follows a) HATU, THF (or DMF), DIPEA; b) 4N HCl in 1,4-doxane; d) i. NH 2 OH—HCl, K 2 CO 3 (or DIPEA), EtOH; ii. Ac 2 O, AcOH; e) Zn, AcOH; f) DMAP, pyridine, THF; g) LiOH, THF; h) HATU, RCO 2 H (R 3 ⁇ COR) or R—N ⁇ C ⁇ O (R 3 ⁇ CONHR).
  • Benzyl (S)-4-(3-(3-(N-acetoxycarbamimidoyl)phenyl)-2-((4-methylphenyl)sulfonamido)propanoyl)piperazine-1-carboxylate Prepared from benzyl (S)-4-(3-(3-(N-hydroxycarbamimidoyl)phenyl)-2-((4-methylphenyl)sulfonamido)propanoyl)piperazine-1-carboxylate (0.132 g, 0.228 mmol) using General Procedure E.
  • Benzyl (S)-4-(3-(3-(N-hydroxycarbamimidoyl)phenyl)-2-((4-methylphenyl)sulfonamido)propanoyl)piperazine-1-carboxylate Prepared from benzyl (S)-4-(3-(3-cyanophenyl)-2-((4-methylphenyl)sulfonamido)propanoyl)piperazine-1-carboxylate (0.24 g, 0.228 mmol) using General Procedure D.
  • Benzyl (S)-4-(3-(3-cyanophenyl)-2-((4-methylphenyl)sulfonamido)propanoyl)piperazine-1-carboxylate Prepared from benzyl (S)-4-(2-amino-3-(3-cyanophenyl)propanoyl)piperazine-1-carboxylate (0.243 g, 0.522 mmol) using General Procedure C. Purified by MPLC (0-75% EtOAc/Hexanes). Yield (0.124 g, 45.6%). LRMS (ESI) C 29 H 30 N 4 O 5 S found [M+H]: 547.2.
  • Benzyl (S)-4-(2-amino-3-(3-cyanophenyl)propanoyl)piperazine-1-carboxylate Prepared from benzyl (S)-4-(2-((tert-butoxycarbonyl)amino)-3-(3-cyanophenyl)propanoyl)piperazine-1-carboxylate (0.257 g, 0.522 mmol) using General Procedure B.
  • Fluorescent inhibitor and chromogenic proteolytic assays were performed in general accordance with the procedures described in Example 4 for compounds prepared in Example 8.
  • the microenvironment of solid tumors is characterized by the presence of activated stromal cells, which produce an abundance of inflammatory mediators and growth factors that have been shown to play a critical role in tumor progression.
  • Macrophages and myofibroblasts are two major components of the tumor microenvironment.
  • HGF and other factors produced by macrophages and myofibroblasts that modulate oncogenic signaling pathways in tumor cells include MET were investigated.
  • An objective of this example is to understand the nature of tumor-derived factors that are responsible for activation of stromal cells and determine how the presence of genetic alterations in tumor cells alters communication of tumor cells with the stroma.
  • HGF or MSP from the tumor microenvironment are also important regulators of responsiveness of cancer cells to antineoplastic therapies.
  • RON phosphorylation and migration and invasion assays of breast cancer cells RON receptor tyrosine kinase activation confers resistance to tamoxifen in the MCF7 and T47D breast cancer cell lines.
  • MDA-MB-231 express RON but we have not been able to detect phosphorylated RON (pRON) following MSP stimulation.
  • Detection and quantification of pRON in T47D cells was performed using a sandwich ELISA assy.
  • RON capture antibody R&D Systems, AF691
  • cell lysates are added to wells, followed by incubation with an anti-phosphotyrosine-HRP antibody and then addition of a TMB substrate.
  • Optical density of wells was determined by reading plates at 450 nm in a plate reader.
  • Triple-negative MDA-MB-231 breast cancer cells co-express MET, hepsin and HGFA but lower levels of RON and matriptase while T47D cells have good expression of RON.
  • MRC5 fibroblasts were plated in the bottom well of a Boyden chamber, and incubated overnight to condition the attractant media.
  • MDA-MB-231 or T47D cells +/ ⁇ inhibitors were plated above on Matrigel coated inserts (8.0 ⁇ m membrane inserts, 12-well; Corning 3422) and incubated in FBS media overnight.
  • Inhibitors were added to fresh media and then cells were plated above on the inserts. The cells were fixed and stained at the 24 hour time point. The inserts were then removed and mounted on glass plates where the number of migrated cells were imaged and counted at 4 fields per membrane using a light microscope at 20 ⁇ .
  • the two triplex inhibitors of HGFA, matriptase, and hepsin, 7115 and 7054 (1 ⁇ M) abrogate the MRC5-mediated migration and invasion of MDA-MB-231 cells through Matrigel by blocking active HGF production.
  • the inhibitors tested are as effective as HAI-1, an endogenous inhibitor of matriptase, hepsin, and HGFA.
  • activation buffer 0.1 M Tris, 0.15 M NaCl, 0.01 M CaCl 2

Abstract

The present invention generally relates to compounds that are useful for inhibiting one or more of hepatocyte growth factor activator, matriptase, hepsin, Factor Xa, or thrombin. The present invention also relates to various methods of using the inhibitor compounds including treating a malignancy, a pre-malignant condition, or cancer by administering an effective amount of the inhibitor to a subject in need thereof.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of U.S. application Ser. No. 15/556,804, filed Sep. 8, 2017, which is the 371 National Stage of International Application No. PCT/US2016/020516, filed Mar. 2, 2016 and issued as U.S. Pat. No. 11,130,780, which claims the benefit of U.S. Provisional Patent Application No. 62/220,998, filed Sep. 19, 2015, and U.S. Provisional Patent Application No. 62/130,117, filed Mar. 9, 2015, each of which is incorporated herein by reference in its entirety.
    • FIELD OF THE INVENTION
  • The present invention generally relates to compounds that are useful for inhibiting one or more serine proteases including Hepatocyte Growth Factor Activator, matriptase, and hepsin. The present invention also relates to various methods of using the inhibitor compounds including treating a malignancy, a pre-malignant condition, or cancer by administering an effective amount of the inhibitor to a subject in need thereof.
    • BACKGROUND OF THE INVENTION
  • Proteases, also known as proteinases, peptidases, or proteolytic enzymes, are enzymes that degrade proteins by hydrolyzing peptide bonds between amino acid residues. It is known that proteases regulate numerous physiological processes which enable or stimulate the growth and metastasis of tumor cells. This involves the proteolytic degradation of the extracellular matrix proteins surrounding the tumor cells, which enables the invasion of tumor cells metastasizing from the tumors into the surrounding tissue and the lymph system or the blood system. Proteases are also involved in the activation of growth factors that stimulate the proliferation of cancer cells, thus enabling tumors to grow. Theses proteolytic enzymes include matrix metalloproteases, membrane-bound metalloproteases, lysosomal cysteine proteases, and a large number of serine proteases such as urokinase, plasmin, elastase, thrombin, and cathepsin G. In addition, a family of serine proteases called type II transmembrane serine proteases (TTSPs) has been found to be important in tissue homeostasis and in cancer, in particular with tumor metastasis.
  • One member of this enzyme class, matriptase (matriptase-1, MT-SP1, TADG-15, CAP3, epithin, and ST14), is a trypsin-like serine protease expressed by cells of epithelial origin and overexpressed in a wide variety of human cancers. Unlike most proteases, which are either secreted from or retained in the cell, matriptase, as a TTSP, is readily accessible on the cell surface and hence a good target for a variety of therapies, including vaccines, monoclonal antibodies and small molecule compounds. Inhibition of the enzyme results in concomitant inhibition of two crucial mediators of tumorigenesis, hepatocyte growth factor (HGF) and the urokinase-type plasminogen activator (uPA).
  • Hepsin is another member of the type II transmembrane serine protease family. Hepsin is thought to play a role in cell growth and is known to be produced at a particularly high level in the liver as well as in human hepatoma cells, some cancer cells, and nerve cells. Hepatocyte Growth Factor Activator (HGFA) is a trypsin-like protease but is a plasma protease.
  • Hepsin, matriptase and HGFA are differentially expressed and have upregulated function in numerous tumor types including multiple myeloma, breast, prostate, lung, liver, and pancreatic. These proteases cleave the single-chain zymogen precursors, pro-HGF (hepatocyte growth factor), and pro-MSP (macrophage stimulating protein) into active two-chain heterodimeric forms. Active HGF and MSP are activating ligands for the oncogenic receptor tyrosine kinases (RTKs), c-MET and RON, respectively.
  • Increased activity of hepsin, matriptase, and/or HGFA, resulting from either expression or upregulation of these proteases and/or downregulation of their endogenous serine protease inhibitors (serpins), HAI-1 (SPINT1), HAI-2 (SPINT2), and protein C inhibitor (PCI), has been demonstrated in almost every tumor type driven by c-MET and/or RON pathway signaling. This increased protease function has been clearly associated with increased metastatic cancer phenotypes and direct inhibition of this protease activity has been demonstrated to reduce this metastatic potential in multiple tumor types. The biological reason for the redundancy of activation by these three different proteases and the tight regulation by serpins in cancer is not yet understood. Furthermore, since HGF/c-MET and MSP/RON signaling are necessary for development and normal cell physiology, selective inhibitors of each protease involved in individual tumors need to be identified when developing as therapeutics in order to limit potential toxicities.
  • Matriptase inhibitors are of therapeutic importance, but development has been a challenging task. To date, a number of small molecule inhibitors and inhibitory antibodies have been reported. See, for example; Enyedy et al., J. Med. Chem. 2001, 44, 1349-1355; Steinmetzer et al., J. Med. Chem., 2006, 49: 4116-4126, and Farady et al., J Mol Biol, 2007, 369: 1041-1051. Also a series of peptide-based matriptase inhibitors was recently described by Marsault et al., ACS Med Chem. Lett., 2012, 3: 530-534.
  • As compared to matriptase, inhibitory antibodies have also been reported but relatively few inhibitors are known for hepsin and HFGA. Small molecule hepsin inhibitors were discovered through high-throughput screening (Chevillet, J. R., et al. Mol. Cancer Ther. 2008, 7, 3343) but the only reported HGFA inhibitors are the non-selective serine protease inhibitors, Nafamostat and Leupeptin (Shimomura, T., et al., Cytotechnology, 1992, 8, 219).
  • Although some progress has been made toward inhibitors of matriptase, hepsin, and HGFA, there remains a need for small molecular weight inhibitors of matriptase, hepsin, and HGFA that are both potent and selective for one of more of these enzymes. Such compounds have significant therapeutic value, in particular for the treatment of cancer and other conditions involving tumor progression and migration and abnormal cell differentiation and proliferation or hematological malignancies. Compounds having improved selectivity, solubility, metabolic stability, half-life, and oral bioavailability are particularly desirable.
    • SUMMARY OF THE INVENTION
  • Generally, the present invention relates to compounds that are useful for inhibiting one or more serine proteases including Hepatocyte Growth Factor Activator, matriptase, hepsin, thrombin, and Factor Xa along with various methods of use. In various aspects, the present invention is directed to compounds of Formula (I), as a single stereoisomer or as a mixture thereof:
  • Figure US20220169676A1-20220602-C00001
  • wherein R1 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl, or
    substituted or unsubstituted heteroaryl;
    B1 is selected from the group consisting of:
  • Figure US20220169676A1-20220602-C00002
  • C1 is a group selected from the group consisting of:
  • Figure US20220169676A1-20220602-C00003
    • W is CH, CH2, N, or NH;
  • R2, R3, R4, R5, R6, R7, and R8 are each independently hydrogen, substituted or unsubstituted alkyl or cycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted aryl or heteroaryl, with the proviso that when R2 is methyl, then R3 cannot also be methyl and vice versa; and
    m is 0 to 5, or a pharmaceutically acceptable salt thereof.
  • The present invention also relates to compounds of Formula (II):

  • Y—(P5)b—(P4)n—(P3)m—P2—P1—Z  (II)
  • wherein
    n is 0 or 1;
    m is 0 or 1;
    b is 0 or 1;
    Y is H, acetyl, tert-butyloxycarbonyl, benzyloxymethyl acetyl, carboxybenzyl, benzyl, —C(O)R9, —SOOR9, —COOR9, —C(O)NHR9, —(CH2)xaryl-R9, heteroaryl-R9, -cycloalkyl-R9, a fluorophore, biotin, or a reporter tag;
    x is 0, 1, or 2;
    R9 is C1 to C12 alkyl, cycloalkyl, alkylaryl, or aryl;
    P1 is a residue of an amino acid selected from the group consisting of Arg, D-Arg, Lys, substituted Lys, and an alpha-amino acid of the following:
  • Figure US20220169676A1-20220602-C00004
  • or an unnatural amino acid residue;
    P2 is a residue of an amino acid selected from the group consisting Leu, Phe, Met, Thr, Val, Tyr, Trp, Ser, Pro, His, Glu, Gln, Asp, Arg, Lys, Ile, Ala, Gly, Asn, hLeu, NptGly, L-Orn, L-Cha, Nle, hTyr, Nva, Orn, Cha, and an unnatural amino acid residue;
    P3 is a residue of an amino acid selected from the group consisting Asp, Glu, Arg, Lys, Met, Trp, Leu, Gln, Phe, Tyr, His, hArg, D-Trp, L-Orn, D-Gln, L-Met(O), L-Nle(OBzl), Agp, hCha, hTyr, hPhe, D-Arg, Nle(OBzl), Orn, Met(O), and an unnatural amino acid residue;
    P4 is a residue of an amino acid selected from the group consisting Arg, Lys, Met, Try, Trp, Ser, His, Phe, Thr, Asn, Pro, Gln, Asp, Glu, Chg, Idc, dhLeu, Agp, D-Ser, Agp, His(3-Bom), Lys(2-Cl-Z), L-Orn, L-Arg(NO2), L-Nle(OBzl), L-DAB(Z), and an unnatural amino acid residue;
    P5 is a residue of an amino acid selected from the group consisting Lys, Arg, Leu, Phe, Met, Thr, Val, Tyr, Trp, Ser, Pro, His, Glu, Gln, Asp, Ile, Ala, Gly, Asn, and an unnatural amino acid residue; and
    Z is Val, Ser, Lys, Ala, Gly, Trp, Tyr, Phe, Arg, Thr, Leu, Ile, Met, His, Nle, Phg, Pro, Gln, Asn, —CH2Cl, or a substituted or unsubstituted ring substituent selected from the group consisting of:
  • Figure US20220169676A1-20220602-C00005
    Figure US20220169676A1-20220602-C00006
  • The present invention further relates to pharmaceutical compositions comprising a therapeutically effective amount of at least one compound as described herein.
  • The present invention also relates to various methods of use including a method of inhibiting matriptase, hepsin, or HGFA comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of at least one compound as described herein. Another method includes a method of inhibiting HGF/MET oncogenic signaling comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of at least one compound as described herein.
  • Other methods include a method of inhibiting carcinoma progression and a method of treating a malignancy, a pre-malignant condition, or cancer comprising administering to the subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of at least one compound as described herein.
  • Further, the present invention relates to imaging compositions comprising a radiolabeled compound of Formula (I) or (II) as described herein and a method of detecting cancer comprising administering to a subject an imaging composition comprising the radiolabeled compound; employing a nuclear imaging technique for monitoring or visualizing a distribution of the radiolabeled compound within the body or within a portion thereof; and correlating the distribution of the radiolabeled compound to the existence of cancer.
  • Additionally, the present invention relates to imaging compositions comprising a fluorescent compound of Formula (I) or (II) as described herein and a method of detecting cancer comprising administering to a subject an imaging composition comprising the fluorescent compound; employing an imaging technique for monitoring or visualizing a distribution of the fluorescent compound within the body of within a portion thereof; and correlating the distribution of the fluorescent compound to the existence of cancer.
  • Other objects and features will be in part apparent and in part pointed out hereinafter.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 presents a plot of the results for the HGFA competition assay of inhibitor Ac-KQLR (SEQ ID NO: 1)-Kt.
  • FIG. 2 presents a plot of the results for the fluorescent inhibitor assay for inhibitor Boc-QLR-AMC and HGFA.
  • FIG. 3 presents a plot of the results for the fluorescent inhibitor assay for inhibitor Boc-QAR-AMC and hepsin.
  • FIG. 4 presents a plot of the results for the fluorescent inhibitor assay for inhibitor Boc-QAR-AMC and matriptase.
  • FIG. 5 presents a plot of the results of a dilution recovery experiments with Ac-KQLR (SEQ ID NO: 1)-Kt and HGFA.
  • FIG. 6 presents a plot of the results of a dilution recovery experiments with Ac-KQLR (SEQ ID NO: 1)-Kt and HGFA.
  • FIG. 7 shows the inhibition of HGFA-mediated scHGF (pro-HGF) cleavage by inhibitors. Immunoblot of scHGF cleavage reactions: Pro-HGF (30 ng) was cleaved with 1 nM HGFA in the presence of inhibitors (5-fold dilutions from 12.5 μM).
  • FIG. 8 shows the inhibition of HGFA-mediated scMSP (pro-MSP) cleavage by inhibitors. Immunoblot of scMSP cleavage reactions: Pro-MSP (50 ng) was cleaved with 10 nM HGFA in the presence of inhibitors (5-fold dilutions from 12.5 μM).
  • FIG. 9 shows MDA-MB-231 c-MET phosphorylation of cells treated with pro-HGF/HGFA reactions (3-fold dilutions of inhibitors starting at 100 μM). A. Immunoblot of pY1234/135 c-MET; B. % inhibition of c-MET phosphorylation.
  • FIG. 10 presents a plot of the results of a chromogenic kinetic enzyme assay for matriptase and selected inhibitor compounds.
  • FIG. 11 presents a plot of the results of a chromogenic kinetic enzyme assay for matriptase and selected inhibitor compounds.
  • FIG. 12 presents a plot of the results of a chromogenic kinetic enzyme assay for hepsin and selected inhibitor compounds.
  • FIG. 13 presents a plot of the results of a chromogenic kinetic enzyme assay for matriptase and selected inhibitor compounds.
  • FIG. 14 presents a plot of the results of a chromogenic kinetic enzyme assay for matriptase and selected inhibitor compounds.
  • FIG. 15 presents a plot of the results of a chromogenic kinetic enzyme assay for matriptase and selected inhibitor compounds.
  • FIG. 16 presents a plot of the results of a chromogenic kinetic enzyme assay for hepsin and selected inhibitor compounds.
  • FIG. 17 presents a plot of the results of a chromogenic kinetic enzyme assay for hepsin and selected inhibitor compounds.
  • FIG. 18 shows MDA-MB-231 vs T47D breast cancer cells following MSP stimulation. A. Immunoblot of total RON and MAPK of breast cancer cells; B. RON phosphorylation ELISA assay.
  • FIG. 19 shows the inhibition of MRC-5 mediated/pro-HGF migration and invasion of triple negative human MDA-MB-231 breast cancer cells using selected inhibitor compounds.
  • FIG. 20 shows the MSP-MS profiling for HGFA substrate cleavage and specificity.
  • FIG. 21 shows iceLogo figures. A. Shows frequency at which specific amino acids are present at each position. B. Comparison of P4 and P4′ amino acid frequency of the 22 peptides that were cleaved versus all possible peptides that contained an arginine.
    •  DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • In various aspects, the present invention generally relates to compounds that are useful for inhibiting one or more serine proteases, including Hepatocyte Growth Factor Activator, matriptase, hepsin, thrombin, and Factor Xa along with various methods of use. In other aspects, the present invention also relates to various methods of using the inhibitor compounds including treating a malignancy, a pre-malignant condition, or cancer by administering an effective amount of the inhibitor to a subject in need thereof.
  • In accordance with the present invention, one class of compounds useful for inhibiting one or more of hepatocyte growth factor activator, matriptase, and hepsin includes benzamidine compounds of Formula (I), as a single stereoisomer or as a mixture thereof:
  • Figure US20220169676A1-20220602-C00007
  • wherein R1 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
    B1 is selected from the group consisting of:
  • Figure US20220169676A1-20220602-C00008
  • C1 is a group selected from the group consisting of:
  • Figure US20220169676A1-20220602-C00009
    • W is CH, CH2, N, or NH;
  • R2, R3, R4, R5, R6, R7, and R8 are each independently hydrogen, substituted or unsubstituted alkyl or cycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted aryl or heteroaryl, with the proviso that when R2 is methyl, then R3 cannot also be methyl and vice versa; and
    m is 0 to 5, or a pharmaceutically acceptable salt of Formula (I).
  • In various embodiments, R1 is substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl, or a substituted or unsubstituted nitrogen-containing aromatic ring. For example, the substituted C1-C6 alkyl, substituted C3-C6 cycloalkyl, substituted phenyl, substituted naphthyl, or substituted nitrogen-containing aromatic ring can comprise one or more substituents comprising halo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, halo-substituted C1-C4 alkyl, or amino. In certain embodiments, R1 is an group selected from the group consisting of:
  • Figure US20220169676A1-20220602-C00010
  • In some embodiments, C1 is a group selected from the group consisting of:
  • Figure US20220169676A1-20220602-C00011
    • W is CH or N;
  • R2, R3, R4, R5, R6, R7, and R8 are each independently hydrogen, substituted or unsubstituted alkyl or cycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted aryl or heteroaryl, with the proviso that when R2 is methyl, then R3 cannot also be methyl and vice versa; and
    m is 0 to 5, or a pharmaceutically acceptable salt thereof.
  • In some embodiments, R2, R3, R4, R5, R6, R7, and R8 are each independently hydrogen, substituted or unsubstituted C1-C10 alkyl or cycloalkyl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In particular embodiments, R2 is hydrogen; R3 is hydrogen, C1-C6 alkyl, benzyl, or halo-substituted benzyl; R4 and R5 are each independently hydrogen, C1-C6 alkyl, halo- or alkoxy-substituted C1-C6 alkyl, phenyl, phenethyl, benzyl, halo- or alkoxy-substituted benzyl; substituted or unsubstituted 3-benzothiophenyl, or substituted or unsubstituted 1-morpholinyl; R6 is hydrogen, C1-C4 alkoxy; and/or R7 and R8 are each independently hydrogen or C1-C6 alkyl.
  • In certain embodiments, C1 is
  • Figure US20220169676A1-20220602-C00012
  • R2 is hydrogen; and R3 is hydrogen, C1-C6 alkyl, benzyl, or halo-substituted benzyl. In these and other embodiments, the compound of Formula (I) is a selective inhibitor of hepsin.
  • In accordance with the present invention, another class of compounds useful for inhibiting one or more of HGFA, matriptase, and hepsin includes polypeptide of Formula (II):

  • Y—(P5)b—(P4)n—(P3)m—P2—P1—Z  (II)
  • wherein
    n is 0 or 1;
    m is 0 or 1;
    b is 0 or 1;
    Y is H, acetyl, tert-butyloxycarbonyl, benzyloxymethyl acetyl, carboxybenzyl, fluroene, benzyl, —C(O)R9, —SOOR9, —COOR9, —C(O)NHR9, —(CH2)xaryl-R9, heteroaryl-R9, -cycloalkyl-R9, a fluorophore, biotin, or a reporter tag;
    x is 0, 1, or 2;
    R9 is C1 to C12 alkyl, cycloalkyl, alkylaryl, or aryl;
    P1 is a residue of an amino acid selected from the group consisting of Arg, D-Arg, Lys, substituted Lys, and an alpha-amino acid of the following:
  • Figure US20220169676A1-20220602-C00013
  • or an unnatural amino acid residue;
    P2 is a residue of an amino acid selected from the group consisting Leu, Phe, Met, Thr, Val, Tyr, Trp, Ser, Pro, His, Glu, Gln, Asp, Arg, Lys, Ile, Ala, Gly, Asn, hLeu, NptGly, L-Om, L-Cha, Nle, hTyr, Nva, Orn, Cha, and an unnatural amino acid residue;
    P3 is a residue of an amino acid selected from the group consisting Asp, Glu, Arg, Lys, Met, Trp, Leu, Gln, Phe, Tyr, His, hArg, D-Trp, L-Om, D-Gln, L-Met(O), L-Nle(OBzl), Agp, hCha, hTyr, hPhe, D-Arg, Nle(OBzl), Orn, Met(O), and an unnatural amino acid residue;
    P4 is a residue of an amino acid selected from the group consisting Arg, Lys, Met, Try, Trp, Ser, His, Phe, Thr, Asn, Pro, Gln, Asp, Glu, Chg, Idc, dhLeu, Agp, D-Ser, Agp, His(3-Bom), Lys(2-Cl-Z), L-Om, L-Arg(NO2), L-Nle(OBzl), L-DAB(Z), and an unnatural amino acid residue;
    P5 is a residue of an amino acid selected from the group consisting Lys, Arg, Leu, Phe, Met, Thr, Val, Tyr, Trp, Ser, Pro, His, Glu, Gln, Asp, Ile, Ala, Gly, Asn, and an unnatural amino acid residue; and
    Z is Val, Ser, Lys, Ala, Gly, Trp, Tyr, Phe, Arg, Thr, Leu, Ile, Met, His, Nle, Phg, Pro, Gln, Asn, —CH2Cl, or a substituted or unsubstituted ring substituent selected from the group consisting of:
  • Figure US20220169676A1-20220602-C00014
    Figure US20220169676A1-20220602-C00015
  • As understood herein, when two or more amino acids combine to form a peptide (e.g., of Formula (II)), the elements of water are removed, and what remains of each amino acid is called an amino-acid residue.
  • In various embodiments, the polypeptide of Formula (II) include one or more of the following:
  • Y is H, acetyl, tert-butyloxycarbonyl, benzyloxymethyl acetyl, carboxybenzyl, fluroene, benzyl, —C(O)R9, —SOOR9, —COOR9, —C(O)NHR9, —(CH2)xaryl-R9, heteroaryl-R9, -cycloalkyl-R9, or a fluorophore;
    x is 0, 1, or 2;
    R9 is C1 to C12 alkyl, cycloalkyl, alkylaryl, or aryl;
    P2 is a residue of an amino acid selected from the group consisting Leu, Phe, Met, Thr, Val, Tyr, Trp, Ser, Pro, His, Glu, Gln, Asp, Arg, Lys, Ile, Ala, Gly, Asn, hLeu, NptGly, L-Orn, L-Cha, Nle, hTyr, Nva, Orn, Cha, and an unnatural amino acid residue;
    P3 is a residue of an amino acid selected from the group consisting Asp, Glu, Arg, Lys, Met, Trp, Leu, Gln, Phe, Tyr, His, hArg, D-Trp, L-Orn, D-Gln, L-Met(O), L-Nle(OBzl), Agp, hCha, hTyr, hPhe, D-Arg, Nle(OBzl), Orn, Met(O), and an unnatural amino acid residue;
    P4 is a residue of an amino acid selected from the group consisting Arg, Lys, Met, Try, Trp, Ser, His, Phe, Thr, Asn, Pro, Gln, Asp, Glu, Chg, Idc, dhLeu, Agp, D-Ser, Agp, His(3-Bom), Lys(2-Cl-Z), L-Orn, L-Arg(NO2), L-Nle(OBzl), L-DAB(Z), and an unnatural amino acid residue;
    P5 is a residue of an amino acid selected from the group consisting Lys, Arg, Leu, Phe, Met, Thr, Val, Tyr, Trp, Ser, Pro, His, Glu, Gln, Asp, Ile, Ala, Gly, Asn, and an unnatural amino acid residue; and
    Z is Val, Ser, Lys, Ala, Gly, Trp, Tyr, Phe, Arg, Thr, Leu, Ile, Met, His, Nle, Phg, Pro, Gln, Asn, —CH2Cl, a thiazole of Formula (III), or a benzothiazole of Formula (IV) or (V)
  • Figure US20220169676A1-20220602-C00016
  • J1 is C(O), SO2, CH2 or heterocyclo;
    K1 is a D- or L-amino acid, wherein the C-terminus is —COOH, —C(O)NH2, —OH, —OR10, —NH2, —NR11R12, —H or heterocyclo;
    R10 is C1 to C12 alkyl, cycloalkyl, alkylaryl, or aryl;
    R11 and R12 are each independently H, C1 to C12 alkyl, cycloalkyl, alkylaryl, aryl, or heterocyclo; and R11 and R12 together can form a ring; and/or
    Li is H, alkyl, cycloalkyl, alkylaryl, benzyl, substituted benzyl, 2- or 3- or 4-piperdinyl, 2- or 3- or 4-pyridinyl, alkyl, cycloalkyl, aryl, heterocyclo, or heteroaryl.
  • In various embodiments, P1, P2, P3, P4 and P5 can each independently be an unnatural amino acid residue. The unnatural amino acids can be selected from the group listed in the following Table. The unnatural amino acids can be the D- and/or L-isomers.
  • Abbreviation Structure
    His(3-Bom)
    Figure US20220169676A1-20220602-C00017
    Agp
    Figure US20220169676A1-20220602-C00018
    Lys(2-Cl-Z)
    Figure US20220169676A1-20220602-C00019
    hArg
    Figure US20220169676A1-20220602-C00020
    Thyr
    Figure US20220169676A1-20220602-C00021
    Inp
    Figure US20220169676A1-20220602-C00022
    Pip
    Figure US20220169676A1-20220602-C00023
    Phg
    Figure US20220169676A1-20220602-C00024
    hTyr
    Figure US20220169676A1-20220602-C00025
    hPhe
    Figure US20220169676A1-20220602-C00026
    hLeu
    Figure US20220169676A1-20220602-C00027
    NptGly
    Figure US20220169676A1-20220602-C00028
    DAB(Z)
    Figure US20220169676A1-20220602-C00029
    Nle(OBzl)
    Figure US20220169676A1-20220602-C00030
    3-Pal
    Figure US20220169676A1-20220602-C00031
    4-Pal
    Figure US20220169676A1-20220602-C00032
    hCha
    Figure US20220169676A1-20220602-C00033
    Orn
    Figure US20220169676A1-20220602-C00034
    Met(O)
    Figure US20220169676A1-20220602-C00035
    Cha
    Figure US20220169676A1-20220602-C00036
    Arg(NO2)
    Figure US20220169676A1-20220602-C00037
    Hyp
    Figure US20220169676A1-20220602-C00038
    Oic
    Figure US20220169676A1-20220602-C00039
    hPro
    Figure US20220169676A1-20220602-C00040
    Hyp(Bzl)
    Figure US20220169676A1-20220602-C00041
    Asp(All)
    Figure US20220169676A1-20220602-C00042
    Asp(Bzl)
    Figure US20220169676A1-20220602-C00043
    Nle
    Figure US20220169676A1-20220602-C00044
    MeAla
    Figure US20220169676A1-20220602-C00045
    βA1a
    Figure US20220169676A1-20220602-C00046
    Gla
    Figure US20220169676A1-20220602-C00047
    Asp(Me)
    Figure US20220169676A1-20220602-C00048
    Glu(Me)
    Figure US20220169676A1-20220602-C00049
    Glu(All)
    Figure US20220169676A1-20220602-C00050
    Glu(Chx)
    Figure US20220169676A1-20220602-C00051
    Glu(Bz1)
    Figure US20220169676A1-20220602-C00052
    Api
    Figure US20220169676A1-20220602-C00053
    Dap
    Figure US20220169676A1-20220602-C00054
    Lys(TFA)
    Figure US20220169676A1-20220602-C00055
    His(Bzl)
    Figure US20220169676A1-20220602-C00056
    Aad
    Figure US20220169676A1-20220602-C00057
    Cit
    Figure US20220169676A1-20220602-C00058
    hCit
    Figure US20220169676A1-20220602-C00059
    Lys(Ac)
    Figure US20220169676A1-20220602-C00060
    Lys(2Cl-Z)
    Figure US20220169676A1-20220602-C00061
    Arg(Me)
    Figure US20220169676A1-20220602-C00062
    Arg(Me)2
    Figure US20220169676A1-20220602-C00063
    3-Pal
    Figure US20220169676A1-20220602-C00064
    4-Pal
    Figure US20220169676A1-20220602-C00065
    Phe(4-F)
    Figure US20220169676A1-20220602-C00066
    Phe(3,4-F)
    Figure US20220169676A1-20220602-C00067
    Phe(F5)
    Figure US20220169676A1-20220602-C00068
    Phe(3,4-Cl)
    Figure US20220169676A1-20220602-C00069
    Phe(4-NH2)
    Figure US20220169676A1-20220602-C00070
    Phe(2-F)
    Figure US20220169676A1-20220602-C00071
    Phe(3-F)
    Figure US20220169676A1-20220602-C00072
    Phe(2-Cl)
    Figure US20220169676A1-20220602-C00073
    Phe(3-C1)
    Figure US20220169676A1-20220602-C00074
    Phe(4-C1)
    Figure US20220169676A1-20220602-C00075
    Phe(4-I)
    Figure US20220169676A1-20220602-C00076
    Phe(3-I)
    Figure US20220169676A1-20220602-C00077
    Phe(4-NO2)
    Figure US20220169676A1-20220602-C00078
    Phe(4-guan)
    Figure US20220169676A1-20220602-C00079
    Ser(Bzl)
    Figure US20220169676A1-20220602-C00080
    hSer(Bzl)
    Figure US20220169676A1-20220602-C00081
    Thr(Bzl)
    Figure US20220169676A1-20220602-C00082
    Cys(Bzl)
    Figure US20220169676A1-20220602-C00083
    Phe(4-Br)
    Figure US20220169676A1-20220602-C00084
    Phe(4-Me)
    Figure US20220169676A1-20220602-C00085
    Ala(2-th)
    Figure US20220169676A1-20220602-C00086
    Cys(4-MeBzl)
    Figure US20220169676A1-20220602-C00087
    Cys(4-MeOBzl)
    Figure US20220169676A1-20220602-C00088
    Tyr(Bzl)
    Figure US20220169676A1-20220602-C00089
    Dht
    Figure US20220169676A1-20220602-C00090
    Tyr(Me)
    Figure US20220169676A1-20220602-C00091
    hTyr(Me)
    Figure US20220169676A1-20220602-C00092
    Tyr(2,6-Cl-Bzl)
    Figure US20220169676A1-20220602-C00093
    Bpa
    Figure US20220169676A1-20220602-C00094
    1-Nal
    Figure US20220169676A1-20220602-C00095
    2-Nal
    Figure US20220169676A1-20220602-C00096
    Abu
    Figure US20220169676A1-20220602-C00097
    Trp(Me)
    Figure US20220169676A1-20220602-C00098
    Abu(Bth)
    Figure US20220169676A1-20220602-C00099
    Bip
    Figure US20220169676A1-20220602-C00100
    hSer
    Figure US20220169676A1-20220602-C00101
    Hnv
    Figure US20220169676A1-20220602-C00102
    Met(O2)
    Figure US20220169676A1-20220602-C00103
    AC5C
    Figure US20220169676A1-20220602-C00104
    Nva
    Figure US20220169676A1-20220602-C00105
    2-Aoc
    Figure US20220169676A1-20220602-C00106
    Tle
    Figure US20220169676A1-20220602-C00107
    4-NO2-3-F-Phe
    Figure US20220169676A1-20220602-C00108
    Chg
    Figure US20220169676A1-20220602-C00109
    Tic
    Figure US20220169676A1-20220602-C00110
    AllyGly
    Figure US20220169676A1-20220602-C00111
  • In accordance with the present invention, another class of compounds useful for inhibiting one or more of HGFA, matriptase, and hepsin includes cyclic peptides of Formula (II):

  • Y—(P5)b—(P4)n—(P3)m—P2—P1—Z  (II)
  • wherein
    n is 0 or 1;
    m is 0 or 1;
    b is 0 or 1;
    Y is H, acetyl, tert-butyloxycarbonyl, benzyloxymethyl acetyl, carboxybenzyl, fluroene, benzyl, —C(O)R9, —SOOR9, —COOR9, —C(O)NHR9, —(CH2)xaryl-R9, heteroaryl-R9, -cycloalkyl-R9, or a fluorophore;
    x is 0, 1, or 2;
    R9 is C1 to C12 alkyl, cycloalkyl, alkylaryl, or aryl;
    P1 is a residue of an amino acid selected from the group consisting Arg, D-Arg, Lys, substituted Lys, and an unnatural amino acid residue;
    P2 is a residue of an amino acid selected from the group consisting Leu, Phe, Met, Thr, Val, Tyr, Trp, Ser, Pro, His, Glu, Gln, Asp, Arg, Lys, Ile, Ala, Gly, Asn, hLeu, NptGly, L-Orn, L-Cha, Nle, hTyr, Nva, Orn, Cha, and an unnatural amino acid residue;
    P3 is a residue of an amino acid selected from the group consisting Asp, Glu, Arg, Lys, Met, Trp, Leu, Gln, Phe, Tyr, His, hArg, D-Trp, L-Orn, D-Gln, L-Met(O), L-Nle(OBzl), Agp, hCha, hTyr, hPhe, D-Arg, Nle(OBzl), Orn, Met(O), and an unnatural amino acid residue;
    P4 is a residue of an amino acid selected from the group consisting Arg, Lys, Met, Try, Trp, Ser, His, Phe, Thr, Asn, Pro, Gln, Asp, Glu, Chg, Idc, dhLeu, Agp, D-Ser, Agp, His(3-Bom), Lys(2-Cl-Z), L-Orn, L-Arg(NO2), L-Nle(OBzl), L-DAB(Z), and an unnatural amino acid residue;
    P5 is a residue of an amino acid selected from the group consisting Lys, Arg, Leu, Phe, Met, Thr, Val, Tyr, Trp, Ser, Pro, His, Glu, Gln, Asp, Ile, Ala, Gly, Asn, and an unnatural amino acid residue;
    P3 can bond with P5 and form a cyclic peptide; and
    P2 can bond with P4 and form a cyclic peptide.
  • In various embodiment, a compound useful for inhibiting HGFA includes a compound of Formula (II):

  • Y—(P5)b—(P4)n—(P3)m—P2—P1—Z  (II)
  • wherein
    n is 0 or 1;
    m is 0 or 1;
    b is 0 or 1;
    Y is H, acetyl, tert-butyloxycarbonyl, benzyloxymethyl acetyl, carboxybenzyl, fluroene, benzyl, —C(O)R9, —SOOR9, —COOR9, —C(O)NHR9, —(CH2)xaryl-R9, heteroaryl-R9, -cycloalkyl-R9, or a fluorophore;
    x is 0, 1, or 2;
    R9 is C1 to C12 alkyl, cycloalkyl, alkylaryl, or aryl;
    • R1 is Arg;
  • R2 is selected from the group consisting of Leu, Met, Phe, Tyr, Trp, hLeu, NptGly, Nle, hTyr, and Nva;
    P3 is selected from the group consisting of His, Gln, Arg, Lys, Leu, Phe, Trp, Tyr, hArg, D-Trp, Agp, hCha, hTyr, hPhe, and D-Arg; and
    P4 is selected from the group consisting of Thr, Asn, Ser, Arg, Lys, Phe, Trp, His(Bom), Agp, Lys(2-Cl-Z), dhLeu, Ide, and Chg.
  • In other embodiments, a compound useful for inhibiting matriptase includes a compound of Formula (II):

  • Y—(P5)b—(P4)n—(P3)m—P2—P1—Z  (II)
  • wherein
    n is 0 or 1;
    m is 0 or 1;
    b is 0 or 1;
    Y is H, acetyl, tert-butyloxycarbonyl, benzyloxymethyl acetyl, carboxybenzyl, fluroene, benzyl, —C(O)R9, —SOOR9, —COOR9, —C(O)NHR9, —(CH2)xaryl-R9, heteroaryl-R9, -cycloalkyl-R9, or a fluorophore;
    x is 0, 1, or 2;
    R9 is C1 to C12 alkyl, cycloalkyl, alkylaryl, or aryl;
    R1 is selected from the group consisting of Arg, and Lys;
    R2 is selected from the group consisting of Phe, Ala, Arg, Asn, Gln, Glu, Gly, His, Leu, Lys, Met, Pro, and Ser;
    R3 is selected from the group consisting of Arg, Leu, Trp, Phe, His, Gln, Lys, D-Trp, and D-Arg; and
    R4 is selected from the group consisting of Pro, Phe, Thr, Asn, Trp, Gln, Ser, Lys, and Arg, His(Bom).
  • In further embodiments, a compound useful for inhibiting hepsin includes a compound of Formula (II):

  • Y—(P5)b—(P4)n—(P3)m—P2—P1—Z  (II)
  • wherein
    n is 0 or 1;
    m is 0 or 1;
    b is 0 or 1;
    Y is H, acetyl, tert-butyloxycarbonyl, benzyloxymethyl acetyl, carboxybenzyl, fluroene, benzyl, —C(O)R9, —SOOR9, —COOR9, —C(O)NHR9, —(CH2)xaryl-R9, heteroaryl-R9, -cycloalkyl-R9, or a fluorophore;
    x is 0, 1, or 2;
    R9 is C1 to C12 alkyl, cycloalkyl, alkylaryl, or aryl;
    • R1 is Arg;
  • R2 is selected from the group consisting of Pro, Arg, Asn, Asp, Gln, Ile, Leu, Lys, Phe, Thr, Trp, Tyr, Orn, Cha, Nle, and Nva;
    R3 is selected from the group consisting of Leu, Trp, Phe, His, Gln, Lys, Arg, D-Gln, Agp, Nle (OBzl), Orn, Met(O), D-Trp, and D-Arg; and
    R4 is selected from the group consisting of Pro, Phe, Thr, Asn, Trp, Gln, Ser, Arg, Lys, Agp, DAB(Z), Nle (OBzl), Orn, Arg(NO2), and His(Bom).
  • In various embodiments, P1 can be an amino acid residue of Arg. P2 can be an amino acid residue of Leu, Phe or Met. P3 can be an amino acid residue of Arg, Lys, Met, or Trp. P4 can be an amino acid residue of Arg, Lys, or Try. In these and other embodiments, the compound of Formula (II) is a selective inhibitor of HGFA.
  • In various embodiments, Z is a benzothiazole of Formula (IV). In these and other embodiments, J1 is C(O) and/or K1 is an amino acid residue of Val.
  • In various embodiments, when Z is a benzothiazole of Formula (V), then Li is a substituted benzyl group. Exemplary substituted benzyl groups include, but are not limited to: 2-, 3-, and 4-carboxybenzyl and the C1-C5 esters thereof.
  • In some embodiments, m is 1, n is 1, and P4—P3—P2—P1 of Formula (II) is a tetrapeptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, and mixtures thereof.
  • In some embodiments, the compound of Formula (II) is a tetrapeptide selected from the group consisting of:
  • Figure US20220169676A1-20220602-C00112
    Figure US20220169676A1-20220602-C00113
    Figure US20220169676A1-20220602-C00114
    Figure US20220169676A1-20220602-C00115
    Figure US20220169676A1-20220602-C00116
  • In some embodiments, the compound of Formula (II) is a tripeptide selected from the group consisting of.
  • Figure US20220169676A1-20220602-C00117
  • In some embodiments, the compound of Formula (II) is a dipeptide selected from the group consisting of:
  • Figure US20220169676A1-20220602-C00118
  • In some embodiments, the compound of Formula (II) is a cyclic peptide of the following structure:
  • Figure US20220169676A1-20220602-C00119
  • In various embodiments, Y is a fluorophore. The fluorophore can be selected from the group consisting of Cy3, Cy3.5, Cy5, Cy5.5, Cy7, and Cy7.5.
  • In some embodiments, the compound of Formula (II) is selected from the group consisting of.
  • Figure US20220169676A1-20220602-C00120
  • The compounds of Formulas (I) and (II) are useful for inhibiting one or more of matriptase, hepsin, and/or HGFA. Accordingly, the present invention is also directed to a method of inhibiting matriptase, hepsin, and/or HGFA comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (I) or (II). In certain, embodiments the compounds are highly selective for one of matriptase, hepsin, or HGFA.
  • As noted, matriptase, hepsin, and/or HGFA are involved in various cancerous disease conditions. Thus, the present invention is directed to various methods of using the inhibitor compounds to treat cancer in a subject (e.g., a human). One method includes inhibiting HGF/MET oncogenic signaling by administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (I) or (II). Another method includes inhibiting MPS/RON oncogene signaling by administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (I) or (II). Yet another method including reversing resistance to a kinase inhibitor by blocking HGF and/or MPS production and/or activation by administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (I) or (II).
  • Another method includes inhibiting carcinoma progression comprising by administering to the subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (I) or (II).
  • A further method includes treating a malignancy, a pre-malignant condition, or cancer in a subject comprising administering to the subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (I) or (II). The cancer can be selected from the group consisting of breast, ovarian, prostate, endometrial, colon, pancreatic, head and neck, gastric, renal, brain, liver, bladder, kidney, lung, esophageal, leukemia, multiple myeloma, lymphoma, and melanoma. For example, the malignancy and the pre-malignant condition can be a condition of the breast. Also, the pre-malignant condition can be selected from the group consisting of a typical ductal hyperplasia of the breast, actinic keratosis, leukoplakia, Barrett's epithelium (columnar metaplasia) of the esophagus, ulcerative colitis, adenomatous colorectal polyps, erythroplasia of Queyrat, Bowen's disease, bowenoid papulosis, vulvar intraepthelial neoplasia, and dysplastic changes to the cervix. In various methods, the cancer can also be metastasized.
  • In the various methods of the present invention, the compounds of Formula (I) or (II) can also be administered in combination with an anticancer compound, radiation therapy, a compound that induces apoptosis, a surgical procedure, or any combination thereof.
  • In accordance with the various methods of the present invention, a pharmaceutical composition comprising an inhibitor compound of Formula (I) or (II) is administered to the subject in need thereof. The pharmaceutical composition can be administered by a routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, parenteral, topical, sublingual, or rectal means. In various embodiments, administration is selected from the group consisting of oral, intranasal, intraperitoneal, intravenous, intramuscular, intratumoral, rectal, and transdermal.
  • The determination of a therapeutically effective dose for any one or more of the inhibitor compounds described herein is within the capability of those skilled in the art. A therapeutically effective dose refers to that amount of active ingredient which provides the desired result. The exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active ingredient or to maintain the desired effect. Factors which can be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions can be administered every 3 to 4 days, every week, or once every two weeks depending on the half-life and clearance rate of the particular formulation.
  • Typically, the normal dosage amount of the inhibitor can vary from about 0.05 to about 100 mg per kg body weight depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. It will generally be administered so that a daily oral dose in the range, for example, from about 0.1 mg to about 75 mg, from about 0.5 mg to about 50 mg, or from about 1 mg to about 25 mg per kg body weight is given. The active ingredient can be administered in a single dose per day, or alternatively, in divided does (e.g., twice per day, three time a day, four times a day, etc.). In general, lower doses can be administered when a parenteral route is employed. Thus, for example, for intravenous administration, a dose in the range, for example, from about 0.05 mg to about 30 mg, from about 0.1 mg to about 25 mg, or from about 0.1 mg to about 20 mg per kg body weight can be used.
  • A pharmaceutical composition for oral administration can be formulated using pharmaceutically acceptable carriers known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the subject. In certain embodiments, the composition is formulated for parenteral administration. Further details on techniques for formulation and administration can be found in the latest edition of REMINGTON'S PHARMACEUTICAL SCIENCES (Mack Publishing Co., Easton, Pa., which is incorporated herein by reference). After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. Such labeling would include amount, frequency, and method of administration.
  • In addition to the active ingredients (e.g., the inhibitor compound), the pharmaceutical composition can contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries that facilitate processing of the active compounds into preparations which can be used pharmaceutically. As used herein, the term “pharmaceutically acceptable carrier” means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material, or formulation auxiliary of any type. Some examples of materials which can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil; and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; detergents such as TWEEN 80; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; artificial cerebral spinal fluid (CSF), and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring, and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator based on the desired route of administration.
  • The compounds of the present invention can also be used in various nuclear imaging techniques when labeled with a suitable radionuclide. Accordingly, an imaging composition in accordance with the present invention comprises a radiolabeled compound of Formula (I) or (II), wherein the labeled compound comprises a radioisotope selected from the group consisting of 11C, 13N, 15O, 18F, 75Br, 124I, 125I, and 131I. Methods known in the art for radiolabeling the compounds of the present invention may be used.
  • Imaging methods in accordance with the present invention include a method of detecting cancer comprising:
  • administering to a subject a radiolabeled compound of Formula (I) or (II);
  • employing a nuclear imaging technique for monitoring or visualizing a distribution of the radiolabeled compound within the body or within a portion thereof; and
  • correlating the distribution of the radiolabeled compound to the existence of cancer.
  • In various embodiments, the nuclear imaging technique is positron emission tomography (PET) or photon emission computed tomography (SPECT).
  • Imaging methods in accordance with the present invention include a method of detecting cancer comprising:
  • administering to a subject a fluorescent compound of Formula (I) or (II);
  • employing an imaging technique for monitoring or visualizing a distribution of the fluorescent compound within the body or within a portion thereof; and
  • correlating the distribution of the fluorescent compound to the existence of cancer.
  • As used herein, the abbreviations of the naturally occurring amino acids are as follows:
  • Three One
    letter letter
    Amino acid code code
    alanine Ala A
    arginine Arg R
    asparagine Asn N
    aspartic acid Asp D
    cysteine Cys C
    glutamic acid Glu E
    glutamine Gln Q
    glycine Gly G
    histidine His H
    isoleucine Ile I
    leucine Leu L
    lysine Lys K
    methionine Met M
    phenylalanine Phe F
    proline Pro P
    serine Ser S
    threonine Thr T
    tryptophan Trp W
    tyrosine Tyr Y
    valine Val V
  • The naturally occurring amino acids described herein are the L-isomer unless denoted as a D-isomer.
  • Having described the invention in detail, it will be apparent that modifications and variations are possible without departing from the scope of the invention defined in the appended claims.
    • EXAMPLES
  • The following non-limiting examples are provided to further illustrate the present invention.
    • Example 1. General Synthesis, Purification, and Analytical Chemistry Procedures
  • Starting materials, reagents, and solvents were purchased from commercial vendors unless otherwise noted. 1H NMR spectra were measured on a Varian 400 MHz NMR instrument. The chemical shifts were reported ppm relative to tetramethylsilane (TMS) using residual solvent peak as the reference unless otherwise noted. The following abbreviations were used to express the multiplicities: s=singlet; d=doublet; t=triplet; q=quartet; m=multiplet; br=broad. High-performance liquid chromatography (HPLC) was carried out on GILSON GX-281 using Waters C18 5 μM, 4.6*50 mm and Waters Prep C18 5 μM, 19*150 mm reverse phase columns, eluted with a gradient system of 5:95 to 95:5 acetonitrile:water with a buffer consisting of 0.05% TFA. Purity assessment and mass spectra (MS) data were obtained using a Hewlett-Packard HPLC/MSD using electrospray ionization (ESI) for detection. All reactions were monitored by thin layer chromatography (TLC) carried out on Merck silica gel plates (0.25 mm thick, 60F254), visualized by using UV absorbance (254 nm) or dyes such as ninhydrin, KMnO4, p-anisaldehyde or ceric ammonium molybdate (CAM). Silica gel chromatography was carried out on a Teledyne ISCO CombiFlash purification system using pre-packed silica gel columns (12 g-330 g sizes). All compounds used for biological assays are greater than 95% purity based on NMR and HPLC by UV absorbance at 210 nm and 254 nm wavelengths.
    • Example 2. Synthesis of Tetrapeptide Ketothiazole Inhibitor Compounds
  • The tetrapeptide ketothiazoles (kt) listed in Table 2.1 were synthesized in accordance with the general schemes 2A and 2B shown below and the procedures described below.
  • TABLE 2.1
    Tetrapeptide ketothiazoles.
    Figure US20220169676A1-20220602-C00121
    Compound No. Ac—P4—P3—P2—P1—kt
    5 Ac-KQLR(SEQ ID NO: 1)-kt
    5-1 Ac-KQLdR-kt
    5a Ac-KHLR(SEQ ID NO: 2)-kt
    5a-1 Ac-KHLdR-kt
    5b Ac-WQLR(SEQ ID NO: 3)-kt
    5b-1 Ac-WQLdR-kt
    5c Ac-KQFR(SEQ ID NO: 4)-kt
    5c-1 Ac-KQFdR-kt
    5d Ac-KFLR(SEQ ID NO: 5)-kt
    5e Ac-RQLR(SEQ ID NO: 6)-kt
    5e-1 Ac-RQLdR-kt
    5f Ac-SQLR(SEQ ID NO: 7)-kt
    5g Ac-KRLR(SEQ ID NO: 8)-kt
    5h Ac-WRLR(SEQ ID NO: 9)-kt
    6 Ac-SKLR(SEQ ID NO: 10)-kt
    6-1 Ac-SKLdR-kt
    6a Ac-SHLR(SEQ ID NO: 11)-kt
    6a-1 Ac-SHLdR-kt
    6b Ac-WKLR(SEQ ID NO: 12)-kt
    6b-1 Ac-WKLdR-kt
    6c Ac-SKFR(SEQ ID NO: 13)-kt
    6c-1 Ac-SKFdR-kt
    6d Ac-NKLR(SEQ ID NO: 14)-kt
    6e Ac-SRLR(SEQ ID NO: 15)-kt
    6e-1 Ac-SdRLR-kt
    6e-2 Ac-SRLdR-kt
    6e-3 Ac-SdRLdR-kt
    6f Ac-TKLR(SEQ ID NO: 16)-kt
    6g Ac-SWLR(SEQ ID NO: 17)-kt
    6h Ac-RKLR(SEQ ID NO: 18)-kt
  • Figure US20220169676A1-20220602-C00122
  • Figure US20220169676A1-20220602-C00123
  • Tripeptide synthesis: Tripeptide intermediates were synthesized on a 0.1 mmol scale using a CEM Liberty Microwave Peptide Synthesizer and Fmoc-amino acid-preloaded 2-Cl-trityl resins. Standard peptide coupling conditions were employed utilizing 5 equiv. of Fmoc-amino acid/4.5 equiv. HBTU/10 equiv. N,N-Diisopropylethylamine (iPr2NEt) in DMF was added and the mixture was heated at 75° C. for 5 minutes by microwave. Piperidine/DMF (20% v/v) was employed for the deprotection of the Fmoc protecting group using the microwave for 5 minutes.
  • Acetyl (Ac) capping of the tripeptides: The tripeptide resin was suspended in 15 mL of 0.5 M Ac2O/DMF and 1 M iPr2NEt/DMF. The mixture was shaken at room temperature for 1 hour. The resin was filtered and washed with DMF (10 mL×4) followed by CH2Cl2 (10 mL×4).
  • Cleavage of tripeptide resin: Ac-capped tripeptide resin was suspended and shaken in 15 mL of 25% v/v HFIP/CH2Cl2 for 1 hour. The mixture was filtered. The filtrate was concentrated then dried in vacuo, giving rise to crude Ac-capped tripeptide product.
  • Ac-KQFR (SEQ ID NO: 4) ketothiazole (5c). Under nitrogen atmosphere, at 0° C. anhydrous DMF (5 mL) was added into the round bottom flask containing Ac-capped KQF tripeptide (0.081 g, 0.1 mmol) and HATU (0.042 g, 0.11 mmol). After stirring for 10 minutes, arginine ketothiazole (0.042 g, 0.1 mmol), then N,N-diisopropylethylamine (0.065 g, 0.5 mmol) were added. The mixture was stirred overnight while being warmed to room temperature naturally. The majority of DMF was removed and to the resulting residue was added 20 mL of water. The precipitate that formed was filtered and dried. To this precipitate was added 5 mL of TFA/thioanisole/water (95/2.5/2.5 (v/v/v)). The mixture was stirred at room temperature for 4 hours and then was added to 40 mL of cold ether. The precipitated crude product was collected by centrifugation, followed by carefully decanting out the ether solvent. The crude product was purified by HPLC (C18, 15*150 mm column; eluent: acetonitrile/water (0.1% TFA)) to give Ac-KQFR (SEQ ID NO: 4) ketothiazole (0.032 g) in 46% yield. At the same time the isomer KQFR (SEQ ID NO: 4)* ketothiazole (0.020 g) was also collected. 1H NMR (400 MHz, DEUTERIUM OXIDE) 6 ppm 1.35 (m, 2H) 1.45-1.77 (m, 7H) 1.78-2.04 (m, 6H) 2.06-2.29 (m, 2H) 2.92 (t, J=7.63 Hz, 2H) 3.00 (m, 2H) 3.13 (m, 2H) 4.12-4.20 (m, 1H) 4.21-4.29 (m, 1H) 4.59 (t, J=7.63 Hz, 1H) 5.30-5.45 (m, 1H) 7.17 (m, 5H) 8.04 (br. s., 1H) 8.07 (br. s., 1H). MS (ESI): found: [M+H]+, 687.5.
  • Ac-SQLR (SEQ ID NO: 7) ketothiazole (5f) (yield: 42%) 1H NMR (400 MHz, DEUTERIUM OXIDE) δ ppm 0.85 (d, J=5.87 Hz, 3H) 0.90 (d, J=5.87 Hz, 3H) 1.48-1.76 (m, 5H) 1.77-1.88 (m, 1H) 1.89-2.02 (m, 1H) 2.02-2.20 (m, 5H) 2.26-2.47 (m, 2H) 3.11-3.32 (m, 2H) 3.84 (tt, J=11.44, 5.77 Hz, 2H) 4.25-4.45 (m, 3H) 5.47 (dd, J=9.39, 4.30 Hz, 1H) 8.06 (d, J=3.13 Hz, 1H) 8.11 (d, J=3.13 Hz, 1H). MS (ESI): found: [M+H]+, 612.5.
  • Ac-SRLR (SEQ ID NO: 15) ketothiazole (6e) (yield: 26%) 1H NMR (400 MHz, DEUTERIUM OXIDE) δ ppm 0.85 (d, J=5.87 Hz, 3H) 0.91 (d, J=5.87 Hz, 3H) 1.52-1.77 (m, 8H) 1.79-1.89 (m, 2H) 1.99-2.18 (m, 4H) 3.09-3.34 (m, 4H) 3.83 (tt, J=11.35, 5.67 Hz, 2H) 4.29-4.45 (m, 3H) 5.46 (dd, J=9.20, 4.11 Hz, 1H) 8.06 (d, J=3.13 Hz, 1H) 8.12 (d, J=3.13 Hz, 1H). MS (ESI): found: [M+H]+, 640.5.
  • Ac-TKLR (SEQ ID NO: 16) ketothiazole (6f) (yield: 59%) 1H NMR (400 MHz, DEUTERIUM OXIDE) δ ppm 0.85 (d, J=5.87 Hz, 3H) 0.91 (d, J=5.48 Hz, 3H) 1.12-1.24 (m, 3H) 1.32-1.90 (m, 12H) 1.99-2.18 (m, 4H) 2.98 (t, J=7.43 Hz, 2H) 3.15-3.30 (m, 2H) 4.07-4.19 (m, 1H) 4.24 (d, J=5.48 Hz, 1H) 4.34 (td, J=8.90, 5.67 Hz, 2H) 5.45 (dd, J=9.19, 4.50 Hz, 1H) 8.07 (d, J=3.13 Hz, 1H) 8.12 (d, J=3.13 Hz, 1H). MS (ESI): found: [M+H]+, 626.5.
  • Ac-KFLR (SEQ ID NO: 5) ketothiazole (5d) (yield: 43%) 1H NMR (400 MHz, DEUTERIUM OXIDE) δ ppm 0.85 (d, J=6.26 Hz, 3H) 0.90 (d, J=6.26 Hz, 3H) 1.13-1.38 (m, 2H) 1.40-1.77 (m, 9H) 1.78-1.91 (m, 1H) 1.99 (s, 3H) 2.04-2.17 (m, 1H) 2.82-3.05 (m, 3H) 3.09-3.32 (m, 3H) 4.08-4.21 (m, 1H) 4.37 (dd, J=8.80, 6.06 Hz, 1H) 4.65 (dd, J=8.61, 6.26 Hz, 1H) 5.44 (dd, J=9.19, 4.50 Hz, 1H) 7.15-7.43 (m, 5H) 8.08 (d, J=3.13 Hz, 1H) 8.13 (d, J=3.13 Hz, 1H). MS (ESI): found: [M+H]+, 672.5.
  • Ac-NKLR (SEQ ID NO: 14) ketothiazole (6d) (yield: 39%) 1H NMR (400 MHz, DEUTERIUM OXIDE) δ ppm 0.85 (d, J=5.48 Hz, 3H) 0.91 (d, J=5.87 Hz, 3H) 1.32-1.48 (m, 2H) 1.48-1.91 (m, 10H) 1.93-2.17 (m, 4H) 2.62-2.84 (m, 2H) 2.98 (t, J=7.63 Hz, 2H) 3.14-3.30 (m, 2H) 4.20-4.42 (m, 2H) 4.63 (t, J=7.04 Hz, 1H) 5.45 (dd, J=9.39, 4.30 Hz, 1H) 8.06 (d, J=3.13 Hz, 1H) 8.11 (d, J=3.13 Hz, 1H). MS (ESI): found: [M+H]+, 639.5.
  • Ac-RQLR (SEQ ID NO: 6) ketothiazole (5e) (yield: 13%) 1H NMR (400 MHz, DEUTERIUM OXIDE) δ ppm 0.85 (d, J=5.87 Hz, 3H) 0.91 (d, J=5.87 Hz, 3H) 1.45-1.89 (m, 10H) 1.90-2.19 (m, 6H) 2.35 (td, J=7.43, 3.91 Hz, 2H) 3.14-3.28 (m, 4H) 4.25 (dd, J=8.02, 6.06 Hz, 1H) 4.30-4.43 (m, 2H) 5.47 (dd, J=9.39, 4.30 Hz, 1H) 8.07 (d, J=3.13 Hz, 1H) 8.12 (d, J=3.13 Hz, 1H). MS (ESI): found: [M+H]+, 681.5.
  • Ac-WOLR(SEQ ID NO: 3) ketothiazole (5b) (yield: 13%) 1H NMR (400 MHz, DEUTERIUM OXIDE) δ ppm 0.81 (d, J=5.87 Hz, 3H) 0.88 (d, J=5.48 Hz, 3H) 1.37-1.69 (m, 6H) 1.70-1.91 (m, 3H) 1.91-2.10 (m, 5H) 2.98-3.35 (m, 4H) 3.92-4.06 (m, 1H) 4.11-4.23 (m, 1H) 4.48 (t, J=6.65 Hz, 1H) 5.39 (m, 1H) 7.09 (t, J=7.24 Hz, 1H) 7.14-7.26 (m, 2H) 7.43 (d, J=8.22 Hz, 1H) 7.52 (d, J=7.43 Hz, 1H) 8.00 (d, J=2.74 Hz, 1H) 8.05 (d, J=2.74 Hz, 1H). MS (ESI): found: [M+H]+, 711.5.
  • Ac-KHLR (SEQ ID NO: 2) ketothiazole (5a) (yield: 52%) 1H NMR (400 MHz, DEUTERIUM OXIDE) δ ppm 0.82 (d, J=4.30 Hz, 3H) 0.87 (d, J=4.70 Hz, 3H) 1.22-1.44 (m, 2H) 1.44-1.73 (m, 9H) 1.74-1.87 (m, 1H) 1.96 (s, 3H) 2.06 (m, 1H) 2.83-2.99 (m, 2H) 3.02-3.36 (m, 4H) 4.06-4.22 (m, 1H) 4.34 (m, 1H) 4.58-4.72 (m, 1H) 5.43 (dd, J=8.61, 4.30 Hz, 1H) 7.23 (s, 1H) 8.03 (d, J=2.35 Hz, 1H) 8.08 (d, J=2.35 Hz, 1H) 8.58 (s, 1H). MS (ESI): found: [M+H]+, 662.5.
  • Ac-SKLR (SEQ ID NO: 10) ketothiazole (6) (yield: 57%) 1H NMR (400 MHz, DEUTERIUM OXIDE) δ ppm 0.81 (d, J=4.70 Hz, 3H) 0.87 (d, J=4.30 Hz, 3H) 1.26-1.91 (m, 12H) 1.93-2.16 (m, 4H) 2.94 (t, J=7.43 Hz, 2H) 3.18 (m, 2H) 3.79 (t, J=6.46 Hz, 2H) 4.18-4.46 (m, 3H) 5.43 (dd, J=9.00, 3.91 Hz, 1H) 8.03 (d, J=2.74 Hz, 1H) 8.08 (d, J=2.74 Hz, 1H). MS (ESI): found: [M+H]+, 612.5.
  • Ac-SHLR (SEQ ID NO: 11) ketothiazole (6a) (yield: 32%) 1H NMR (400 MHz, DEUTERIUM OXIDE) δ ppm 0.81 (d, J=5.09 Hz, 3H) 0.86 (d, J=5.09 Hz, 3H) 1.41-1.60 (m, 3H) 1.60-1.72 (m, 2H) 1.73-1.88 (m, 1H) 1.90-2.15 (m, 4H) 2.99-3.37 (m, 4H) 3.63-3.83 (m, 2H) 4.20-4.41 (m, 2H) 4.68 (dd, J=8.61, 5.48 Hz, 1H) 5.44 (dd, J=8.61, 3.13 Hz, 1H) 7.24 (s, 1H) 8.03 (d, J=2.35 Hz, 1H) 8.08 (d, J=2.35 Hz, 1H) 8.57 (s, 1H). MS (ESI): found: [M+H]+, 621.5.
  • Ac-SKFR (SEQ ID NO: 13) ketothiazole (6c) (yield: 46%) 1H NMR (400 MHz, DEUTERIUM OXIDE) δ ppm 1.25 (m, 2H) 1.42-1.81 (m, 7H) 1.86-2.11 (m, 4H) 2.80-3.06 (m, 4H) 3.13 (m, 2H) 3.64-3.86 (m, 2H) 4.17-4.28 (m, 1H) 4.32 (t, J=5.67 Hz, 1H) 4.56 (t, J=7.83 Hz, 1H) 5.38 (dd, J=8.61, 4.30 Hz, 1H) 7.00-7.36 (m, 5H) 8.04 (d, J=2.74 Hz, 1H) 8.07 (d, J=2.74 Hz, 1H). MS (ESI): found: [M+H]+, 646.5.
  • Ac-WKLR (SEQ ID NO: 12) ketothiazole (6b) (yield: 38%) 1H NMR (400 MHz, DEUTERIUM OXIDE) δ ppm 0.86 (d, J=5.48 Hz, 3H) 0.93 (d, J=5.48 Hz, 3H) 1.09-1.20 (m, 2H) 1.39-1.71 (m, 9H) 1.73-1.88 (m, 1H) 1.98 (s, 3H) 2.01-2.14 (m, 1H) 2.80-2.94 (m, 2H) 3.10-3.27 (m, 4H) 4.04-4.13 (m, 1H) 4.15-4.24 (m, 1H) 4.45-4.59 (m, 1H) 5.42 (dd, J=9.00, 3.91 Hz, 1H) 7.08-7.17 (m, 1H) 7.18-7.28 (m, 2H) 7.47 (d, J=7.83 Hz, 1H) 7.57 (d, J=7.83 Hz, 1H) 7.93 (dd, J=13.50, 6.85 Hz, 1H) 8.05 (d, J=2.74 Hz, 1H) 8.09 (d, J=2.74 Hz, 1H). MS (ESI): found: [M+H]+, 711.8.
  • Ac-KQLR (SEQ ID NO: 1) ketothiazole (5) (yield: 32%) 1H NMR (400 MHz, DEUTERIUM OXIDE) δ ppm 0.80 (d, J=5.09 Hz, 3H) 0.86 (d, J=5.09 Hz, 3H) 1.26-1.84 (m, 12H) 1.84-2.13 (m, 6H) 2.29 (m, 2H) 2.93 (t, J=7.43 Hz, 2H) 3.17 (m, 2H) 4.18 (t, J=7.04 Hz, 1H) 4.23-4.37 (m, 2H) 5.35-5.51 (m, 1H) 8.01 (d, J=2.74 Hz, 1H) 8.07 (d, J=2.74 Hz, 1H). MS (ESI): found: [M+H]+, 653.5.
  • Ac-KRLR (SEQ ID NO: 8)-ketothiazole (5g) (yield: 44%) 1H NMR (400 MHz, DEUTERIUM OXIDE) δ ppm 0.77-0.91 (m, 6H) 1.26-1.45 (m, 3H) 1.46-1.58 (m, 5H) 1.58-1.70 (m, 7H) 1.70-1.85 (m, 4H) 1.97 (s, 3H) 1.99-2.11 (m, 2H) 2.93 (t, J=7.63 Hz, 2H) 3.15 (dt, J=13.79, 6.99 Hz, 4H) 4.17 (dd, J=8.22, 5.87 Hz, 1H) 4.24-4.30 (m, 1H) 4.30-4.37 (m, 1H) 5.41 (dd, J=9.20, 4.11 Hz, 1H) 8.02 (d, J=2.74 Hz, 1H) 8.07 (d, J=3.13 Hz, 1H) MS (ESI): found: [M+H]+, 681.7.
  • Ac-WRLR (SEQ ID NO: 9)-ketothiazole (5h) (yield: 24%) 1H NMR (400 MHz, DEUTERIUM OXIDE) δ ppm 0.82 (d, J=5.87 Hz, 3H) 0.89 (d, J=5.87 Hz, 3H) 1.10-1.32 (m, 3H) 1.34-1.45 (m, 2H) 1.48 (d, J=6.65 Hz, 3H) 1.53-1.68 (m, 3H) 1.68-1.83 (m, 1H) 1.95 (s, 3H) 2.02 (d, J=10.56 Hz, 1H) 2.97 (t, J=5.87 Hz, 2H) 3.12 (t, J=6.85 Hz, 2H) 3.15-3.22 (m, 2H) 4.02 (dd, J=8.02, 5.67 Hz, 1H) 4.15 (t, J=7.63 Hz, 1H) 4.47 (t, J=7.04 Hz, 1H) 5.37 (dd, J=9.00, 4.30 Hz, 1H) 7.02-7.12 (m, 1H) 7.17 (t, J=7.63 Hz, 1H) 7.21 (s, 1H) 7.42 (d, J=8.22 Hz, 1H) 7.51 (d, J=7.83 Hz, 1H) 8.00 (d, J=3.13 Hz, 1H) 8.05 (d, J=3.13 Hz, 1H) MS (ESI): found: [M+H]+, 739.7.
  • Ac-SWLR (SEQ ID NO: 17)-ketothiazole (62) (yield: 20%) 1H NMR (400 MHz, DEUTERIUM OXIDE) δ ppm 0.74 (d, J=6.65 Hz, 3H) 0.71 (d, J=6.26 Hz, 3H) 0.99-1.15 (m, 2H) 1.35 (t, J=7.04 Hz, 2H) 1.51-1.64 (m, 3H) 1.72 (s, 3H) 1.76 (br. s., 1H) 2.00 (dd, J=13.69, 4.70 Hz, 2H) 3.00-3.18 (m, 3H) 3.25 (d, J=5.48 Hz, 2H) 3.60-3.81 (m, 3H) 4.11-4.26 (m, 2H) 4.62 (t, J=5.87 Hz, 1H) 5.33 (dd, J=9.59, 4.11 Hz, 1H) 7.08-7.15 (m, 1H) 7.15 (s, 1H) 7.17-7.23 (m, 1H) 7.43 (d, J=8.22 Hz, 1H) 7.57 (d, J=8.22 Hz, 1H) 7.63 (br. s., 1H) 7.77 (br. s., 1H) 8.00 (d, J=3.13 Hz, 1H) 8.06 (d, J=2.74 Hz, 1H) MS (ESI): found: [M+H]+, 670.5.
  • Ac-RKLR (SEQ ID NO: 18)-ketothiazole (6h) (yield: 31%) 1H NMR (400 MHz, DEUTERIUM OXIDE) δ ppm 0.76-0.91 (m, 6H) 1.24-1.47 (m, 3H) 1.47-1.56 (m, 3H) 1.56-1.70 (m, 7H) 1.70-1.86 (m, 4H) 1.97 (s, 3H) 2.00-2.12 (m, 1H) 2.93 (t, J=7.63 Hz, 2H) 3.06-3.24 (m, 4H) 4.19 (t, J=7.04 Hz, 1H) 4.27 (dd, J=8.80, 6.06 Hz, 1H) 4.33 (d, J=9.00 Hz, 1H) 5.41 (dd, J=9.00, 4.70 Hz, 1H) 8.03 (d, J=3.13 Hz, 1H) 8.08 (d, J=3.13 Hz, 1H) MS (ESI): found: [M+H]+, 681.7.
    • Example 3. Synthesis of Cyclic Peptides
  • The cyclic peptide is listed in Table 3.1 were synthesized in accordance with the general schemes 3A and 3B and cyclization schemes 3C, 3D, 3E, and 3F shown below and the procedures described below.
  • Figure US20220169676A1-20220602-C00124
  • Figure US20220169676A1-20220602-C00125
  • TABLE 3.1
    Y—P5—P4—P3—P2—P1—Z
    Compound
    No. Y-cyclo(P5-P4-P3)-P2-P1-Z Cyclization
    7074 H-cyclo(KQD)RR-kt P3-P5
  • Cbz-K(Boc)F-OMe (3): Compound 1 (0.1 mmol) and compound 2 (0.1 mmol) was taken in dry CH2Cl2 (5 mL) and cooled to 0° C. and diisopropyletheylamine (DIPEA) (0.3 mmol) and propylphosphonic anhydride (T3P) (0.1 mmol, 50% solution in ethyl acetate) were added dropwise to the reaction mixture respectively. The reaction mixture was stirred for 1 hr at room temperature under nitrogen atmosphere. The completion of the reaction was confirmed by LCMS monitoring. On completion, the reaction mixture was diluted with 5 mL and washed with 10% citric acid, saturated Na2CO3 solution and brine respectively. The organic layer was dried over sodium sulfate and concentrated under reduced pressure to obtain the compound 3 as white solid (yield: 80%, Chemical Formula: C29H39N3O7, Exact Mass: 541.28, ESIMS: 564.6 [M+Na+]).
  • Cbz-K(Boc)F-OH (4): Compound 3 (0.1 mmol) was taken in 4 mL THF-H2O (1:1) mixture and LiOH.H2O (0.3 mmol) was added to the solution. The reaction mixture was stirred for 15 minutes at room temperature and the completion of the reaction was confirmed by LCMS monitoring. On completion, the THF was evaporated under reduced pressure and the water layer was cooled to 0° C. The water layer was brought to pH 6.5 by dropwise addition of cold 0.5 M HCl solution and kept on ice for 15 minutes to complete the precipitation of the product as white solid. The precipitate was isolated by filtration and dried under reduced pressure to obtain the compound 4 as white solid (Yield: 83%, Chemical Formula: C28H37N3O7, Exact Mass: 527.26, ESIMS: 528.3 [M+H+]).
  • Cbz-K(Boc)FD(t-Bu)-OMe (6): Compound 4 (0.1 mmol) and compound 5 (0.1 mmol) was taken in dry CH2Cl2 (5 mL) and cooled to 0° C. and diisopropyletheylamine (DIPEA) (0.3 mmol) and propylphosphonic anhydride (T3P) (0.1 mmol, 50% solution in ethyl acetate) were added dropwise to the reaction mixture respectively. The reaction mixture was stirred for 1 hr at room temperature under nitrogen atmosphere. The completion of the reaction was confirmed by LCMS monitoring. On completion, the reaction mixture was diluted with 5 mL and washed with 10% citric acid, saturated Na2CO3 solution and brine respectively. The organic layer was dried over sodium sulfate and concentrated under reduced pressure to obtain the compound 3 as white solid (yield: 80%, Chemical Formula: C37H52N4O10 Exact Mass: 712.37, ESIMS: 713.4 [M+H+]).
  • Cbz-KFD-OMe (7): Trifluoroacetic acid (TFA) (3 mL) was added to the compound 6 and the reaction mixture was stirred for 1 hr. The completion of the reaction was confirmed by LCMS monitoring. On completion, the TFA was evaporated under reduced pressure by azeotroping with toluene and the dry mass was triturated with diethyl ether to obtain the pure compound 7 as white solid (Yield: 92%, Chemical Formula: C28H36N4O8, Exact Mass: 556.25, ESIMS: 557.3 [M+H+]).
  • Cbz-cyclo(KFD)-OH (PK-1-71): Compound 7 (0.09 mmol) was taken in 25 mL DMF and DIPEA (0.27 mmol) and diphenyl phosphoryl azide (0.1 mmol) was added to the solution. The reaction mixture was stirred for 12 hr at room temperature under nitrogen atmosphere and the completion of the reaction was confirmed by LCMS monitoring. The DMF was evaporated under reduced pressure and the crude product was purified by normal phase column chromatography using silica gel column and 5% MeOH in dichloromethane as eluent to obtain the product PK-1-71 as white solid (yield: 68%, Chemical Formula: C28H34N4O7, Exact Mass: 538.24, ESIMS: 539.4 [M+H+],) 1H NMR (400 MHz, METHANOL-d4) d 8.03 (s, 1H), 7.97 (s, 1H), 7.42-7.49 (m, 2H), 7.29-7.35 (m, 6H), 7.17-7.23 (m, J=7.80 Hz, 5H), 7.10-7.16 (m, 2H), 3.69 (td, J=6.65, 13.30 Hz, 1H), 3.19 (q, J=7.43 Hz, 1H), 2.98 (s, 1H), 2.85 (s, 1H), 2.74 (s, 1H), 1.36 (s, 3H), 1.34 (t, J=3.33 Hz, 8H).
  • ((7S,10S,13S,Z)-13-acetamido-10-(3-amino-3-oxopropyl)-9,12-dioxo-2-oxa-8,11-diaza-1(1,4)-benzenacyclotetradecaphan-4-ene-7-carbonyl)-L-arginine (CJ-1-55). methyl N2-((S)-2-((S)-2-((S)-2-acetamido-3-(4-(allyloxy)phenyl)propanamido)-5-amino-5-oxopentanamido)pent-4-enoyl)-Nw-((2,2,4,5,7-pentamethyl-2,3-dihydrobenzofuran-6-yl)sulfonyl)-L-argininate [calculated for Chemical Formula: C44H62N8O11S, Exact Mass: 910.43, MS(ESI): found: [M+H]+, 911.4, (0.18 g, 0.2 mmol)] was dissolved in DCM (125 mL). Grubbs second generation catalyst (50 mg, 0.06 mmol) was added and then the stirred reaction mixture was heated to reflux. The reaction as filtered and purified by silica gel chromatography (17 mg, 0.019 mmol). The product was dissolved in water (1 mL) and THF (1 mL), then LiOH (2 mg, 0.084 mmol) was added, and the reaction stirred for 1 hour. The THF was removed and 2 drops of 3N HCl were added to precipitate the Pbf-protected acid. The solid was dissolved in 3 mL of TFA/water/thioanisole (95:2.5:2.5) and stirred for 3 hours. The solvent was removed under reduced pressure and the residue was purified by C18 reverse phase HPLC (5-95% Acetonitrile/water/0.05% TFA). After lyopholization of pure fractions the title compound (4.4 mg) was obtained as the TFA salt. Calculated for Chemical Formula: C28H40N8O8, Exact Mass: 616.30, MS(ESI): found: [M+H]+ 617.3.
  • Figure US20220169676A1-20220602-C00126
  • Figure US20220169676A1-20220602-C00127
    Figure US20220169676A1-20220602-C00128
  • (2S,5S,13S)-13-amino-2-(3-amino-3-oxopropyl)-N—((S)-5-guanidino-1-(((S)-5-guanidino-1-oxo-1-(thiazol-2-yl)pentan-2-yl)amino)-1-oxopentan-2-yl)-3,7,14-trioxo-1,4,8-triazacyclotetradecane-5-carboxamide (7074). A solution of (6S,9S,12S)-9-(3-amino-3-oxopropyl)-6-(4-aminobutyl)-12-(((S)-1-methoxy-1-oxo-5-(3-((2,2,4,5,7-pentamethyl-2,3-dihydrobenzofuran-6-yl)sulfonyl)guanidino)pentan-2-yl)carbamoyl)-2,2-dimethyl-4,7,10-trioxo-3-oxa-5,8,11-triazatetradecan-14-oic acid [calculated for Chemical Formula: C40H65N9O13S, Exact Mass: 911.44, MS(ESI): found: [M+H]+, 912.4; (0.3 g, 0.33 mmol)] in DMF (10 mL) was slowly added to a stirred solution of DPPA (0.66 mmol, 0.15 mL) and DIPEA (0.66 mmol, 0.12 mL) in DMF (140 mL). The solvent was concentrated under reduced pressure and the residue purified by silica gel chromatography to give 100 mg of the fully protected cycloamide. This product (56 mg, 0.063 mmol) was dissolved in water (2 mL) and THF (2 mL) and then 2 mL of MeOH. LiOH (5 mg, 0.21 mmol) was added and the reaction stirred for 1 hour. 2 drops of 3N HCl was added and the reaction was then concentrated in vacuo to give 52 mg of Boc/Pbf-protected acid. This product (52 mg, 0.059 mmol) was dissolved in 5 mL of DMF, placed under a nitrogen atmosphere and cooled to with an ice-bath. To this stirred solution was added HATU (27 mg, 0.071 mmol), DIPEA (0.36 mmol, 0.063 mL), and then a solution of H-Arg(Mtr)-kt-HCl salt (29 mg, 0.06 mmol) in DMF. The reaction was allowed to come to room temperature and then stirred overnight. The reaction was added to water and the precipitate filtered to give the product as a mixture of two peaks by LCMS (51 mg crude). The solid was dissolved in 5 mL of TFA/water/thioanisole (95:2.5:2.5) and stirred for 6 hours. The solvent was removed under reduced pressure and the residue was purified by C18 reverse phase HPLC (5-95% Acetonitrile/water/0.05% TFA). After lyopholization of fractions, the title compound (12 mg) was obtained as a 3:1 ratio of D and L diastereomers (mixture of R and S isomers of the alpha keto carbon). Calculated for Chemical Formula: C30H50N14O7S, Exact Mass: 750.37, MS(ESI): found: [M+H]+, 751.4.
  • Figure US20220169676A1-20220602-C00129
  • Figure US20220169676A1-20220602-C00130
  • Figure US20220169676A1-20220602-C00131
    • Example 4. Inhibition Studies with Ketothiazoles
  • The compounds prepared in Example 2 were subjected to a series of inhibitions studies. The compounds were first tested in an HGFA enzymatic assay using the fluorogenic substrate Boc-QLR-AMC with a recombinant form of the HGFA serine protease domain.
    • Synthesis of Boc-QLR-AMC Fluorogenic Substrate
  • Boc-R(NO2)-AMC. Under nitrogen atmosphere, pyridine (60 mL) was added into the round bottom flask containing Boc-R(NO2)—OH (4.653 g, 14.6 mmol) and 7-amino-4-methylcoumarin (3.829 g, 21.9 mmol). Diisopropylcarbodiimide (2.023 g, 16.0 mmol) was added and the mixture was stirred overnight. The mixture was filtered. The filtrate was concentrated then dried in vacuo. The resultant residue was purified by silica gel chromatography with dichloromethane/methanol combinations as eluent giving rise to Boc-R(NO2)-AMC (2.964 g) in 43% yield. MS (ESI): found [M+H]+, 477.4.
  • HCl.H2N—R(NO2)-AMC. 4 N HCl in dioxane (25 mL) was added into the round bottom flask containing Boc-R(NO2)-AMC (2.964 g, 6.2 mmol) and the mixture stirred for 2 hours. The dioxane was removed in vacuo and to the resultant residue methanol was added then concentrated in vacuo three times, giving rise to the title compound in quantitative yield. MS (ESI): found [M+H]+, 377.3.
  • Boc-QL-OH. Under nitrogen atmosphere, anhydrous DMF (10 mL) was added into the round bottom flask containing Boc-Q-OH (0.500 g, 2.0 mmol), H-L-OMe-HCl (0.406 g, 2.2 mmol), EDCI.HCl (0.467 g, 2.4 mmol), and HOBt (0.466 g, 3.1 mmol). N,N-diisopropylethylamine (0.787 g, 6.1 mmol) was added and the mixture was stirred overnight.
  • The majority of DMF was removed in vacuo and to the resulting residue was added 20 mL of water. The precipitate was isolated by filtration then purified by silica gel chromatography with dichloromethane/methanol combinations as eluent to give Boc-QL-OMe (0.711 g) in 95% yield. MS (ESI): found [M+Na]+, 396.4. Methanol/water (1:1 v/v, 10 mL) was added into the round bottom flask containing the Boc-QL-OMe (0.711 g, mmol) and LiOH (0.068 g, 2.8 mmol). The reaction was stirred overnight. The mixture was concentrated in vacuo and to the resulting residue was added 30 mL of water. 0.5 M HCl was added dropwise until pH=4.5 was reached, then the mixture was extracted three times with ethyl acetate. The ethyl acetate layers were collected, dried with Na2SO4, then concentrated in vacuo to give rise to Boc-QL-OH (0.603 g) in 49% yield. MS (ESI): found [M+Na]+, 373.4.
  • Boc-QLR(NO2)-AMC. Under nitrogen atmosphere, anhydrous DMF (10 mL) was added into the round bottom flask containing Boc-QL-OH (0.603 g, 1.7 mmol), HCl.H2N—R(NO2)-AMC (0.406 g, 2.2 mmol), EDCI.HCl (0.322 g, 1.7 mmol), and HOBt (0.257 g, 1.7 mmol). N,N-diisopropylethylamine (0.904 g, 7.0 mmol) was added and the mixture was stirred overnight. The majority of DMF was removed in vacuo and to the resulting residue was added 20 mL of water. The mixture was extracted three times with ethyl acetate. The ethyl acetate layers were collected, dried with Na2SO4, then concentrated in vacuo. The resultant residue was purified by silica gel chromatography with dichloromethane/methanol combinations as eluent giving rise to Boc-QLR(NO2)-AMC (0.250 g) in 20% yield. MS (ESI): found [M+H]+, 718.5.
  • Boc-QLR-AMC. Into the solution of Boc-QLR(NO2)-AMC (0.250 g, 0.35 mmol) in MeOH (15 mL) was added Pd/C (10%) (0.111 g) followed by several drops of acetic acid. The mixture was stirred under hydrogen atmosphere for 21 hours. Additional Pd/C (10%) (0.184 g) was added with a few drops of acetic acid. The mixture was stirred for 24 hours, then filtered. The filtrate was concentrated. ⅕ of the resulting residue was purified by HPLC (C18, 15*150 mm column; eluent: acetonitrile/water (0.05% TFA)) to give the title compound (0.037 g) in 78% yield. 1H NMR (400 MHz, METHANOL-d4) δ ppm 0.92 (d, J=6.30 Hz, 3H) 0.98 (d, J=6.26 Hz, 3H) 1.45 (s, 9H) 1.54-2.14 (m, 9H) 2.25-2.41 (m, 2H) 2.49 (s, 3H) 3.17-3.29 (m, 2H) 4.00-4.14 (m, 1H) 4.34-4.47 (m, 1H) 4.49-4.61 (m, 1H) 6.28 (s, 1H) 7.46-7.60 (m, 1H) 7.71-7.80 (m, 1H) 7.80-7.89 (m, 1H). MS (ESI): found: [M+H]+, 673.6.
  • Expression and purification of N-terminal His-tag HGFA serine protease domain: Using primers identified as SEQ ID NO 1, SEQ ID NO 2, and standard PCR protocols, the nucleotide sequence encoding amino acids 373-655 of HGFA was synthesized. This PCR product was cloned into the SfoI-HindIII sites of a modified pFastBac HT baculovirus expression vector (Addgene, Cambridge, Mass.). This vector contains a six amino His tag followed by a seven amino spacer and a seven amino acid TEV cleavage site placed immediately downstream of the Honey Bee melittin signal peptide. Using a modified Bac to Bac Expression System (Life Technologies, Carlsbad, Calif.), recombinant HGFA bacmids were obtained by transforming DH10Bac Escherichia coli cells. To obtain HGFA containing baculovirus, purified bacmids were transfected into Sf9 insect cells. After 5 days in culture at 27° C., media was harvested from transfected Sf9 cells. This media was used to prepare baculovirus infected insect cells (BIICs). These BIIICs were used to infect High 5 insect cells. Four days post infection, media was harvested and recombinant protein prepared as follows. Media was chilled to 4° C. and spun at 4000×g for 20 minutes (all subsequent steps were performed at 4° C. unless noted). Clarified media was passed first through a Whatman GF/B 1 um (#1821-047, GE Healthcare Life Sciences, Piscataway, N.J.) and then a 0.22 um PES membrane (#99955, TPP Techno Plastic Products AG, Trasadingen, Switzerland) and then concentrated using a Pall Centramate tangential flow system and Centramate T-series Cassette (#OS010T12, Pall Corporation, Port Washington, N.Y.). Concentrated media was then buffer exchanged in two steps, five volumes of 50 mM Na-phosphate, 500 mM NaCl, pH 6.2, followed by five volumes of 50 mM Na-phosphate, 500 mM NaCl, pH 7.5. The concentrated and buffered exchanged insect cell media was again filtered as above and made 25 mM imidazole (#I202, Sigma-Aldrich, St. Louis, Mo.) and was mixed with nickel agarose beads (#H-321-25, Gold Biotechnology, Inc., St. Louis Mo.). After mixing this slurry for 12 hours, nickel agarose beads were allowed to settle by gravity and then loaded into a column. Beads were washed with buffer (25 mM Na-phosphate, 500 mM NaCl, 25 mM imidazole, pH 8) and the bound protein eluted using (25 mM Na-phosphate, 500 mM NaCl, 250 mM imidazole, pH 8). Using a Amicon Ultra-4 Centrifugal filters (#UFC801008, Merck Millipore, Ltd., Tullagreen, Ireland), peak protein fractions were concentrated and run over a Superdex-200 10/300 GL column (GE Healthcare Life Sciences, Piscataway, N.J.) in 10 mM Tris, 200 mM NaCl, 0.2 mM EDTA, pH 8. HGFA containing fractions were pooled, concentrated, made 50% glycerol, and stored at minus 20° C. Protein was quantitated using a modified Lowry protein assay (#500-0006, Bio-Rad Laboratories, Hercules, Calif.).
  • Chromogenic Kinetic Enzyme InhibitorAssays of HGFA: The inhibitors (0-50 μM final concentration in reaction) were diluted in DMSO (2% DMSO final concentration in reaction) and then mixed with recombinant HGFA (12.5 nM final concentration in reaction) in TNC buffer (25 mM Tris, 150 mM NaCl, 5 mM CaCl2), 0.01% TRITON X-100, pH 8). After incubating for thirty minutes at 25° C., chromogenic substrate, Pefachrome FVIIa, (#093-01, Enzyme Research Laboratories, South Bend, Ind.)) was added to a final concentration of 250 μM in a final reaction volume of 40 microliters. Changes in absorbance at 405 nm were measured over time in a Biotek Synergy 2 plate reader (Winnoski, Vt.). Using Gen 5 2.00 software program (Biotek, Winnoski, Vt.), a four parameter curve fit was used to determine the inhibitor IC50s from a plot of the mean reaction velocity versus the inhibitor concentration. The IC50 values represent the average of three separate experimental determinations.
  • Chromogenic Kinetic Enzyme Assays of Thrombin and Factor Xa: Inhibitors (11-pt serial dilutions, 0-20 μM final concentration) were serially diluted in DMSO (2% DMSO final concentration) and then mixed with recombinant thrombin (0.15 nM final concentration) or Factor Xa (0.35 nM final concentration) in TNC buffer (25 mM Tris, 150 mM NaCl, 5 mM CaCl2), 0.01% TRITON X-100, pH 8) using clear 384 well plates. After incubating for 30 minutes at 25° C., the chromogenic substrate (S2238; D-Phe-Pip-Arg-pNA) for thrombin (Km=14.5 μM) or (S2222; Bz-Ile-Glu-Gly-Arg-pNA) for Factor Xa (Km=200 μM) was added to a final concentration of Km (4×Km (50 μM) for thrombin) in a final reaction volume of 40 microliters. Changes in absorbance at 405 nm were measured over time in a Biotek Synergy 2 plate (Winnoski, Vt.). Using GraphPad Prism version 6.04 software program, (GraphPad Software, San Diego, Calif., www.graphpad.com), a four parameter curve fit was used to determine the inhibitor IC50s from a plot of the mean reaction velocity versus the inhibitor concentration. Ki values were calculated from the IC50 values using the Cheng and Prusoff equation (Ki=IC50/(1+[S]/Km).
  • TABLE 4.1
    HGFA Matriptase
    IC50 IC50 Hepsin Thrombin Factor Xa
    Structure (μM) (μM) IC50 (μM) Ki (nM) Ki (nM)
    Nafamostat 0.80 0.001 0.002
    Leupeptin (Ac-LLR-H 0.535 1.150 0.256
    Ac-KQLR(SEQ ID NO: 1)-kt 0.445 0.005 0.002 >20000 170
    (5)
    Ac-KQLdR-kt (5-1) 5.526 — — — —
    Ac-KHLR(SEQ ID NO: 2)-kt 0.650 — — — —
    (5a)
    Ac-KHLdR-kt (5a-1) 10.931 — — — —
    Ac-WQLR(SEQ ID NO: 3)-kt 0.471 0.049 0.001 — —
    (5b)
    Ac-WQLdR-kt (5b-1) 7.123 — — — —
    Ac-KQFR(SEQ ID NO: 4)-kt 0.470 — — >20000 78.8
    (Sc)
    Ac-KQFdR-kt (5c-1) 7.824 — — — —
    Ac-KFLR(SEQ ID NO: 5)-kt 0.330 0.035 0.022 — —
    (5d)
    Ac-RQLR(SEQ ID NO: 6)-kt 0.270 0.001 0.001 >20000 8.10
    (5e)
    Ac-RQLdR-kt (5e-1) 3.118 — — — —
    Ac-SQLR(SEQ ID NO: 7)-kt 0.180 — — — —
    (5f)
    Ac-KRLR(SEQ ID NO: 8)-kt 0.225 0.014 0.005 — —
    (5g)
    Ac-WRLR(SEQ ID NO: 9)-kt 0.275 0.031 0.0003 — —
    (5h)
    Ac-SKLR(SEQ ID NO: 10)- 0.56 0.048 0.00 >20000 3062
    kt (6)
    Ac-SKLdR-kt (6-1) 6.311 — — — —
    Ac-SHLR(SEQ ID NO: 11)- 1.800 0.560 0.005 — —
    kt (6a)
    Ac-SHLdR-kt (6a-1) 21.218 — — — —
    Ac-WKLR(SEQ ID NO: 12)- 0.320 0.097 0.004 — —
    kt (6b)
    Ac-WKLdR-kt (6b-1) 6.500 — — — —
    Ac-SKFR(SEQ ID NO: 13)-kt 0.520 0.034 0.051 >2000 530.00
    (6c)
    Ac-SKFdR-kt (6c-1) 10.795 — — — —
    Ac-NKLR(SEQ ID NO: 14)- 0.397 — — — —
    kt (6d)
    Ac-SRLR(SEQ ID NO: 15)-kt 0.303 0.024 0.005 — —
    (6e)
    Ac-SdRLR-kt (6e-1) 1.420 — — — —
    Ac-SRLdR-kt (6e-2) 2.241 — — — —
    Ac-SdRLdR-kt (6e-3) 11.920 — — — —
    Ac-TKLR(SEQ ID NO: 16)- 0.567 — — — —
    kt (6f)
    Ac-SWLR(SEQ ID NO: 17)- 0.435 0.175 0.009 3698 759
    kt (6g)
    Ac-RKLR(SEQ ID NO: 18)- 0.370 — — — —
    kt (6h)
    Ac-NKLR(SEQ ID NO: 14)- 0.4 — — — —
    kt
    H-KQLdR-kt 11.31 — — — —
    H-KQLR(SEQ ID NO: 1)-Kt 0.44 — — — —
    Ac-LLR-kt 1.48
  • HGFA Competition Assay of inhibitor Ac-KQLR (SEQ ID NO: 1)-Kt (5) and substrate: To determine whether the ketothiazoles are behaving as competitive inhibitors, different amounts of Ac-KQLR (SEQ ID NO: 1)-Kt (5) (0, 0.25, 0.5, and 1.0 μM) were mixed with Pefachrome serially diluted in TNC buffer. HGFA was added to 12.5 nM and changes in absorbance at 405 nm were measured over time in a Biotek Synergy 2 plate reader. From the plots of the mean reaction velocity versus substrate concentration and the Michaelis-Menten enzyme kinetics equation within GraphPad Prism version 6.04 for Windows, the reaction Vmax and subsequent Km for each concentration of inhibitor was determined as shown in the FIG. 1.
  • Fluorescent Kinetic Enzyme Inhibitor Assays of HGFA, matriptase hepsin, and thrombin: Inhibitors (11-pt serial dilutions, 0-20 μM final concentration in reaction) were serially diluted in DMSO (2% DMSO final concentration) and then mixed with either recombinant serine protease domain of HGFA [Z. Han, P. K. Harris, D. E. Jones, R. Chugani, T. Kim, M. Agarwal, W. Shen, S. A. Wildman, J. W. Janetka, Acs Med Chem Lett 2014, 5, 1219-1224], matriptase (Charles Craik, UCSF) or hepsin* (#4776-SE-010, R&D Systems, Minneapolis, Minn.) in black 384 well plates (Corning #3575. Corning, N.Y.). The final assay concentration for HGFA, matriptase and hepsin 7.5 nM, 0.2 nM, and 0.3 nM, respectively in TNC buffer (25 mM Tris, 150 mM NaCl, 5 mM CaCl2), 0.01% TRITON X-100, pH 8). After thirty minutes incubation at room temperature, Boc-QLR-AMC substrate (Km=37 μM) was added to the HGFA assays and Boc-QAR-AMC substrate was added to the matriptase (Km=93 μM) and hepsin (Km=156 μM) assays. The final substrate concentrations for all assays were at the Km for the respective enzymes. Changes in fluorescence (excitation at 380 nm and emission at 460 nm) were measured at room temperature over time in a Biotek Synergy 2 plate reader (Winnoski, Vt.). Using GraphPad Prism version 6.04 software program, (GraphPad Software, San Diego, Calif., www.graphpad.com), a four parameter curve fit was used to determine the inhibitor IC50s from a plot of the mean reaction velocity versus the inhibitor concentration. The IC50 values represent the average of three separate experimental determinations. Ki values were calculated using the Cheng and Prusoff equation (Ki=IC50/(1+[S]/Km).
  • *Hepsin Activation: Recombinant Hepsin (10 μg, 0.44 mg/mL as received from R&D Systems, Catalogue #4776-SE) was diluted to 2.4 μM in TNC buffer (25 mM Tris, 150 mM NaCl, 5 mM CaCl2), 0.01% TRITON X-100, pH 8) and incubated at 37° C. After twenty-four hours, the hepsin was diluted in glycerol to 50%. This stock hepsin (1.2 μM) was stored in a −20° C. freezer and diluted in TNC buffer for use in assays.
  • As shown in the following table, the pro-HGF and pro-MSP tetrapeptides 5 and 6 showed Kis of 53 nM and 81 nM, respectively. These results demonstrate that inhibitor 5 was competitive with substrate to the active-site. The majority of compounds evaluated are more selective for matriptase and hepsin; most pronounced with hepsin where some inhibitors having Kis <1 nM. There are several compounds which are equipotent for HGFA compared to matriptase but leupeptin is 3-fold selective for HGFA over matriptase and only 3-fold favoring hepsin. The pro-HGF peptide (5) is 200-fold more potent for hepsin and 50-fold for matriptase while the pro-MSP peptide (6) is only slightly more potent for matriptase and 70-fold potent for hepsin versus HGFA. Ac-SWLR (SEQ ID NO: 17)-Kt (6g) is equipotent for both HGFA and matriptase with a Ki=66 nM but Ki=1.2 nM for hepsin. 6g, Ac-SKFR (SEQ ID NO: 13)-Kt (6c), Ac-KFLR (SEQ ID NO: 5)-Kt (5d) and Ac-SRLR(SEQ ID NO: 15)-Kt (6e) show HGFA selectivity over both hepsin and matriptase.
  • TABLE 4.2
    HGFA Matriptase Hepsin
    Structure Ki (nM) Ki (nM) Ki (nM)
    Nafamostat 25 0.02 0.53
    Leupeptin (Ac-LLR-H) 188 696 61
    Ac-KQLR(SEQ ID NO: 1)-kt (5) 70 1.60 0.19
    Ac-KQLdR-kt (5-1) — — —
    Ac-KHLR(SEQ ID NO: 2)-kt (5a) 96 22.3 0.41
    Ac-KHLdR-kt (5a-1) — — —
    Ac-WQLR(SEQ ID NO: 3)-kt (5b) 65 32.4 0.21
    Ac-WQLdR-kt (5b-1) — — —
    Ac-KQFR(SEQ ID NO: 4)-kt (Sc) 58 0.69 0.58
    Ac-KQFdR-kt (5c-1) — — —
    Ac-KFLR(SEQ ID NO: 5)-kt (5d) 80 15 2.1
    Ac-RQLR(SEQ ID NO: 6)-kt (5e) 60 0.32 0.28
    Ac-RQLdR-kt (5e-1) — — —
    Ac-SQLR(SEQ ID NO: 7)-kt (5f) 182 9.2 0.34
    Ac-KRLR(SEQ ID NO: 8)-kt (5g) 12 1.1 0.57
    Ac-WRLR(SEQ ID NO: 9)-kt (5h) 21 5.5 0.21
    Ac-SKLR(SEQ ID NO: 10)(SEQ ID 81 58 1.2
    NO: 10)-kt (6)
    Ac-SKLdR-kt (6-1) — — —
    Ac-SHLR(SEQ ID NO: 11)-kt (6a) 332 104.2 0.60
    Ac-SHLdR-kt (6a-1) — — —
    Ac-WKLR(SEQ ID NO: 12)-kt (6b) 56 8.6 0.55
    Ac-WKLdR-kt (6b-1) — — —
    Ac-SKFR(SEQ ID NO: 13)-kt (6c) 57 3.03 8.5
    Ac-SKFdR-kt (6c-1) — — —
    Ac-NKLR(SEQ ID NO: 14)-kt (6d) 79 12 1.4
    Ac-SRLR(SEQ ID NO: 15)-kt (6e) 24 5.8 0.68
    Ac-SdRLR-kt (6e-2) — — —
    Ac-SRLdR-kt (6e-1) — — —
    Ac-SdRLdR-kt (6e-3) — — —
    Ac-TKLR(SEQ ID NO: 16)-kt (6f) 103 8.7 0.61
    Ac-SWLR(SEQ ID NO: 17)-kt (6g) 63 69 1.2
    Ac-RKLR(SEQ ID NO: 18)-kt (6h) 17 0.83 0.47
    Ac-NKLR(SEQ ID NO: 14)-kt 79 12.4 1.41
    Ac-LLR-kt 253.00 27.950 2.288
     Not measured. Km Determinations:
  • In black 384 well plates (Corning #3575), 12.5 nM HGFA was mixed with various amounts of Boc-QLR-AMC and 1 nM matriptase and 0.3 nM hepsin were mixed with various amounts of Boc-QAR-AMC. Changes in fluorescence (excitation at 380 nm and emission at 460 nn) were measured at room temperature over time in a Biotek Synergy 2 plate reader (Winnoski, Vt.). Using plots of the mean reaction velocity versus substrate concentration and the Michaelis-Menten enzyme kinetics equation within GraphPad Prism version 6.04 for Windows (GraphPad Software, San Diego, Calif., www.graphpad.com), the reaction Vmax and subsequent Km for each of the substrates were determined. The plots are presented in FIGS. 2-4.
  • Dilution recovery experiments with Ac-KQLR (SEQ ID NO: 1)-Kt (5) and HGFA: To demonstrate reversibility of HGFA ketothiazole inhibitors and to examine the dissociation of the enzyme-inhibitor complex, dilution recovery experiments were performed. High concentration HGFA (7.5 μM) were mixed with different concentrations of Ac-KQLR (SEQ ID NO: 1)-Kt (5), between 0-120 μM. After incubating for 20 minutes at room temperature, these reactions were diluted rapidly (1:350) in TNC buffer containing 250 μM Boc-QLR-AMC substrate (˜7 times Km). Activity was monitored by recording the change in fluorescence (excitation at 380 nm and emission at 460 nn) over time in a Biotek Synergy 2 plate reader. GraphPad Prism was used to plot the change in fluorescence over time. The results are provided in FIGS. 5 and 6. These results show that Ac-KQLR (SEQ ID NO: 1)-Kt (5) is a reversible inhibitor of HGFA as the enzyme activity is recovered slowly over time even at an inhibitor concentrations 7×Ki.
  • Biochemical Assay for Proteolysis of pro-HGF and pro-MSP by HGFA: A biochemical assay was employed in order to demonstrate that inhibitors can block the proteolytic activation of the endogenous growth factors, pro-HGF and pro-MSP by HGFA in a dose-dependent manner. In order to determine efficiency of our recombinant HGFA we performed a concentration response of HGFA using a fixed concentration of pro-HGF and pro-MSP. Since both the single chain inactive pro-HGF or pro-MSP and the active heterodimers have the same molecular weight, SDS gels were developed under reducing conditions.
  • For pro-HGF proteolysis, inhibitors (0-12.5 μM final concentration in reaction) were diluted in DMSO (2% DMSO final concentration in reaction) and then mixed with recombinant HGFA (1.0 nM final concentration) in TNC buffer. After 30 minutes incubation at room temperature (25° C.), 25 ng of pro-HGF (R&D Systems, NKG011306A) was added. After 1 hour incubation at 37° C., reactions were stopped by adding SDS gel loading buffer containing DTT (reducing) and then run on 12% PAGE. Proteins were transferred to Millipore Immobilon-P membranes (Billerica, Mass.) and then immunoblotted at 4° C. with anti-HGF antibody (R&D Systems, AF-294-NA) and HRP conjugated donkey anti-goat IgG (Santa Cruz, SC-2020) diluted 1:500 and 1:5000 in 5% milk/TBST (5% Carnation nonfat dried milk/10 mM Tris, 150 mM NaCl, 0.05% TWEEN 20, pH 8.0), respectively. Membranes were washed in TBST, immersed in Millipore Luminata Crescendo Western-HRP Substrate for 5 minutes, and then exposures made on a BioRad ChemiDoc MP Imaging System (Hercules, Calif.). For pro-MSP proteolysis assays, the procedures were similar, except that the HGFA concentration was 75 nM, pro-MSP (R&D Systems ZN081306A) concentration was 50 ng per reaction, and 1:500 dilution of anti-MSP antibody (R&D Systems, AF352) was used for MSP detection during immunoblotting.
  • The results are shown in FIGS. 7 and 8 below. Lanes with pro-HGF (FIG. 7) and pro-MSP (FIG. 8) contain one band at 90 and 75 KDa, respectively, whereas activated HGF and MSP appear as two bands as the 60 KDa α-chain and 30 KDa β-chain in HGF and 50 KDa and 25 KDa for MSP (note: MSP Ab only recognizes the α-chain). Shown in FIG. 4, we found that nafamostat and the three inhibitors 5, 5h, 5g all showed a dose-dependent inhibition of pro-HGF activation with similar EC50 values in direct correlation with those found from the HGFA enzyme assay. These inhibitors in addition to 6e also all show dose-dependent inhibition of pro-MSP proteolysis by HGFA as shown in FIG. 7. While it is difficult to quantitate the level of MSP activation since the pro-MSP has some active two-chain MSP present, the EC50 values correlate with the level of potency seen in the enzyme assay. These results show the inhibitors inhibit the processing of both known protein substrates of HGFA.
  • c-MET Phosphorylation (Y1234/1235) in cells treated with HGFA processed pro-HGF and MSP: To show the inhibition provided by the tetrapeptide compounds would have effects on cell signaling through c-MET kinase, a phosphorylation assay using the invasive breast cancer cell line, MDA-MB-231 was developed. This cell line has high expression of c-MET and pro-HGFA but not pro-HGF.
  • MDA-MB-231 cells were maintained in RPMI medium (Sigma-Aldrich R8758, St. Louis, Mo.) containing 10% fetal bovine serum (Sigma F2442) and 1× Penicillin/Streptomycin (Pen/Strep) antibiotics (Thermo Fisher SV30010). For cMet phosphorylation measurements, MDA-MB-231 cells were switched to starve medium (RPMI medium containing 1 mM Sodium Pyruvate (Corning 25-000-ci), 10 mM HEPES (Corning 25-060-ci), 0.225% Glucose (Corning 25-037-ci), 1×PenStrep). After 18 hours, cells were switched to fresh starve media and then treated with HGFA Proteolysis reactions containing 1 nM HGFA, 50 ng pro-HGF and various amounts of inhibitors. After 15 minutes incubation, media was removed by aspiration and the remaining cells were washed twice with cold Dulbeccos Phosphate Buffered Saline (Life Technologies #14190-136). Next cells were scraped into in Lysis Buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.25% Sodium Deoxcholate, pH 7.5) containing 1 mM sodium fluoride, 1 mM sodium orthovanandate, 1× Sigma (P8340) Inhibitor Cocktail, and one Roche Complete Mini, EDTA-free Protease Inhibitor Cocktail tablet per 10 ml buffer and stored frozen. Lysate aliquots were mixed with reducing SDS gel loading buffer and run on 10% PAGE. Immunoblots were performed as described previously, except primary antibodies, anti-phospho cMet (Cell Signaling, CS3077) and anti-total cMet (Cell Signaling, CS3127) were used and diluted in 5% BSA/TBST. Secondary antibodies, HRP-anti rabbit antibody (CS7074) and HRP-anti mouse (CS7076) were used, respectively. All antibodies were used at a 1:1000 dilution. Images were obtained and quantitated using BioRad ChemiDoc MP Imaging System. cMet phosphorylation signals were normalized using the total cMet signals and % inhibition calculated using the ratio of inhibited versus uninhibited HGFA Proteolytic reactions. Results were plotted in GraphPad Prism and a four parameter curve fit was used to determine the inhibitor EC50s.
  • As shown in FIG. 9, several inhibitors were effective at decreasing c-MET phosphorylation in a dose-dependent manner. Thus, these results show that these inhibitors of HGFA can function as non-kinase inhibitors of HGF-mediated c-MET kinase signaling in cancer. The most potent compound 5g had an EC50 of 180 nM.
    • Example 5. Synthesis of Ketobenzothiazole Inhibitor Compounds
  • The polypeptide ketobenzothiazoles (kbt) listed in Table 5.1 were synthesized in accordance with the general scheme 5A shown below and the procedures described below.
  • TABLE 5.1
    Polypeptide Compounds
    Figure US20220169676A1-20220602-C00132
    Compound No. Ac—P3—P2—P1—Kt W1
    1-13A1 H-WFR-kbt H
    1-18A1 H-dWFR-kbt H
    1-15A1 H-dWLR-kbt H
    1-56A1 H-WLR-kbt-COOH COOH
    1-56A1 H-dWLR-kbt-COOH COOH
    1-54A1 H-His(Bom)WLR-kbt H
    7182 H-LLR-kbt V amide Va1-NH2
    7185-1 Fmoc-AR-kbt H
    7185-2 Fmoc-RR-kbt H
    7185-3 Fmoc-NR-kbt H
    7185-4 Fmoc-DR-kbt H
    7185-6 Fmoc-QR-kbt H
    7185-7 Fmoc-ER-kbt H
    7185-8 Fmoc-GR-kbt H
    7185-9 Fmoc-HR-kbt H
    7185-10 Fmoc-IR-kbt H
    7185-11 Fmoc-LR-kbt H
    7185-12 Fmoc-KR-kbt H
    7187-13 Fmoc-MR-kbt H
    7187-14 Fmoc-FR-kbt H
    7187-15 Fmoc-PR-kbt H
    7187-16 Fmoc-SR-kbt H
    7188-17 Fmoc-TR-kbt H
    7188-18 Fmoc-WR-kbt H
    7188-19 Fmoc-YR-kbt H
    7188-20 Fmoc-VR-kbt H
  • Figure US20220169676A1-20220602-C00133
  • Tripeptides were synthesized in 0.5 mmol scale through consecutive coupling of amino acid-preloaded 2-Cl-trityl resin with Fmoc protected amino acids followed by the deprotection of Fmoc group. In the coupling reaction, 5 equiv. Fmoc-amino acid/5 equiv. HBTU/10 equiv. iPr2NEt was used and the mixture was shaken at room temperature overnight. In the deprotection of Fmoc group, piperidine/DMF (20% v/v) was employed and the mixture was shaken from 1 to 4 hours at room temperature to ensure complete reaction.
  • Peptide coupling and deprotection steps of the Fmoc group: Into the reaction vial (with a fritted glass resin support) containing H-Leu-2-Cl trityl, H-Phe-2-Cl trityl resin or H-Xxx-2-Cl trityl resin (0.714 g, 0.5 mmol), DMF/CH2Cl2 (15/15 mL) was added. The mixture was shaken at room temperature for 30 minutes, then filtered. The resulting resin was washed with DMF (10 mL) 2 times. Into another vial containing Fmoc-AA-OH (2.5 mmol) in DMF (20 mL), HBTU (0.853 g, 2.25 mmol) and iPr2NEt was added (0.87 mL, 5 mmol). The mixture was stirred at room temperature for 10 minutes, then added into the reaction vial containing the resin. The mixture was shaken at room temperature overnight, then filtered. The resin was washed with DMF (20 mL×4). To the resulting resin piperidine/DMF (20% v/v, 30 mL) was added. The mixture was shaken for 1-4 hours at room temperature, then filtered. The resin was washed with DMF (10 mL×4).
  • Acetyl capping of the tripeptides: The tripeptide resin was suspended in 30 mL of 0.5 M Ac2O/DMF and 1 M iPr2NEt/DMF. The mixture was shaken at room temperature for 1 hour. The resin was filtered and washed with DMF (10 mL×4) followed by CH2Cl2 (10 mL×4).
  • Cleavage of tripeptide resin: Ac-capped tripeptide resin was suspended and shaken in 30 ml of 25% v/v HFIP/CH2Cl2 for 1 hour. The mixture was filtered. The filtrate was concentrated then dried in vacuo, giving rise to crude product of Acetyl-capped tripeptides.
  • Boc-WF-OMe: Boc-Trp-OH (1 g, 3.28 mmol) and HCl.Phe-OMe (0.708g, 3.28 mmol) was taken in dry dichloromethane (10 mL) under nitrogen atmosphere and the reaction mixture was cooled to 0° C. and N,N-diisopropylethylamine (1.7 mL, 9.84 mmol) and propylphosphonic anhydride (1.9 mL, 3.28 mmol, 50% solution in EtOAc) were added to the solution drop wise respectively. The reaction mixture was then stirred at 25° C. under nitrogen atmosphere for 1 hour and the completion of the reaction was confirmed by LC-MS monitoring. On completion the reaction mixture was diluted with 10 mL dichloromethane and washed with 10% citric acid solution, saturated sodium bicarbonate solution and brine respectively. The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The crude product was triturated with hexane to obtain the title product in pure form as a white solid. Yield: 1.3 g (92.8%). Chemical formula: C23H33N3O5, Exact Mass: 465.55, MS(ESI): found: [M+Na]+, 488.58.
  • Boc-WF-OH: Boc-WF-OMe (0.130 g, 0.279 mmol) was taken in a 1:1 mixture of THF and water and LiOH.H2O (0.035g, 0.873 mmol) was added to it. The reaction mixture was stirred for 30 minutes at 25° C. and the completion of the reaction was confirmed by LCMS monitoring. On completion, the THF was evaporated under reduced pressure and the remaining water layer was cooled to 0° C. The water layer was then brought to pH 6.5 by slow addition of 0.5 M HCl solution in water. The crude product precipitates out on addition of HCl and it was isolated by filtration. The crude product was dried under reduced pressure and triturated with diethyl ether to obtain the pure title product in pure form as white solid. Yield: 0.102g (80%). Exact Mass: 451.21, MS(ESI): found: [M+H]+, 452.26.
  • Boc-WFR(Mtr)-kbt: Boc-WF-OH (35 mg, 0.077 mmol) and HATU (43.9 mg, 0.115 mmol) was taken in dry DMF under nitrogen atmosphere and the reaction mixture was cooled to 0° C. N,N-diisopropylethylamine (0.04 mL, 0.231 mmol) was then added drop wise to the reaction mixture and the reaction mixture was allowed to stir for 15 minutes followed by addition of HCl.Arg(Mtr)-kbt (41.75 mg, 0.077 mmol). The reaction mixture was stirred for 12 hours at 25° C. under nitrogen atmosphere and the completion of the reaction was confirmed by LC-MS monitoring. On completion, the reaction mixture was diluted with EtOAc and washed with 10% citric acid solution, saturated sodium bicarbonate solution and brine respectively. The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The crude product was directly taken to the next step without further purification. Chemical formula: C48H56N8O8S2, Exact Mass: 936.37, MS(ESI): found: [M+H]+, 937.17.
  • H-WFR-kbt (1-13A1): Boc-WFR(Mtr)-kbt (85 mg, crude product from previous step) was taken in 5 mL TFA:thioanisole:H2O (95:2.5:2.5) and the reaction mixture was stirred for 6 hours at 25° C. The completion of the reaction was confirmed by LC-MS monitoring. On completion, the reaction mixture was concentrated under reduced pressure and triturated with diethyl ether to obtain the crude product as brown solid. The crude product was then subjected to reverse phase semi-preparative HPLC (Stationary phase: C18 column, mobile phase: H2O-Acetonitrile with 0.1% TFA in each, 15-65% Acetonitrile in H2O gradient for 20 minutes) to obtain the pure title product as yellow solid. Yield: 20 mg (41% over two steps). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 8.08 (br. s., 1H), 7.67 (d, J=8.22 Hz, 1H), 7.37 (d, J=8.22 Hz, 1H), 7.10-7.25 (m, 5H), 6.94-7.05 (m, 1H), 6.82 (d, J=7.04 Hz, 2H), 6.14-6.29 (m, 1H), 5.12 (d, J=2.74 Hz, 1H), 4.69-4.82 (m, 1H), 4.45 (br. s., 1H), 3.62 (s, 3H), 3.09-3.37 (m, 1H), 2.95 (d, J=5.48 Hz, 2H), 1.62 (s, 1H), 1.43 (br. s., 9H). Chemical formula: C33H36N8O3S, Exact Mass: 624.26, MS (ESI): found: [M+H]+, 625.5.
  • Boc-dWF-OMe: The title compound was synthesized using the same procedure as Boc-WF-OMe starting with Boc-dTrp-OH. Yield: 90%. Chemical formula: C23H33N3O5, Exact Mass: 465.55, MS(ESI): found: [M+Na]+, 488.58.
  • Boc-dWF-OH: The title compound was synthesized using the same procedure as Boc-WF-OH starting with Boc-dWF-OMe. Yield: 80%. Exact Mass: 451.21, MS(ESI): found: [M+H]+, 452.26.
  • Boc-dWFR(Mtr)-kbt: The title compound was synthesized using the same procedure as Boc-WFR(Mtr)-kbt starting with Boc-dWF-OH. The crude product was directly taken to the next step. Chemical formula: C48H56N8O8S2, Exact Mass: 936.37, MS(ESI): found: [M+H]+, 937.17.
  • H-dWFR-kbt (1-18A1): The title compound was synthesized using the same procedure as H-WFR(Mtr)-kbt starting with Boc-dWF-OH. Yield: 25 mg (42% over two steps). Chemical formula: C33H36N8O3S, 1H NMR (400 MHz, METHANOL-d4) δ ppm 8.21 (d, J=6.65 Hz, 1H), 8.11 (d, J=7.43 Hz, 1H), 7.57-7.67 (m, 4H), 7.12-7.36 (m, 10H), 7.01-7.08 (m, 2H), 6.84 (s, 1H), 3.48 (d, J=1.96 Hz, 1H), 3.13 (d, J=6.65 Hz, 4H), 3.01-3.07 (m, 1H), 2.75-2.84 (m, 1H), 2.65 (s, 2H), 2.03 (s, 5H), 1.41 (d, J=8.61 Hz, 1H) Exact Mass: 624.26, MS (ESI): found: [M+H]+, 625.5.
  • Boc-dWL-OMe: The title compound was synthesized using the same procedure as Boc-WF-OMe starting with Boc-dTrp-OH and HCl.H-Leu-OMe. Yield: 92%. Chemical formula: C23H33N3O5, Exact Mass: 431.24, MS(ESI): found: [M+Na]+, 454.3.
  • Boc-dWL-OH: The title compound was synthesized using the same procedure as Boc-WF-OH starting with Boc-dWF-OMe. Yield: 83%. Exact Mass: 417.23, MS(ESI): found: [M+H]+, 418.26.
  • Boc-dWLR(Mtr)kbt: The title compound was synthesized using the same procedure as Boc-WFR(Mtr)-kbt starting with Boc-dWL-OH. The crude product was directly taken to the next step. Chemical formula: C45H58N8O8S2, Exact Mass: 902.38, MS(ESI): found: [M+H]+, 903.5.
  • H-dWLR-kbt (1-15A1): The title compound was synthesized using the same procedure as H-WFR(Mtr)-kbt starting with Boc-dWLR(Mtr)kbt. Yield: 22 mg (41% over two steps). Chemical formula: C C30H38N8O3S, 1H NMR (400 MHz, METHANOL-d4) δ ppm 10.58 (br. s., OH), 8.82 (s, 1H), 8.22-8.32 (m, 2H), 7.70 (dd, J=8.02, 16.24 Hz, 0H), 7.57-7.64 (m, 1H), 7.37 (d, J=6.26 Hz, 1H), 7.22 (d, J=13.30 Hz, 0H), 7.11-7.18 (m, 2H), 7.02-7.10 (m, 1H), 5.55-5.67 (m, 1H), 4.47-4.58 (m, OH), 4.35 (dd, J=5.09, 10.17 Hz, 0H), 4.05-4.31 (m, 2H), 3.37-3.55 (m, 1H), 3.07-3.27 (m, 3H), 2.65 (s, 1H), 2.18 (dd, J=6.06, 13.11 Hz, 1H), 1.57-1.95 (m, 3H), 1.16-1.52 (m, 2H), 1.06 (td, J=7.14, 13.89 Hz, 1H), 0.91-1.00 (m, 2H), 0.65-0.81 (m, 6H) Exact Mass: 624.26, MS (ESI): found: [M+H]+, 625.5.
  • H-dWFRkbt-COOH (1-45A1): The title compound was synthesized using the same procedure as WFR(Mtr)kbt starting with Boc-dWFR(Mtr)kbt-COOH. Yield: 24 mg (43% over two steps). Chemical formula: C34H36N8O5S, 1H NMR (400 MHz, METHANOL-d4) δ ppm 10.58 (br. s., OH), 8.82 (s, 1H), 8.22-8.32 (m, 2H), 7.70 (dd, J=8.02, 16.24 Hz, 0H), 7.57-7.64 (m, 1H), 7.37 (d, J=6.26 Hz, 1H), 7.22 (d, J=13.30 Hz, 0H), 7.11-7.18 (m, 2H), 7.02-7.10 (m, 1H), 5.55-5.67 (m, 1H), 4.47-4.58 (m, OH), 4.35 (dd, J=5.09, 10.17 Hz, 0H), 4.05-4.31 (m, 2H), 3.37-3.55 (m, 1H), 3.07-3.27 (m, 3H), 2.65 (s, 1H), 2.18 (dd, J=6.06, 13.11 Hz, 1H), 1.57-1.95 (m, 3H), 1.16-1.52 (m, 2H), 1.06 (td, J=7.14, 13.89 Hz, 1H), 0.91-1.00 (m, 2H), 0.65-0.81 (m, 6H) Exact Mass: 668.253, MS (ESI): found: [M+H]+, 669.5.
  • H-WLRkbt-COOH (1-56A1): The title compound was synthesized using the same procedure as WLR(Mtr)kbt starting with Boc-WLR(Mtr)kbt-COOH. Yield: 26 mg (44% over two steps). Chemical formula: C31H38N8O5S, 1H NMR (400 MHz, METHANOL-d4) δ ppm 8.77-8.84 (m, 1H), 8.22-8.32 (m, 3H), 7.57-7.71 (m, 1H), 7.31-7.42 (m, 2H), 7.04-7.23 (m, 3H), 4.09-4.13 (m, 1H), 3.48 (s, 1H), 3.22-3.27 (m, 2H), 3.13 (s, 1H), 2.65 (s, 2H), 1.62 (d, J=7.04 Hz, 1H), 1.17 (s, 1H), 0.90-1.00 (m, 6H), 0.65-0.80 (m, 7H) Exact Mass: 634.269, MS (ESI): found: [M+H]+, 635.8.
  • H-dWLRkbt-COOH (1-56A1): The title compound was synthesized using the same procedure as dWLR(Mtr)kbt starting with Boc-dWLR(Mtr)kbt-COOH. Yield: 25 mg (42% over two steps). Chemical formula: C31H38N8O5S, 1H NMR (400 MHz, METHANOL-d4) δ ppm 10.58 (br. s., OH), 8.82 (s, 1H), 8.22-8.32 (m, 2H), 7.70 (dd, J=8.02, 16.24 Hz, 0H), 7.57-7.64 (m, 1H), 7.37 (d, J=6.26 Hz, 1H), 7.22 (d, J=13.30 Hz, 0H), 7.11-7.18 (m, 2H), 7.02-7.10 (m, 1H), 5.55-5.67 (m, 1H), 4.47-4.58 (m, OH), 4.35 (dd, J=5.09, 10.17 Hz, 0H), 4.05-4.31 (m, 2H), 3.37-3.55 (m, 1H), 3.07-3.27 (m, 3H), 2.65 (s, 1H), 2.18 (dd, J=6.06, 13.11 Hz, 1H), 1.57-1.95 (m, 3H), 1.16-1.52 (m, 2H), 1.06 (td, J=7.14, 13.89 Hz, 1H), 0.91-1.00 (m, 2H), 0.65-0.81 (m, 6H) Exact Mass: 634.269, MS (ESI): found: [M+H]+, 635.8.
  • Fmoc-H(Bom)WL-OMe: The title compound was synthesized using same procedure described as Boc-WF-OMe starting from Fmoc-His(Bom)-OH and HCl.H-WL-OMe. The crude product was directly taken to the next step. Chemical formula: C47H50N6O7, Exact Mass: 810.5, MS(ESI): found: [M+H]+, 811.78.
  • Fmoc-H(Bom)WL-OH: The title compound was synthesized using same procedure described as Boc-WF-OH starting from Fmoc-His(Bom)WL-OMe. Yield: 76%. Chemical formula: C46H48N6O7, Exact Mass: 796.35, MS(ESI): found: [M+H]+, 797.78.
  • Fmoc-H(Bom)WLR(Mtr)-Kbt: The title compound was synthesized using same procedure described as Boc-WF-RKbt starting from Fmoc-His(Bom)WL-OH and HCl.H-Arg(Mtr)-Kbt. Yield: 65%. Exact Mass: 1281.514, MS(ESI): found: [M+H]+, 1262.7.
  • H(Bom)WLR-Kbt (1-54A1): The title compound was synthesized using same procedure described as H-WF-RKbt starting from Fmoc-His(Bom)WLR(Mtr)Kbt, followed by a treatment with 4M HCl solution. Yield: 20% over three steps. Exact Chemical formula: C44H53N11O5S, 1H NMR (400 MHz, METHANOL-d4) δ ppm 7.89 (d, J=7.83 Hz, 4H), 7.71 (d, J=7.43 Hz, 4H), 7.46-7.52 (m, 4H), 7.39-7.45 (m, 4H), 4.49 (t, J=5.28 Hz, 2H), 3.83 (d, J=5.48 Hz, 5H), 3.42 (d, J=12.13 Hz, 4H), 2.99 (t, J=11.54 Hz, 4H), 1.88 (br. s., 6H), 1.75 (br. s., 8H), 1.44-1.60 (m, 2H) Mass: 847.3, MS(ESI): found: [M+H]+, 848.7.
  • H(Bom)dWLR-Kbt (1-58A1): The title compound was synthesized using same procedure described as H-WF-RKbt starting from Fmoc-dHis(Bom)WLR(Mtr)Kbt, followed by a treatment with 4M HCl solution. Yield: 36% over three steps. Exact Chemical formula: C44H53N11O5S, 1H NMR (400 MHz, METHANOL-d4) δ ppm 7.89 (d, J=7.83 Hz, 4H), 7.71 (d, J=7.43 Hz, 4H), 7.46-7.52 (m, 4H), 7.39-7.45 (m, 4H), 4.49 (t, J=5.28 Hz, 2H), 3.83 (d, J=5.48 Hz, 5H), 3.42 (d, J=12.13 Hz, 4H), 2.99 (t, J=11.54 Hz, 4H), 1.88 (br. s., 6H), 1.75 (br. s., 8H), 1.44-1.60 (m, 2H) Mass: 847.3, MS(ESI): found: [M+H]+, 848.7.
  • Boc-LL-OMe: The title compound was synthesized using the same procedure as Boc-dWL-OMe starting with Boc-Leu-OH and HCl.H-Leu-OMe.
  • Boc-LL-OH: The title compound was synthesized using the same procedure as Boc-dWL-OH starting with Boc-LL-OMe. Exact Mass: 417.5 MS(ESI): found: [M+H]+ 418.6
  • H-LLR-kbt V amide (7182). Synthesized in a similar manner to H-WFRkbt from Boc-LLR(Mtr)-Kbt V amide. Yield 4.6 mg. Chemical Formula: C31H49N9O5S, Exact Mass: 659.36, MS(ESI): found: [M+H]+, 660.6.
  • Boc-WL-OH: The title compound was synthesized using the same procedure as Boc-dWL-OH starting with Boc-WL-OMe. Exact Mass: 417.2, MS(ESI): found: [M+H]+, 418.3.
  • H-WLR-kbt V amide (7181). Synthesized in a similar manner to H-dWLR-kbt from Boc-WLR(Mtr)-kbt V amide. Yield 4.5 mg. Chemical Formula: C36H48N10O5S, Exact Mass: 732.35, MS(ESI): found: [M+H]+, 733.6.
  • Boc-R(Mtr)L-OH: The title compound was synthesized using the same procedure as Boc-dWL-OH starting with Boc-R(Mtr)L-OMe. Exact Mass: MS(ESI): 599.7 found: [M+H]+, 600.8.
  • H-RLR-kbt V amide (7180). Yield 5 mg. 1H NMR (400 MHz, METHANOL-d4) δ ppm 8.90 (d, J=7.04 Hz, 0H), 8.65 (s, 1H), 8.35 (d, J=8.61 Hz, 1H), 8.28 (d, J=8.61 Hz, 1H), 8.10 (d, J=9.00 Hz, 1H), 5.53-5.61 (m, 1H), 4.42-4.55 (m, 2H), 3.92 (t, J=5.87 Hz, 1H), 3.18 (t, J=6.85 Hz, 2H), 2.20 (qd, J=6.81, 13.60 Hz, 2H), 1.86-1.98 (m, 3H), 1.70-1.82 (m, 3H), 1.56-1.68 (m, 3H), 1.07 (dd, J=4.30, 6.65 Hz, 6H), 0.96 (d, J=6.26 Hz, 16H). Chemical Formula: C31H50N2O5S, Exact Mass: 702.37, MS(ESI): found: [M+H]+, 703.6.
  • Fmoc-A-R-kbt (7185-1). Under nitrogen atmosphere, Fmoc-A-OH (0.02 mmol) was dissolved in DMF (10 mL) and then HATU (0.02 mmol) was added. After stirring for 10 minutes, H-R(Mtr)-kbt-HCl (0.0185 mmol) and N,N-diisopropylethylamine (0.1 mmol) were added. The mixture was stirred at room temperature for 4 hours. The solvent was removed and then 1.5 mL of cleavage cocktail (38:1:1 TFA/water/thioanisole) was added and then the reaction was stirred for 4 hours. After concentration in vacuo, the residue was purified by C18 reverse phase HPLC to give the title compound as a lyophilized white powder.
  • Fmoc-RR-kbt (7185-2). The title compound was synthesized using the same procedure as (7185-1). Chemical formula C34H39N9O4S, Exact Mass 669.28, MS(ESI): found [M+H]+ 670.4.
  • Fmoc-NR-kbt (7185-3). The title compound was synthesized using the same procedure as (7185-1). Chemical formula C32H33N7O5S, Exact Mass 627.23, MS(ESI): found [M+H]+ 628.3.
  • Fmoc-DR-kbt (7185-4). The title compound was synthesized using the same procedure as (7185-1). Chemical formula C32H32N6O6S, Exact Mass, 628.21, MS(ESI): found [M+H]+ 629.3.
  • Fmoc-QR-kbt (7185-6). The title compound was synthesized using the same procedure as (7185-1). Chemical formula C33H35N7O5S, Exact Mass 641.24, MS(ESI): found [M+H]+ 642.4.
  • Fmoc-ER-kbt (7185-7). The title compound was synthesized using the same procedure as (7185-1). Chemical formula C33H34N6O6S, Exact Mass 642.23, MS(ESI): found [M+H]+ 643.3.
  • Fmoc-GR-kbt (7185-8). The title compound was synthesized using the same procedure as (7185-1). Chemical formula C30H30N6O4S, Exact Mass 570.2, MS(ESI): found [M+H]+ 571.3.
  • Fmoc-HR-kbt (7185-9). The title compound was synthesized using the same procedure as (7185-1). Chemical formula C34H34N8O4S, Exact Mass 650.24, MS(ESI): found [M+H]+ 651.4.
  • Fmoc-IR-kbt (7185-10). The title compound was synthesized using the same procedure as (7185-1). Chemical formula C34H38N6O4S, Exact Mass 626.27, MS(ESI): found [M+H]+ 627.4.
  • Fmoc-LR-kbt (7185-11). The title compound was synthesized using the same procedure as (7185-1). Chemical formula C34H38N6O4S, Exact Mass 626.27, MS(ESI): found [M+H]+ 627.4.
  • Fmoc-KR-kbt (7185-12). The title compound was synthesized using the same procedure as (7185-1). Chemical formula C34H39N7O4S, Exact Mass 641.28, MS(ESI): found [M+H]+ 642.5.
  • Fmoc-MR-kbt (7187-13). The title compound was synthesized using the same procedure as (7185-1). Chemical formula C32H34N6O4S2, Exact Mass 630.21, MS(ESI): found [M+H]+ 631.3.
  • Fmoc-FR-kbt (7187-14). The title compound was synthesized using the same procedure as (7185-1). Chemical formula C37H36N6O4S, Exact Mass 660.25, MS(ESI): found [M+H]+ 661.4.
  • Fmoc-PR-kbt (7187-15). The title compound was synthesized using the same procedure as (7185-1). Chemical formula C33H34N6O4S, Exact Mass 610.24, MS(ESI): found [M+H]+ 611.5.
  • Fmoc-SR-kbt (7187-16). The title compound was synthesized using the same procedure as (7185-1). Chemical formula C31H32N6O5S, Exact Mass 600.22, MS(ESI): found [M+H]+ 601.3.
  • Fmoc-TR-kbt (7188-17). The title compound was synthesized using the same procedure as (7185-1). Chemical formula C32H34N6O5S, Exact Mass 614.23, MS(ESI): found [M+H]+ 615.4.
  • Fmoc-WR-kbt (7188-18). The title compound was synthesized using the same procedure as (7185-1). Chemical formula C39H37N7O4S, Exact Mass 699.26, MS(ESI): found [M+H]+ 700.4.
  • Fmoc-YR-kbt (7188-19). The title compound was synthesized using the same procedure as (7185-1). Chemical formula C37H36N6O5S, Exact Mass 676.25, MS(ESI): found [M+H]+ 677.4.
  • Fmoc-VR-kbt (7188-20). The title compound was synthesized using the same procedure as (7185-1). Chemical formula C33H36N6O4S, Exact Mass 612.25, MS(ESI): found [M+H]+ 613.5.
  • The tetrapeptide ketothiazoles listed in Table 5.2 were synthesized in accordance with the procedures and schemes described below.
  • TABLE 5.2
    Tetrapeptide ketobenzothiazoles.
    Figure US20220169676A1-20220602-C00134
    Compound No. Y—P4—P3—P2—P1—Z W1
    7115 Ac-KRLR(SEQ ID NO: 8)-Kbt-Va1-NH2
    Figure US20220169676A1-20220602-C00135
    7054 Ac-KRLR(SEQ ID NO: 8)-Kbt H
    7117 H-WRLR(SEQ ID NO: 9)-Kbt H
    1-45A1 H-dWFR-kbt-COOH COOH
    7055 Ac-KQLR(SEQ ID NO: 1)-Kbt-Va1-NH2
    Figure US20220169676A1-20220602-C00136
    7116 Ac-SKLR(SEQ ID NO: 10)-Kbt-Val- NH2
    Figure US20220169676A1-20220602-C00137
    7124 Ac-SKLR(SEQ ID NO: 10)-Kbt-Trp- NH2
    Figure US20220169676A1-20220602-C00138
    7125 Ac-SKLR(SEQ ID NO: 10)-Kbt-Phe- NHs
    Figure US20220169676A1-20220602-C00139
    7006 Ac-KQLR(SEQ ID NO: 1)-Kbt H
    7126 Ac-SKLR(SEQ ID NO: 10)-Kbt-4- pyridinylamide
    Figure US20220169676A1-20220602-C00140
    7053 Ac-SKLR(SEQ ID NO: 10)-Kbt H
    7063 Ac-FLFR(SEQ ID NO: 19)-Kbt H
    7118 Ac-SKLR(SEQ ID NO: 10)-Kbt-COOH
    Figure US20220169676A1-20220602-C00141
    7064 Ac-WLFR(SEQ ID NO: 20)-Kbt H
    7139 Ac-SKLR(SEQ ID NO: 10)-Kbt- benzylamide
    Figure US20220169676A1-20220602-C00142
    7140 Ac-SKLR(SEQ ID NO: 10)-Kbt-4- piperidinylamide
    Figure US20220169676A1-20220602-C00143
    7165 Ac-KRLR(SEQ ID NO: 8)-Kbt-5-COOH
    Figure US20220169676A1-20220602-C00144
  • Procedure for the Preparation of Tetrapeptide Ketobenzothiazole: Tripeptides were synthesized in 0.5 mmol scale through consecutive coupling of amino acid-preloaded 2-Cl-trityl resin with Fmoc protected amino acids followed by the deprotection of Fmoc group. In the coupling reaction, 5 equiv. Fmoc-amino acid/4.5 equiv. HBTU/10 equiv. iPr2NEt was used and the mixture was shaken at room temperature overnight. In the deprotection of Fmoc group, piperidine/DMF (20% v/v) was employed and the mixture was shaken for 4 hours at room temperature.
  • Figure US20220169676A1-20220602-C00145
  • Peptide coupling and deprotection of Fmoc: Into the reaction vial (with a fritted glass resin support) containing H-Leu-2-Cl-trityl resin (0.714 g, 0.5 mmol), DMF/CH2Cl2 (15/15 mL) was added. The mixture was shaken at room temperature for 30 minutes, then filtered. The resulting resin was washed with DMF (10 mL×2). Into another vial containing Fmoc-AA-OH (2.5 mmol) in DMF (20 mL), HBTU (0.853 g, 2.25 mmol) and iPr2NEt was added (0.87 mL, 5 mmol). The mixture was stirred at room temperature for 10 minutes, then added into the reaction vial containing the resin. The mixture was shaken at room temperature overnight, then filtered. The resin was washed with DMF (20 mL×4). To the resulting resin piperidine/DMF (20% v/v, 30 mL) was added. The mixture was shaken for 4 hours at room temperature, then filtered. The resin was washed with DMF (10 mL×4).
  • Acetyl capping of the tripeptides: The tripeptide resin was suspended in 30 mL of 0.5 M Ac2O/DMF and 1 M iPr2NEt/DMF. The mixture was shaken at room temperature for 1 hour. The resin was filtered and washed with DMF (10 mL×4) followed by CH2Cl2 (10 mL×4).
  • Cleavage of tripeptide resin: Ac-capped tripeptide resin was suspended and shaked in 30 ml of 25% v/v HFIP/CH2Cl2 for 1 hour. The mixture was filtered. The filtrate was concentrated then dried in vacuo, giving rise to crude product of Ac-capped tripeptide.
  • Figure US20220169676A1-20220602-C00146
  • BocHN-Arg(Mtr) ketobenzothiazole. At −78° C., n-BuLi/Hex (2.5M) (14 mL, 35 mmol) was added dropwise into the solution of benzothiazole (4.87 g, 36 mmol) in THF (50 mL) over 15 minutes. After the mixture was stirred for additional half an hour, the solution of Boc-HN-Arg(Mtr) Weinreb amide (1.06 g, 2 mmol) in THF (15 mL) was added slowly over 50 min. For synthesis of Weinreb amide, see Han et al., “Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer, Acs Med Chem Lett (2014) 5, 1219-1224. The mixture was stirred at −78° C. for additional 2 hours. The reaction was quenched with aqueous NH4Cl and the aqueous layer was extracted with AcOEt. The organic phase was collected, dried with Na2SO4, then concentrated. The resulting residue was purified by silica gel chromatography with CHCl3/MeOH combination as eluent to give the title compound (1.14 g) in 94% yield. 1H NMR (400 MHz, METHANOL-d4) δ ppm 1.43 (s, 9H) 1.53-1.78 (m, 4H) 2.05 (s, 3H) 2.55 (s, 3H) 2.61 (s, 3H) 3.17-3.29 (m, 2H) 3.82 (s, 3H) 5.19-5.43 (m, 1H) 6.57 (s, 1H) 7.53-7.71 (m, 2H) 8.06-8.28 (m, 2H). MS(ESI): found: [M+H]+, 604.4.
  • HCl.H2N-Arg(Mtr) ketobenzothiazole. The mixture of BocHN-Arg(Mtr) ketobenzothiazole (1.0 g, 1.66 mmol) in 30 mL of HCl/dioxane (1.5 M) was stirred at room temperature. The reaction was monitored by LCMS until completion. The solvent was removed then the resulting residue was dried in vacuo to the tile product in quantitative yield. 1H NMR (400 MHz, METHANOL-d4) δ ppm 1.60-1.86 (m, 2H) 2.00-2.20 (m, 4H) 2.24-2.36 (m, 1H) 2.53 (s, 3H) 2.61 (s, 3H) 3.84 (s, 3H) 5.14-5.40 (m, 1H) 6.65 (s, 1H) 7.59-7.78 (m, 2H)_8.10-8.34 (m, 2H). MS(ESI): found: [M+H]+504.4.
  • Figure US20220169676A1-20220602-C00147
  • Ac-KQLR (SEQ ID NO: 1) ketobenzothiazole (7006). Under nitrogen atmosphere, at 0° C. anhydrous DMF (5 mL) was added into the round bottom flask containing AcHN-K(Boc)-Q(Trt)-L-OH tripeptide (0.064 g, 0.083 mmol) and HATU (0.035 g, 0.091 mmol). After stirring for 10 minutes, Mtr-protected arginine ketobenzothiazole (0.068 g, 0.013 mmol), then N,N-diisopropylethylamine (0.053 g, 0.41 mmol) were added. The mixture was stirred at room temperature for 4 hours while being warmed to room temperature naturally. DMF was removed and to the resulting residue water (20 mL) was added. The precipitate formed was filtered and dried. To this precipitate 5 mL of TFA/thioanisole/water (95/2.5/2.5 (v/v/v)) was added. The mixture was stirred at room temperature for 4 hours. Then cold ether (40 mL) was added. The resulting precipitate, which is the crude product, was collected by centrifugation, then by decanting out carefully ether solvent. The crude product was purified by HPLC (C18, 15*150 mm column; eluent: acetonitrile/water (0.05% TFA)) to give Ac-KQLR (SEQ ID NO: 1) ketobenzothiazole (0.030 g) in 43% yield. 1H NMR (400 MHz, METHANOL-d4) δ ppm 0.88 (d, J=6.26 Hz, 3H) 0.92 (d, J=6.26 Hz, 3H) 1.36-1.90 (m, 12H) 1.90-2.26 (m, 3H) 2.02 (s, 3H) 2.26-2.44 (m, 2H) 2.87-2.97 (m, 2H) 3.20-3.40 (m, 2H) 4.21-4.29 (m, 1H) 4.31-4.38 (m, 1H) 4.39-4.48 (m, 1H) 5.63-5.78 (m, 1H) 7.54-7.74 (m, 2H) 8.08-8.16 (m, 1H) 8.19-8.29 (m, 1H). MS(ESI): found: [M+H]+, 703.6.
  • Ac-SKLR (SEQ ID NO: 10) ketobenzothiazole (7053). (yield: 23%). Synthesized using the same procedure as for Ac-KQLR (SEQ ID NO: 1) ketobenzothiazole. 1H NMR (400 MHz, METHANOL-d4) δ ppm 0.87 (d, J=6.65 Hz, 3H) 0.91 (d, J=6.65 Hz, 3H) 1.36-2.08 (m, 12H) 2.01 (s, 3H) 2.10-2.29 (m, 1H) 2.82-3.04 (m, 2H) 3.22-3.38 (m, 2H) 3.65-3.93 (m, 2H) 4.24-4.53 (m, 3H) 5.58-5.74 (m, 1H) 7.56-7.71 (m, 2H) 8.08-8.16 (m, 1H) 8.18-8.25 (m, 1H). MS(ESI): found: [M+H]+, 662.5.
  • Ac-KRLR (SEQ ID NO: 8) ketobenzothiazole (7054). (yield: 38%). Synthesized using the same procedure as for Ac-KQLR (SEQ ID NO: 1) ketobenzothiazole. 1H NMR (400 MHz, METHANOL-d4) δ ppm 0.90 (d, J=6.80 Hz, 3H) 0.94 (d, J=6.80 Hz, 3H) 1.36-1.96 (m, 16H) 1.99 (s, 3H) 2.09-2.34 (m, 1H) 2.87-2.98 (m, 2H) 3.14-3.23 (m, 2H) 3.25-3.33 (m, 2H) 4.20-4.30 (m, 1H) 4.33-4.52 (m, 2H) 5.54-5.76 (m, 1H) 7.59-7.70 (m, 2H) 8.10-8.16 (m, 1H) 8.18-8.23 (m, 1H). MS(ESI): found: [M+H]+, 731.7.
  • Ac-FLFR (SEQ ID NO: 19) ketobenzothiazole (7063). (yield: 47%). Synthesized using the same procedure as for Ac-KQLR (SEQ ID NO: 1) ketobenzothiazole. 1H NMR (400 MHz, METHANOL-d4) δ ppm 0.85 (d, J=6.26 Hz, 3H) 0.90 (d, J=6.26 Hz, 3H) 1.36-1.63 (m, 3H) 1.66-1.99 (m, 3H) 1.91 (s, 3H) 2.05-2.25 (m, 1H) 2.80-2.91 (m, 1H) 2.92-3.02 (m, 1H) 3.02-3.18 (m, 2H) 3.20-3.33 (m, 2H) 4.19-4.39 (m, 1H) 4.47-4.70 (m, 2H) 5.64-5.75 (m, 1H) 7.01-7.33 (m, 10H) 7.57-7.71 (m, 2H) 8.10-8.17 (m, 1H) 8.19-8.25 (m, 1H). MS(ESI): found: [M+H]+, 741.6.
  • Ac-WLFR (SEQ ID NO: 20) ketobenzothiazole (7064). (yield: 19%). Synthesized using the same procedure as for Ac-KQLR (SEQ ID NO: 1) ketobenzothiazole. 1H NMR (400 MHz, METHANOL-d4) δ ppm 0.79 (d, J=6.26 Hz, 3H) 0.84 (d, J=6.26 Hz, 3H) 1.32-1.50 (m, 3H) 1.62-1.91 (m, 3H) 1.95 (s, 3H) 2.06-2.21 (m, 1H) 2.88-3.00 (m, 1H) 3.05-3.29 (m, 5H) 4.14-4.33 (m, 1H) 4.50-4.72 (m, 2H) 5.61-5.77 (m, 1H) 6.96-7.03 (m, 1H) 7.04-7.20 (m, 7H) 7.29-7.37 (m, 1H) 7.54-7.71 (m, 3H) 7.85-7.97 (m, 1H) 8.10-8.16 (m, 1H) 8.18-8.26 (m, 1H). MS(ESI): found: [M+H]+, 780.6.
  • WRLR (SEQ ID NO: 9) ketobenzothiazole (7117). (yield: 39%). Synthesized using the same procedure as for Ac-KQLR (SEQ ID NO: 1) ketobenzothiazole, starting with the coupling of BocHN-W-R(Mtr)-L-OH tripeptide and Mtr-protected arginine ketobenzothiazole. 1H NMR (400 MHz, METHANOL-d4) δ ppm 0.94 (d, J=6.65 Hz, 3H) 0.95 (d, J=6.65 Hz, 3H) 1.48-1.99 (m, 10H) 2.12-2.30 (m, 1H) 3.14-3.23 (m, 3H) 3.24-3.29 (m, 2H) 3.39-3.52 (m, 1H) 4.18-4.29 (m, 1H) 4.37-4.53 (m, 2H) 5.61-5.68 (m, 1H) 7.01-7.09 (m, 1H) 7.10-7.17 (m, 1H) 7.22 (s, 1H) 7.34-7.41 (m, 1H) 7.58-7.71 (m, 3H) 8.10-8.16 (m, 1H) 8.17-8.24 (m, 1H) 8.25-8.33 (m, 1H). MS(ESI): found: [M+H]+, 747.7.
  • Figure US20220169676A1-20220602-C00148
  • BocHN-Arg(Mtr) ketobenzothiazole-6-COOH. At −78° C., nBuLi/Hex (2.5M) (28.5 mL, 71.4 mmol) was added dropwise into the solution of 6-carboxybenzothiazole (6.57 g, 37 mmol) in THF (450 mL) over 25 minutes. After the mixture was stirred for additional half an hour, the solution of Boc-HN-Arg(Mtr) Weinreb amide (1.63 g, 3.08 mmol) in THF (60 mL) was added slowly over 20 minutes at −78° C. After the addition then the mixture was stirred at −24° C. to −20° C. for 1.5 hours. The reaction was quenched with saturated aqueous NH4Cl (270 mL). The layers were separated and the aqueous layer was extracted with AcOEt. The organic phase was collected and washed with water, 5% citric acid, then dried with Na2SO4 and concentrated. The resulting residue was purified by silica gel chromatography with CH2Cl2/MeOH combination as eluent to give the title compound (0.91 g) in 46% yield. 1H NMR (400 MHz, METHANOL-d4) δ ppm 1.43 (s, 9H) 1.66 (m, 4H) 2.03 (s, 3H) 2.54 (s, 3H) 2.60 (s, 3H) 3.22-3.29 (m, 2H) 3.80 (s, 3H) 5.18-5.41 (m, 1H) 6.55 (s, 1H) 8.20 (m, 2H) 8.79 (s, 1H). MS(ESI): found: [M+H]+, 648.4.
  • Figure US20220169676A1-20220602-C00149
  • BocHN-Arg(Mtr) ketobenzothiazole-6-CONH-Val-amide. Under nitrogen atmosphere, at 0° C. anhydrous DMF (5 mL) was added into the round bottom flask containing BocHN-Arg(Mtr) ketobenzothiazole-COOH (0.060 g, 0.093 mmol) and HATU (0.042 g, 0.11 mmol). After stirring for 10 minutes, L-valine amide hydrochloride (0.017 g, 0.11 mmol), then N,N-diisopropylethylamine (0.062 g, 0.55 mmol) were added. The mixture was stirred overnight while being warmed to room temperature naturally. DMF was removed and to the resulting residue 20 mL water was added. The precipitate formed was filtered and dried. The product was purified by silica gel chromatography with CHCl3/MeOH combination as eluent to give the title compound (0.049 g) in 70% yield 1H NMR (400 MHz, METHANOL-d4) δ ppm 1.06 (d, J=1.57 Hz, 3H) 1.08 (d, J=1.96 Hz, 3H) 1.42 (s, 9H) 1.56-1.79 (m, 4H) 2.04 (s, 3H) 2.15-2.30 (m, 1H) 2.55 (s, 3H) 2.60 (s, 3H) 3.20-3.28 (m, 2H) 3.80 (s, 3H) 4.45 (d, J=7.43 Hz, 1H) 5.19-5.41 (m, 1H) 6.57 (s, 1H) 8.00-8.12 (m, 1H) 8.13-8.29 (m, 1H) 8.62 (s, 1H). MS(ESI): found: [M+H]+, 746.5.
  • HCl.H2N-Arg(Mtr) ketobenzothiazole-6-CONH-Val-amide. The mixture of BocHN-Arg(Mtr) ketobenzothiazole-(C═O)-V-amide (0.049 g, 0.066 mmol) in 10 mL of HCl/dioxane (2.5 M) was stirred at room temperature. The reaction was monitored by LCMS until completion. The solvent was removed then the resulting residue was dried in vacuo to the tile product in quantitative yield. 1H NMR (400 MHz, METHANOL-d4) δ ppm 1.06 (d, J=3.13 Hz, 3H) 1.08 (d, J=3.13 Hz, 3H) 1.58-1.91 (m, 2H) 1.95-2.41 (m, 6H) 2.52 (s, 3H) 2.61 (s, 3H) 3.85 (s, 3H) 4.46 (d, J=7.40 Hz, 1H) 5.16-5.38 (m, 1H) 6.66 (bs, 1H) 7.99-8.18 (m, 1H) 8.22-8.39 (m, 1H) 8.55-8.78 (m, 1H). MS(ESI): found: [M+H]+, 646.5.
  • Figure US20220169676A1-20220602-C00150
  • Ac-KQLR (SEQ ID NO: 1) ketobenzothiazole-6-CONH-Val-amide (7055). The title compound was synthesized using the same procedure as for the tetrapeptide ketothiazoles, starting with the coupling of protected Ac-K(Boc)-Q(Trt)-L-OH tripeptide and HCl.H2N-Arg(Mtr) ketobenzothiazole-(C═O)-V-amide. Yield: 11%. 1H NMR (400 MHz, METHANOL-d4) δ ppm 0.87 (d, J=6.00 Hz, 3H) 0.92 (d, J=6.00 Hz, 3H) 1.06 (d, J=2.74 Hz, 3H) 1.08 (d, J=2.74 Hz, 3H) 1.37-2.14 (m, 14H) 2.02 (s, 3H) 2.14-2.43 (m, 4H) 2.87-3.00 (m, 2H) 3.22-3.38 (m, 2H) 4.20-4.29 (m, 1H) 4.29-4.38 (m, 1H) 4.39-4.50 (m, 2H) 5.58-5.75 (m, 1H) 8.05-8.14 (m, 1H) 8.24-8.33 (m, 1H) 8.62-8.67 (m, 1H). MS(ESI): found: [M+H]+, 845.7.
  • Ac-SKLR (SEQ ID NO: 10) ketobenzothiazole-6-CONH-Val-amide (7116). The title compound was synthesized using the same procedure as for Ac-KQLR (SEQ ID NO: 1) ketobenzothiazole-(C═O)-V-amide. Yield: 24%. 1H NMR (400 MHz, METHANOL-d4) δ ppm 0.87 (d, J=6.46 Hz, 3H) 0.91 (d, J=6.46 Hz, 3H) 1.06 (d, J=2.54 Hz, 3H) 1.07 (d, J=2.54 Hz, 3H) 1.37-1.97 (m, 12H) 2.01 (s, 3H) 2.13-2.28 (m, 2H) 2.79-3.03 (m, 2H) 3.22-3.38 (m, 2H) 3.67-3.98 (m, 2H) 4.23-4.54 (m, 4H) 5.49-5.77 (m, 1H) 8.07-8.12 (m, 1H) 8.25-8.32 (m, 1H) 8.61-8.66 (m, 1H). MS(ESI): found: [M+H]+, 804.7.
  • Ac-KRLR (SEQ ID NO: 8) ketobenzothiazole-6-CONH-Val-amide (7115). The title compound was synthesized using the same procedure as for Ac-KQLR (SEQ ID NO: 1) ketobenzothiazole-(C═O)-V-amide. Yield: 28%. 1H NMR (400 MHz, METHANOL-d4) δ ppm 0.92 (dd, J=11.15, 6.46 Hz, 6H) 1.07 (dd, J=6.65, 2.74 Hz, 6H) 1.35-1.95 (m, 16H) 1.99 (s, 3H) 2.14-2.27 (m, 2H) 2.87-2.98 (m, 2H) 3.14-3.21 (m, 2H) 3.25-3.33 (m, 2H) 4.21-4.28 (m, 1H) 4.33-4.39 (m, 1H) 4.40-4.49 (m, 2H) 5.46-5.74 (m, 1H) 8.07-8.12 (m, 1H) 8.24-8.33 (m, 1H) 8.61-8.68 (m, 1H). MS(ESI): found: [M+H]+, 873.7.
  • Figure US20220169676A1-20220602-C00151
  • H-R (Mtr) ketobenzothiazole-(C═O)-NHBn(4-COOMe)-HCl. The title compound was synthesized from using the same procedure as HCl.H-Arg(Mtr) ketobenzothiazole-6-CONH-Val-amide. Yield, 85 mg, MS(ESI): found: [M+H]+, 695.4.
  • Figure US20220169676A1-20220602-C00152
  • Ac-KRLR (SEQ ID NO: 8) ketobenzothiazole-(C═O)-NHBn(4-COOMe) (23a). The title compound was synthesized from H-R ketobenzothiazole-(C═O)-NHBn(4-COOMe)-HCl using the same procedure as Ac-KQLR (SEQ ID NO: 1) ketobenzothiazole-6-CONH-Val-amide and was purified by HPLC. Yield: 23% over two steps. 1H NMR (400 MHz, METHANOL-d4) δ ppm 0.90 (d, J=6.26 Hz, 3H) 0.93 (d, J=6.65 Hz, 3H) 1.37-1.95 (m, 16H) 1.99 (s, 3H) 2.13-2.28 (m, 1H) 2.87-2.97 (m, 2H) 3.13-3.23 (m, 2H) 3.25-3.32 (m, 2H) 3.89 (s, 3H) 4.21-4.28 (m, 1H) 4.32-4.41 (m, 1H) 4.41-4.50 (m, 1H) 4.69 (s, 2H) 5.56-5.66 (m, 1H) 7.50 (d, J=7.83 Hz, 2H) 8.00 (d, J=8.22 Hz, 2H) 8.09-8.13 (m, 1H) 8.27-8.32 (m, 1H) 8.62-8.67 (m, 1H). MS(ESI): found: [M+H]+, 922.8.
  • H-R (Mtr) ketobenzothiazole-(C═O)-NHBn(3-COOMe)-HCl. The title compound was synthesized from using the same procedure as HCl.H-Arg(Mtr) ketobenzothiazole-6-CONH-Val-amide. Yield, 80 mg, MS(ESI): found: [M+H]+, 695.4.
  • Ac-KRLR (SEQ ID NO: 8) ketobenzothiazole-(C═O)-NHBn(3-COOMe) (23b). The title compound was synthesized from H-R ketobenzothiazole-(C═O)-NHBn(3-COOMe)-HCl using the same procedure as Ac-KQLR (SEQ ID NO: 1) ketobenzothiazole-6-CONH-Val-amide and was purified by HPLC. Yield: 19% over two steps. 1H NMR (400 MHz, METHANOL-d4) δ ppm 0.90 (d, J=6.65 Hz, 3H) 0.93 (d, J=6.26 Hz, 3H) 1.40-1.95 (m, 16H) 1.99 (s, 3H) 2.13-2.27 (m, 1H) 2.88-2.97 (m, 2H) 3.13-3.23 (m, 2H) 3.25-3.31 (m, 2H) 3.89 (s, 3H) 4.21-4.28 (m, 1H) 4.33-4.41 (m, 1H) 4.41-4.50 (m, 1H) 4.68 (s, 2H) 5.57-5.66 (m, 1H) 7.43-7.52 (m, 1H) 7.61-7.69 (m, 1H) 7.90-7.97 (m, 1H) 8.03-8.08 (m, 1H) 8.09-8.13 (m, 1H) 8.26-8.31 (m, 1H) 8.58-8.68 (m, 1H). MS(ESI): found: [M+H]+, 922.8.
  • Ac-KRLR (SEQ ID NO: 8) ketobenzothiazole-(C═O)-NHBn(3-COOH) (23c). Compound 23b (0.01 g, 0.010 mmol) was taken in 0.5 mL 0.05M LiOH solution and the reaction mixture was stirred for 1.5 hours at room temperature. On completion, the pH of the reaction mixture was brought to 2 by dropwise addition of 1N HCl solution. The crude product was purified by HPLC. Yield: 44%. 1H NMR (400 MHz, METHANOL-d4) δ ppm 0.90 (d, J=6.65 Hz, 3H) 0.93 (d, J=6.65 Hz, 3H) 1.37-1.93 (m, 16H) 1.99 (s, 3H) 2.13-2.27 (m, 1H) 2.88-2.96 (m, 2H) 3.14-3.21 (m, 2H) 3.25-3.30 (m, 2H) 4.20-4.28 (m, 1H) 4.32-4.41 (m, 1H) 4.41-4.50 (m, 1H) 4.64-4.73 (m, 2H) 5.56-5.65 (m, 1H) 7.43-7.50 (m, 1H) 7.61-7.67 (m, 1H) 7.91-7.97 (m, 1H) 8.04-8.09 (m, 1H) 8.09-8.15 (m, 1H) 8.26-8.31 (m, 1H) 8.62-8.67 (m, 1H). MS(ESI): found: [M+H]+, 908.8.
  • Ac-KRLR (SEQ ID NO: 8) ketobenzothiazole-(C═O)-NHBn(4-COOH) (23d). The title compound was synthesized using the same procedure as 23c starting with 23a. Yield: 44%. 1H NMR (400 MHz, METHANOL-d4) δ ppm 0.91 (d, J=6.65 Hz, 3H) 0.93 (d, J=6.26 Hz, 3H) 1.33-1.95 (m, 16H) 1.99 (s, 3H) 2.14-2.27 (m, 1H) 2.88-2.96 (m, 2H) 3.14-3.21 (m, 2H) 3.25-3.30 (m, 2H) 4.19-4.28 (m, 1H) 4.33-4.41 (m, 1H) 4.41-4.50 (m, 1H) 4.61-4.76 (m, 2H) 5.54-5.69 (m, 1H) 7.46-7.52 (m, 2H) 7.98-8.04 (m, 2H) 8.09-8.15 (m, 1H) 8.27-8.32 (m, 1H) 8.62-8.68 (m, 1H). MS(ESI): found: [M+H]+, 908.8.
  • Ac-S(tBu)-K(Boc)-L-R(Mtr)-ketobenzothiazole-6-COOH. Under nitrogen atmosphere at −78° C., nBuLi/Hex (2.5M) (28.5 mL, 71.4 mmol) was added dropwise into the solution of 6-carboxybenzothiazole (6.566 g, 37 mmol) in THF (450 mL) over 25 minutes. After the mixture was stirred for additional half an hour, the solution of Boc-HN-Arg(Mtr) Weinreb amide (1.633 g, 3.08 mmol) in THF (60 mL) was added slowly over 20 min at −78° C. After the addition then the mixture was stirred at −24° C. to −20° C. for 1.5 hours. The reaction was quenched with saturated aqueous NH4Cl (270 mL). The layers were separated and the aqueous layer was extracted with AcOEt. The organic phase was collected and washed with water and brine, dried with Na2SO4, then concentrated in vacuo. To the resulting residue MeOH (50 mL) was added. The mixture was cooled at −25° C. and sodium borohydride (0.706 g, 18.7 mmol) was added. The mixture was stirred at −25˜−20° C. for 1 hour. Acetone (10 mL) was added to quench the reaction and the mixture was stirred for 15 minutes then concentrated in vacuo. The residue was suspended in water, acidified to pH 3-4, and extracted with AcOEt. The organic phase was washed with brine, dried with Na2SO4, then concentrated in vacuo. The resulting residue was dissolved in CH2Cl2/MeOH (17/3 v/v, 40 mL), cooled to 0° C. Into it, (trimethylsilyl)diazomethane (2 M in hexane, 9.2 mL, 18.4 mmol) was added dropwise over 25 minutes. The mixture was stirred at 0° C. for 1 hour. MeOH (5 mL) was added and the mixture was concentrated in vacuo. The residue was purified by silica gel chromatography with CHCl3/MeOH combination as eluent to give BocHN-Arg(Mtr)-CH(OH)benzothiazole-6-COOMe a (0.445 g, mixture of diastereomers) in 22% yield. MS(ESI): found: [M+H]+, 664.5.
  • The mixture of a (0.44 g, 0.66 mmol) in TFA/CH2Cl2 (1/4 v/v, 18 mL) was stirred at room temperature for 2 hours. The solvents were removed and the residue was dried in vacuo to give TFA-H2N-Arg(Mtr)-CH(OH)benzothiazole-6-COOMe b (0.45 g, mixture of diastereomers) in quantitative yield. MS(ESI): found: [M+H]+, 564.5.
  • Under nitrogen atmosphere, at 0° C. anhydrous DMF (13 mL) was added into the round bottom flask containing Ac-S(tBu)-K(Boc)-L-OH (0.3650 g, 0.67 mmol) and HATU (0.255 g, 0.67 mmol). The mixture was stirred for 10 minutes, then b (0.40 g, 0.56 mmol) and N,N-diisopropylethylamine (0.49 mL, 2.8 mmol) were added sequentially. The mixture was stirred overnight while being warmed to room temperature naturally. DMF was removed and to the resulting residue, water (20 mL) was added. The precipitate formed was collected and purified by silica gel chromatography with CHCl3/MeOH combination as eluent. The fractions with Ac-S(tBu)-K(Boc)-L-Arg(Mtr)-CH(OH)benzothiazole-6-COOMe c (mixture of diastereomers) confirmed by LCMS [MS(ESI): found: [M+H]+, 1090.8], were collected, and concentrated in vacuo. The residue c was dissolved in THF/H2O (15 mL/10 mL) and LiOH (0.036 g, 1.5 mmol) was added. The mixture was stirred overnight, then concentrated. The concentrated mixture was acidified to pH 4.0 with 0.25 N HCl aqueous solution and extracted with AcOEt. The organic phase was collected, dried with Na2SO4 and concentrated in vacuo to give Ac-S(tBu)-K(Boc)-L-Arg(Mtr)-CH(OH)benzothiazole-6-COOH d (mixture of diastereomers) (0.52 g) in 86% yield. MS(ESI): found: [M+H]+, 1076.8. d was used in the next step without further purification.
  • Into the solution of d (0.30 g, 0.28 mmol) in CH2Cl2 (100 mL), Dess-Martin periodinane (DMP) (0.198 g, 0.47 mmol) was added. The mixture was stirred at room temperature for 3 hours, then additional DMP (0.12 g, 0.28 mmol) was added. The mixture was stirred overnight, then quenched with 1 M Na2S2O3 aqueous solution. The organic phase was separated and the aqueous was extracted with CH2Cl2 2 times. The organic phases were combined, dried with Na2SO4 and concentrated in vacuo. The resulting residue was purified by silica gel chromatography with CH2Cl2/MeOH combination as eluent to give the title compound Ac-S(tBu)-K(Boc)-L-R(Mtr)-ketobenzothiazole-COOH (0.186 g) in 62% yield. 1H NMR (400 MHz, METHANOL-d4) δ ppm 0.88 (d, J=5.87 Hz, 3H) 0.92 (d, J=6.26 Hz, 3H) 1.18 (s, 9H) 1.27-1.90 (m, 21H) 1.92-2.19 (m, 7H) 2.54 (s, 3H) 2.60 (s, 3H) 2.95-3.08 (m, 2H) 3.23-3.33 (m, 2H) 3.53-3.70 (m, 2H) 3.79 (s, 3H) 4.18-4.54 (m, 3H) 5.37-5.69 (m, 1H) 6.55 (s, 1H) 8.14-8.25 (m, 2H) 8.79 (s, 1H). MS(ESI): found: [M+H]+, 1074.9.
  • Ac-SKLR (SEQ ID NO: 10)-ketobenzothiazole-6-COOH (7118). To the crude Ac-S(tBu)-K(Boc)-L-R(Mtr)-ketobenzothiazole-COOH received from the DMP oxidation of d (0.053 g, 0.049 mmol), 5 mL of TFA/thioanisole/water (95/2.5/2.5 (v/v/v)) was added. The mixture was stirred at room temperature for 4 hours. Then cold ether (40 mL) was added. The resulting precipitate, which is the crude product, was collected by centrifugation, then by decanting out carefully ether solvent. The crude product was purified by HPLC (C18, 15*150 mm column; eluent: acetonitrile/water (0.05% TFA)) to give the title compound (0.01 g) in 29% yield. 1H NMR (400 MHz, METHANOL-d4) δ ppm 0.75-1.00 (m, 6H) 1.40-2.05 (m, 15H) 2.13-2.27 (m, 1H) 2.87-2.98 (m, 2H) 3.29-3.33 (m, 2H) 3.73-3.91 (m, 2H) 4.25-4.46 (m, 3H) 5.58-5.67 (m, 1H) 8.25-8.29 (m, 2H) 8.83 (s, 1H). MS(ESI): found: [M+H]+, 706.5.
  • Figure US20220169676A1-20220602-C00153
  • Ac-SKLR (SEQ ID NO: 10)-ketobenzothiazole-6-CONH-Phe-amide (7125). The title compound was synthesized using the same procedure as for BocHN-Arg(Mtr) ketobenzothiazole-6-CONH-Val-amide, starting with the coupling of Ac-S(tBu)-K(Boc)-L-R(Mtr)-ketobenzothiazole-COOH and L-phenylalanine amide hydrochloride. Yield: 25%. 1H NMR (400 MHz, METHANOL-d4) δ ppm 0.83-0.93 (m, 6H) 1.35-2.05 (m, 15H) 2.12-2.25 (m, 1H) 2.86-2.97 (m, 2H) 3.02-3.12 (m, 1H) 3.21-3.38 (m, 3H) 3.72-3.90 (m, 2H) 4.25-4.45 (m, 3H) 4.85-4.94 (m, 1H) 5.56-5.64 (m, 1H) 7.17-7.22 (m, 1H) 7.24-7.35 (m, 4H) 7.93-7.99 (m, 1H) 8.20-8.26 (m, 1H) 8.47-8.51 (m, 1H). MS(ESI): found: [M+H]+, 852.7.
  • Ac-SKLR (SEQ ID NO: 10)-ketobenzothiazole-6-CONH-Trp-amide (7124). The title compound was synthesized using the same procedure as for Ac-SKLR(SEQ ID NO: 10)-ketobenzothiazole-6-CONH-Phe-amide. Yield: 24%. 1H NMR (400 MHz, METHANOL-d4) δ ppm 0.84-0.93 (m, 6H) 1.33-2.05 (m, 15H) 2.11-2.25 (m, 1H) 2.83-2.97 (m, 2H) 3.20-3.36 (m, 3H) 3.40-3.50 (m, 1H) 3.71-3.90 (m, 2H) 4.24-4.46 (m, 3H) 4.91-5.00 (m, 1H) 5.54-5.65 (m, 1H) 6.97-7.03 (m, 1H) 7.06-7.11 (m, 1H) 7.18 (s, 1H) 7.30-7.35 (m, 1H) 7.65-7.71 (m, 1H) 7.91-7.97 (m, 1H) 8.00-8.06 (m, 1H) 8.18-8.23 (m, 1H) 8.36-8.39 (m, 1H). MS(ESI): found: [M+H]+, 891.7.
  • Ac-SKLR (SEQ ID NO: 10)-ketobenzothiazole-6-CONH-4-pyridine (7126). The title compound was synthesized using the same procedure as for Ac-SKLR(SEQ ID NO: 10)-ketobenzothiazole-6-CONH-Phe-amide. Yield: 18%. 1H NMR (400 MHz, METHANOL-d4) δ ppm 0.84-0.93 (m, 6H) 1.35-2.05 (m, 15H) 2.15-2.29 (m, 1H) 2.86-2.98 (m, 2H) 3.24-3.37 (m, 2H) 3.73-3.98 (m, 2H) 4.23-4.47 (m, 3H) 5.57-5.69 (m, 1H) 8.23-8.29 (m, 1H) 8.35-8.44 (m, 3H) 8.67-8.72 (m, 2H) 8.85 (s, 1H). MS(ESI): found: [M+H]+, 782.7.
  • Figure US20220169676A1-20220602-C00154
  • Ac-SKLR (SEQ ID NO: 10)-ketobenzothiazole-6-CONH-4-piperidine (7140). Under nitrogen atmosphere, at 0° C. anhydrous DMF (5 mL) was added into the RB flask containing Ac-S(tBu)-K(Boc)-L-Arg(Mtr)-CH(OH)benzothiazole-6-COOH d (0.088 g, 0.081 mmol) and HATU (0.037 g, 0.097 mmol). The mixture was stirred for 10 minutes, then 4-amino-1-Boc-piperidine (0.019 g, 0.097 mmol) and N,N-diisopropylethylamine (0.031 g, 0.24 mmol) were added sequentially. The mixture was stirred while being warmed to room temperature naturally. The reaction was monitored by LCMS until completion. DMF was removed and to the resulting residue, water (20 mL) was added. The precipitate formed was collected and purified by silica gel chromatography with CH2Cl2/MeOH combination as eluent to give Ac-S(tBu)-K(Boc)-L-Arg(Mtr)-CH(OH)benzothiazole-6-CONH-4-1-Boc-piperidine e (0.088 g, mixture of diastereomers) in 86% yield. MS(ESI): found: [M+H]+, 1259.0.
  • Into the solution of e (0.083 g, 0.066 mmol) in CH2Cl2 (15 mL), Dess-Martin periodinane (DMP) (0.042 g, 0.099 mmol) was added. The mixture was stirred at room temperature for 3 hours, then quenched with 1 M Na2S2O3 aqueous solution. The organic phase was separated and the aqueous was extracted with CH2Cl2 2 times. The organic phases were combined, dried with Na2SO4 and concentrated in vacuo. Into the resulting residue 3 mL of TFA/thioanisole/water (95/2.5/2.5 (v/v/v)) was added. The mixture was stirred at room temperature for 4 hours. Then cold ether (40 mL) was added. The resulting precipitate, which is the crude product, was collected by centrifugation, then by decanting out carefully ether solvent. The crude product was purified by HPLC (C18, 15*150 mm column; eluent: acetonitrile/water (0.05% TFA)) to give the title compound Ac-SKLR (SEQ ID NO: 10)-ketobenzothiazole-6-CONH-4-piperidine (0.022 g) in 42% yield. 1H NMR (400 MHz, METHANOL-d4) δ ppm 0.87 (d, J=6.26 Hz, 3H) 0.91 (d, J=6.26 Hz, 3H) 1.33-2.05 (m, 17H) 2.15-2.30 (m, 3H) 2.85-2.98 (m, 2H) 3.10-3.23 (m, 2H) 3.23-3.38 (m, 2H) 3.43-3.55 (m, 2H) 3.72-3.90 (m, 2H) 4.15-4.46 (m, 4H) 5.55-5.71 (m, 1H) 8.06-8.11 (m, 1H) 8.25-8.30 (m, 1H) 8.60-8.63 (m, 1H) MS(ESI): found: [M+H]+, 788.7.
  • Ac-SKLR (SEQ ID NO: 10)-ketobenzothiazole-6-CONH-Bn (7139). The title compound was synthesized using the same procedure as for Ac-SKLR (SEQ ID NO: 10)-ketobenzothiazole-6-CONH-4-piperidine. Yield: 33%. 1H NMR (400 MHz, METHANOL-d4) δ ppm 0.81-0.95 (m, 6H) 1.31-2.09 (m, 15H) 2.12-2.26 (m, 1H) 2.84-2.98 (m, 2H) 3.20-3.40 (m, 2H) 3.65-3.91 (m, 2H) 4.20-4.46 (m, 3H) 4.59-4.66 (m, 2H) 5.57-5.67 (m, 1H) 7.22-7.29 (m, 1H) 7.30-7.41 (m, 4H) 8.08-8.13 (m, 1H) 8.21-8.34 (m, 1H) 8.57-8.67 (m, 1H). MS(ESI): found: [M+H]+, 795.6.
  • Cy5.5-KRLR (SEQ ID NO: 8)-OH (RSC-1177). To H-K(Boc)R(Pbf)L-2-Cl Trt resin [(190 mg, 0.067 mmol), synthesized in a similar fashion to 7-AMINE)] was added 5 mL of DMF and 5 mL of DCM. After 30 min, the solvent was filtered and a solution of Cy5.5-NHS ester (71 mg, 0.10 mmol, Lumiprobe) in DMF (5 mL) and Hunig's Base (0.025 mL, 0.13 mmol) were added, then stirred overnight at room temperature. The solvent was filtered off and the resin washed thoroughly with DMF and DCM, then dried under vacuum. To the resin was added a 1:3 mixture of HFIP and DCM (15 mL) and after 45 minutes of gently shaking, the solvent was removed and then replenished. After 30 minutes of additional shaking, the solvent was removed. The combined filtrates were concentrated in vacuo to give 107 mg of crude material. Purification was achieved with 5-50% MeOH/DCM on silica gel. Yield 65 mg, 73%. Chemical Formula: C76H102N9O10S+Cl−, Exact Mass: 1332.75, MS(ESI): found: [M]+, 1332.9.
  • Figure US20220169676A1-20220602-C00155
  • Cy5.5-KRLR (SEQ ID NO: 8)-cmk (RSC-1179). To a cooled (ice bath) solution of Cy5.5-KRLR (SEQ ID NO: 8)-OH (15 mg, 0.011 mmol) in THF (1 mL) was added N-methylmorpholine (0.011 mmol) and isopropyl chloroformate (0.011 mL, 1M solution in toluene. The reaction mixture was stirred for 10-15 minutes and then trimethylamine (0.011 mmol) and (S)—N—(N-(4-amino-6-chloro-5-oxohexl)carbamimidoyl)-4-methoxy-2,3,6-trimethylbenzenesulfonamide hydrochloride [aE. Gherardi, W. Birchmeier, C. Birchmeier, G. Vande Woude, Nature reviews. Cancer 2012, 12, 89-103; bE. C. Smyth, F. Sclafani, D. Cunningham, Oncotargets Ther 2014, 7, 1001-1014.] (5 mg, 0.011 mmol) in DMF (0.2 mL) were added followed by stirring for an additional 2 hours. The solvent was removed and then 1.5 mL of cleavage cocktail (38:1:1 TFA/water/thioanisole) was added to the resin. After gentle shaking overnight, the solvent was removed in vacuo, triturated in toluene, and then concentrated in vacuo. The residue was purified by C18 reverse phase HPLC to give 10 mg of crude product which was re-purified to give 4 mg of pure title compound as the TFA salt. Chemical Formula: C65H91ClN13O5+Cl−, Exact Mass: 1168.69, MS(ESI): found: [M]+, 1168.8.
  • Cy5.5-KRLR (SEQ ID NO: 8)-kbt (RSC-1178). Synthesized in a similar manner to Ac-KQLR (SEQ ID NO: 1) kbt (3) from Cy5.5-KRLR (SEQ ID NO: 8)-OH. Chemical Formula: C71H93N14O5S+Cl−, Exact Mass: 1253.72, MS(ESI): found: [M]+, 1253.7.
    • Example 6. Inhibition Studies with Polypeptide Ketobenzothiazoles
  • Fluorescent inhibitor and chromogenic proteolytic assays were performed in general accordance with the procedures described in Example 4 for compounds prepared in Examples 5 and 6.
  • The results of the assays are presented in Table 6.1. The results show increased potency of 2-fold of the ketobenzothiazoles over thiazole 5. More importantly when we substitute a Val on the benzothiazole ring 36c as in 8, we increase the HGFA potency another two-fold (Ki 13 nM) but decreased matriptase activity >10-fold (Ki 7 nM) and >3-fold for hepsin (Ki 0.3 nM). Ac-SKLR (SEQ ID NO: 10)-kbt V amide (9) showed a 4-fold enhancement in HGFA potency with no effect on hepsin or matriptase. We discovered Ac-KQLR (SEQ ID NO: 1)-kbt (7) improves potency 2-fold and further substitution of the benzothiazole ring with Valine, Ac-KQLR (SEQ ID NO: 1)-kbt V amide (8) increases potency another 2-fold for HGFA (Ki 13 nM) but decreased matriptase activity >10-fold (Ki 7 nM) and >3-fold for hepsin (Ki 0.3 nM). This result demonstrates that these inhibitor compounds have improved selectivity for HGFA.
  • TABLE 6.1
    Fluorogenic Assay
    HGFA Matriptase
    Compound Ki (nM) Ki Hepsin
    No. Y-P4-P3-P2-P1-Z (nM) (nM) Ki
    7185-1 Fmoc-AR-kbt 7983.5 0.5 272.37
    7185-2 Fmoc-RR-kbt 8633.5 2.0 99.92
    7185-3 Fmoc-NR-kbt >20000 84.1 1.92
    7185-4 Fmoc-DR-kbt >20000 397.9 232.92
    7185-6 Fmoc-QR-kbt 6827 1.6 170.07
    7185-7 Fmoc-ER-kbt >20000 8.4 337.63
    7185-8 Fmoc-GR-kbt 9375 0.1 831.00
    7185-9 Fmoc-HR-kbt 6356.19 66.7 268.07
    7185-10 Fmoc-IR-kbt 6466.05 657.1 297.32
    7185-11 Fmoc-LR-kbt 449.776 425.3 114.90
    7185-12 Fmoc-KR-kbt >20000 0.2 159.25
    7187-13 Fmoc-MR-kbt 1208.00 62.1 489.97
    7187-14 Fmoc-FR-kbt 963.50 1281.5 777.88
    7187-15 Fmoc-PR-kbt >20000 40.4 776.25
    7187-16 Fmoc-SR-kbt >20000 90.00 885.50
    7188-17 Fmoc-TR-kbt >20000 1217.00 436.75
    7188-18 Fmoc-WR-kbt 3197.00 823.5 410.62
    7188-19 Fmoc-YR-kbt 2961.00 331.6 217.38
    7188-20 Fmoc-VR-kbt 4633.83 1488.0 313.60
       1-13A1 H-WFR-kbt 5681.25 1871.5 240.15
       1-18A1 H-dWFR-kbt 2250 135.3 369.80
       1-15A1 H-dWLR-kbt 127.98 34.6 3.58
       1-45A1 H-WFR-kbt-COOH 981 232 1.41
    7171 H-RLR-kbt 83.07 3.3 0.50
       1-56A1 H-WLR-kbt-COOH 1379 1206.5 446.30
       1-57A1 H-dWLR-kbt-COOH 345.9 363.6 136.50
       1-54A1 H-His(Bom)-WLR-kbt 3711.83 1549.8 2.08
       1-58A1 H-His(Bom)-dWLR-kbt 2282.17 1504.7 1.13
    7182 H-LLR-kbt-Val-NH2 82.09 23.6 0.88
    7181 H-WLR-kbt-Val-NH2 73.89 49.2 1.31
    7180 H-RLR-kbt-Val-NH2 12.50 4.2 0.44
    7170 H-WLR-kbt 103.98 33.5 1.52
    7115 Ac-KRLR(SEQ ID NO: 8)-kbt- 5.83 7.415 0.2265
    Val-NH2
    7054 Ac-KRLR(SEQ ID NO: 8)-kbt 6.00 0.540 0.112
    7117 H-WRLR(SEQ ID NO: 9)-kbt 8.75 3.79 0.12
    7055 Ac-KQLR(SEQ ID NO: 1)kbt- 12.00 6.98 0.29
    Val-NH2
    7116 Ac-SKLR(SEQ ID NO: 10)-kbt- 12.98 10.3 0.19
    Val-NH2
    7124 Ac-SKLR(SEQ ID NO: 10)-kbt- 15.75 3.74 0.098
    Trp-NH2
    7125 Ac-SKLR(SEQ ID NO: 10)-kbt- 17.28 6.26 0.14
    Phe-NHS
    7006 Ac-KQLR(SEQ ID NO: 1)-kbt 30.00 0.550 0.09
    7126 Ac-SKLR(SEQ ID NO: 10)-kbt- 31.76 3.95 0.14
    4-pyridinylamide
    7053 Ac-SKLR(SEQ ID NO: 10)-kbt 33.00 3.05 0.16
    7063 Ac-FLFR(SEQ ID NO: 19)-kbt 114.00 3.60 1.44
    7118 Ac-SKLR(SEQ ID NO: 10)-kbt- 131.97 54.8 0.173
    COOH
    7064 Ac-WLFR(SEQ ID NO: 20)-kbt 133.00 5.960 0.347
    7139 Ac-SKLR(SEQ ID NO: 10)-kbt- 9.10 0.360 0.80
    benzylamide
    7140 Ac-SKLR(SEQ ID NO: 10)-kbt- 7.70 1.28 0.20
    4-piperidinylamide 
    7165 Ac-KRLR(SEQ ID NO: 8)-kbt- 6.07 5.14 0.37
    Phe-COOH
    7164 Ac-KRLR(SEQ ID NO: 8)-kbt- 3.33 3.60 0.30
    Benzyl-3-COOH
    7159 Ac-KRLR(SEQ ID NO: 8)-kbt- 7.76 1.80 0.36
    Benzyl-3-COOMe
    7158 Ac-KRLR(SEQ ID NO: 8)-kbt- 5.85 0.98 0.26
    Benzyl-4-COOMe
    1179 Cy5.5-KRLR(SEQ ID NO: 8)- 34.14 172.2 323.53
    cmk
    1178-2 Cy5.5-KRLR(SEQ ID NO: 8)- 608 87.5 3.89
    kbt
  • The results of selectivity assays are presented in Table 6.2.
  • TABLE 6.2
    Fluorogenic Assay
    Thrombin Factor Xa Trypsin
    Compound Ki Ki Ki
    No. Y-P4-P3-P2-P1-Z (nM) (nM) (nM)
    7118 Ac-SKLR(SEQ ID NO: 10)-kbt- >2000 1247 0.03
    COOH
    7006 Ac-KQLR(SEQ ID NO: 1)-kbt >20000 129 0.24
    7055 Ac-KQLR(SEQ ID NO: 1)-kbt- 3212 66 0.07
    Val-NH2
    7053 Ac-SKLR(SEQ ID NO: 10)-kbt >20000 1901 0.16
    7116 Ac-SKLR(SEQ ID NO: 10)-kbt- 4505 385 0.34
    Val-NH2
    7117 H-WRLR(SEQ ID NO: 9)-kbt 4890 2.4 0.96
    7063 Ac-FLFR(SEQ ID NO: 19)-kbt >20000 13.1 0.27
    7054 Ac-KRLR(SEQ ID NO: 8)-kbt >20000 91.9 0.82
    7064 Ac-WLFR(SEQ ID NO: 20)-kbt >20000 1.0
    7115 Ac-KRLR(SEQ ID NO: 8)-kbt- 1560 17.0
    Val-NH2
    7124 Ac-SKLR(SEQ ID NO: 10)-kbt- 1231 163 0.02
    Trp-NH2
    7125 Ac-SKLR(SEQ ID NO: 10)-kbt- 3640 544 0.27
    Phe--NH2
    7126 Ac-SKLR(SEQ ID NO: 10)-kbt- 3431 221 1.06
    pyridine-NH2
    7139 Ac-SKLR(SEQ ID NO: 10)-kbt- 2467 190 0.05
    benzyl
    7140 Ac-SKLR(SEQ ID NO: 10)-kbt- 2948 447 0.41
    piperidine
    7158 Ac-KRLR(SEQ ID NO: 8)-kbt- 20.92 9.0 0.05
    benzyl-4-COOMe
    7159 Ac-KRLR(SEQ ID NO: 8)-kbt- 85.38 14 0.04
    Benzyl-3-COOMe
    7164 Ac-KRLR(SEQ ID NO: 8)-kbt- 1618
    benzyl-4-COOH
    7170 H-WLR-kbt 457.00 532.00 0.050
    7171 H-RLR-kbt 8198 56 0.13
    7182 H-LLR-Val-NH2 101.4 159 0.61
    7181 H-WLR-kbt-Val-NH2 41.04 159 0.01
    7180 H-RLR-kbt-Val-NH2 548 18 0.31
    7165 Ac-KRLR(SEQ ID NO: 8)-kbt- 1944 20.2 1.06
    benzyl-3-COOH
    7187-14 Fmoc-FR-kbt >2000 28.4 14.350
    7185-11 Fmoc-LR-kbt 995 410 19.78
    • Example 7. Inhibition Studies with Cyclic Peptides
  • Fluorescent inhibitor and chromogenic proteolytic assays were performed in general accordance with the procedures described in Example 4 for compounds prepared in Example 3. Table 7.1 presents the results for a cyclic peptide compound 7074.
  • TABLE 7.1
    Fluorogenic Assay
    HGFA Matriptase HGFA
    Ki Ki Ki
    Compound Y-P5-P4-P3-P2-P1-Z (nM) (nM) (nM)
    7074 H-cyclo(KQD)RR-kt 5941.67 0.71 1.55
    • Example 8. Synthesis of Benzamidine Inhibitor Compounds
  • The benzamidine inhibitors listed in Table 8.1 were synthesized in accordance with the general scheme 8A shown below and the procedures described below. Phenylalanine naphthyl sulfonamides were synthesized in accordance with general scheme B and the procedures described below.
  • TABLE 8.1
    Benzamidine inhibitors.
    Figure US20220169676A1-20220602-C00156
    Compound R1 R2 W
    16
    Figure US20220169676A1-20220602-C00157
    Figure US20220169676A1-20220602-C00158
         		C
    17a
    Figure US20220169676A1-20220602-C00159
    Figure US20220169676A1-20220602-C00160
         		N
    18*
    Figure US20220169676A1-20220602-C00161
    Figure US20220169676A1-20220602-C00162
         		C
    25a
    Figure US20220169676A1-20220602-C00163
    Figure US20220169676A1-20220602-C00164
         		N
    25b
    Figure US20220169676A1-20220602-C00165
    Figure US20220169676A1-20220602-C00166
         		C
    25c*
    Figure US20220169676A1-20220602-C00167
    Figure US20220169676A1-20220602-C00168
         		C
    25d
    Figure US20220169676A1-20220602-C00169
    Figure US20220169676A1-20220602-C00170
         		N
    25e
    Figure US20220169676A1-20220602-C00171
    Figure US20220169676A1-20220602-C00172
         		N
    25f*
    Figure US20220169676A1-20220602-C00173
    Figure US20220169676A1-20220602-C00174
         		C
    25g
    Figure US20220169676A1-20220602-C00175
    Figure US20220169676A1-20220602-C00176
         		N
    25h
    Figure US20220169676A1-20220602-C00177
    Figure US20220169676A1-20220602-C00178
         		N
    26
    Figure US20220169676A1-20220602-C00179
    Figure US20220169676A1-20220602-C00180
         		N
    27
    Figure US20220169676A1-20220602-C00181
    Figure US20220169676A1-20220602-C00182
         		N
    *R2 is substituted on the 3-position of the piperidine ring.
  • Figure US20220169676A1-20220602-C00183
    Figure US20220169676A1-20220602-C00184
  • Reagents and conditions in Scheme A are as follows a) HATU, THF (or DMF), DIPEA; b) 4N HCl in 1,4-doxane; c) R1SO2Cl, DMAP, pyridine, THF; d) i. NH2OH—HCl, K2CO3 (or DIPEA), EtOH; e) Ac2O, AcOH; f) Zn, AcOH.
  • Figure US20220169676A1-20220602-C00185
  • Reagents and conditions in Scheme B are as follows a) HATU, THF (or DMF), DIPEA; b) 4N HCl in 1,4-doxane; d) i. NH2OH—HCl, K2CO3 (or DIPEA), EtOH; ii. Ac2O, AcOH; e) Zn, AcOH; f) DMAP, pyridine, THF; g) LiOH, THF; h) HATU, RCO2H (R3═COR) or R—N═C═O (R3═CONHR).
  • General Procedure A: General procedure for the synthesis of amides (20): A solution of N-Boc-3-cyanophenylalanine (19) in dry DMF (0.5 M) was added Hunig's Base (4.0 equiv) followed by HATU (1.3 equiv). The yellow solution was allowed to stir for 10 minutes and was then added amine (1.3 equiv). The resulting mixture was stirred at room temperature. After two hours, the reaction was checked by LCMS and was complete. The reaction mixture was diluted with ethyl acetate, washed with water (1×), brine (2×), dried (MgSO4), filtered and concentrated to oil. The crude product was purified by MPLC (0-75% hexanes/ethyl acetate) to afford pure product.
  • General Procedure B: General procedure for BOC deprotection (21): A solution of N-Boc protected amide in dioxane (0.4 M) was added 4.0 M HCl in dioxane (10 equiv). The resulting mixture was allowed to stir at room temperature. After 4 hours, the reaction was checked by LCMS and was complete. The solvent was removed under reduced pressure to afford pure product.
  • General Procedure C: General procedure for sulfonamideformation (22): A mixture of amide in THF (0.2 M) was added Hunig's Base (10 equiv) and the mixture was stirred until all solids dissolved. The solution was then added DMAP (10 mol %) followed by arylsulfonyl chloride (1.1 equiv) and stirred at room temperature. After 2 hours the reaction was checked by LCMS and was complete. The reaction was diluted with ethyl acetate, washed with saturated NaHCO3 (2×), brine (1×), dried (MgSO4), filtered and concentrated under reduced pressure. The crude material was purified via MPLC (0-75% ethyl acetate/hexanes) to afford pure product as a solid.
  • General Procedure D: General procedure for formation of the amidoxime (23): A suspension of sulfonamide in dry ethanol (0.2M) was added hydroxylamine hydrochloride (2.2 equiv) followed by Hunig's base (2.3 equiv). The resulting mixture was heated to 75° C. for approximately 3 hours which resulted in a homogeneous solution. The reaction mixture was allowed to cool to room temperature, checked by LCMS and was complete. The solvent was removed under reduced pressure to afford the crude amidoxime intermediate as a white solid.
  • General Procedure E: General procedure for acetylation of amidoxime (24). A solution of crude amidoxime in acetic acid (0.2 M) was added acetic anhydride at room temperature. The resulting mixture was allowed to stir at room temperature. After approximately 2 hours the reaction was checked by LCMS and was complete. The solvent was removed under reduced pressure to afford the crude product.
  • General Procedure F: General procedure for preparation of amidines (25) and (26): A solution of O-acetylamidoxime in acetic acid (0.2 M) was added zinc dust (15 equiv) at room temperature. The resulting suspension was stirred for 3 hours at room temperature. The reaction was checked by LCMS and was complete. The mixture was filtered and concentrated under reduced pressure to give the crude product as an oil. The crude product was purified via reverse phase HPLC (5-65% acetonitrile/water/0.05% trifluoroacetic acid) to afford pure product as a white solid after lyophilization.
  • (S)-3-(2-(Naphthalene-2-sulfonamido)-3-oxo-3-(4-phenylpiperidin-1-yl)propyl)benzimidamide (16). Prepared from N-acetoxy-3-[(2S)-2-[(2-naphthylsulfonyl)amino]-3-oxo-3-(4-phenylpiperidin-1-yl)propyl]benzenecarboximidamide using General Procedure F. Purified by reversed-phase HPLC (5-75% acetonitrile/water/0.05% TFA), Yield (0.092 g, 52.5%). 1H NMR (300 MHz, DMSO-d6) δ 9.40 (s, 2H), 9.26 (s, 2H), 8.23-8.50 (m, 2H), 7.94-8.10 (m, 2H), 7.56-7.78 (m, 4H), 7.35-7.56 (m, 2H), 7.07-7.33 (m, 3H), 6.96 (d, J=7.42 Hz, 1H), 6.78 (d, J=7.14 Hz, 1H), 4.49-4.79 (m, 1H), 3.82-4.21 (m, 2H), 3.61-3.79 (m, 1H), 3.41-3.56 (m, 2H), 2.89-3.06 (m, 1H), 2.72-2.89 (m, 1H), 2.59 (t, J=12.22 Hz, 1H), 1.31-1.64 (m, 2H), 0.75-1.08 (m, 1H), 0.38-0.67 (m, 1H). LRMS (ESI) C31H32N4O3S found [M+H]: 541.2.
  • N-Acetoxy-3-[(2S)-2-[(2-naphthylsulfonyl)amino]-3-oxo-3-(4-phenylpiperidin-1-yl)propyl]benzenecarboximidamide. Prepared from N-hydroxy-3-[(2S)-2-[(2-naphthylsulfonyl)amino]-3-oxo-3-(4-phenylpiperidin-1-yl)propyl]benzenecarboximidamide using General Procedure E. Purification by MPLC (0-90% EtOAc/hexanes). Yield (0.17 g, 47.7%). LRMS (ESI) C33H34N4O5S found [M+H]: 599.2.
  • N-Hydroxy-3-[(2S)-2-[(2-naphthylsulfonyl)amino]-3-oxo-3-(4-phenylpiperidin-1-yl)propyl]benzenecarboximidamide. Prepared from tert-butyl (S)-(3-(3-cyanophenyl)-1-oxo-1-(4-phenylpiperazin-1-yl)propan-2-yl)carbamate (0.312 g, 0.589 mmol) using General Procedure D. LRMS (ESI) C31H32N4O4S found [M+H]: 557.2.
  • N-[(2S)-3-(3-Cyanophenyl)-1-oxo-1-(4-phenylpiperidin-1-yl)propan-2-yl]naphthalene-2-sulfonamide. Prepared from 3-[(2S)-2-amino-3-oxo-3-(4-phenylpiperidin-1-yl)propyl]benzonitrile (4.1 g, 20.1 mmol) using General Procedure C. Yield (0.312 g, 79%). LRMS (ESI) C31H29N3O3S found [M+H]: 524.2.
  • 3-[(2S)-2-Amino-3-oxo-3-(4-phenylpiperidin-1-yl)propyl]benzonitrile. Prepared from tert-butyl [(2S)-3-(3-cyanophenyl)-1-oxo-1-(4-phenylpiperidin-1-yl)propan-2-yl]carbamate (0.67 g, 1.54 mmol) using General Procedure B. LRMS (ESI) C21H23N3O found [M+H]: 334.2.
  • tert-butyl [(2S)-3-(3-Cyanophenyl)-1-oxo-1-(4-phenylpiperidin-1-yl)propan-2-yl]carbamate. Prepared from N-Boc-3-cyanophenylalanine (19) (0.56 g, 1.81 mmol) and N-phenylpiperidine (0.32 g, 2.01 mmol) using General Procedure A. Purified by MPLC (0-75% EtOAc/Hexanes). Yield (0.67 g, 85%). LRMS (ESI) C26H31N3O3 found [M+H]: 434.2.
  • (S)-3-(2-(Naphthalene-2-sulfonamido)-3-oxo-3-(4-phenylpiperazin-1-yl)propyl)benzimidamide (25g). Prepared from (S)—N-acetoxy-3-(2-(naphthalene-2-sulfonamido)-3-oxo-3-(4-phenylpiperazin-1-yl)propyl)benzimidamide (0.123 g, 0.205 mmol) using General Procedure F. Purified by reversed-phase HPLC (5-60% acetonitrile/water/0.05% TFA), Yield (0.069 g, 54.7%). 1H NMR (300 MHz, DMSO-d6) δ 9.42 (s, 2H), 9.29 (s, 2H), 8.22-8.51 (m, 2H), 7.85-8.12 (m, 3H), 7.36-7.74 (m, 7H), 7.08-7.28 (m, 2H), 6.61-6.90 (m, 3H), 4.49-4.75 (m, 1H), 3.37-3.61 (m, 1H), 3.19-3.37 (m, 1H), 3.03-3.18 (m, 1H), 2.96 (dd, J=7.00, 13.32 Hz, 2H), 2.52-2.89 (m, 4H), 2.25-2.45 (m, 1H). LRMS (ESI) C30H31N5O3S found [M+H]: 542.2.
  • (S)—N-Acetoxy-3-(2-(naphthalene-2-sulfonamido)-3-oxo-3-(4-phenylpiperazin-1-yl)propyl)benzimidamide. Prepared from N-hydroxy-3-[(2S)-2-[(2-naphthylsulfonyl)amino]-3-oxo-3-(4-phenylpiperidin-1-yl)propyl]benzenecarboximidamide (0.26 mmol) using General Procedure E. Purification by MPLC (0-40% EtOAc/hexanes). Yield (0.123 g, 79%). LRMS (ESI) C32H33N5O5S found [M+H]: 600.2.
  • (S)—N-Hydroxy-3-(2-(naphthalene-2-sulfonamido)-3-oxo-3-(4-phenylpiperazin-1 yl)propyl)benzimidamide. Prepared from (S)—N-(3-(3-cyanophenyl)-1-oxo-1-(4-phenylpiperazin-1-yl)propan-2-yl)naphthalene-2-sulfonamide (0.312 g, 0.589 mmol) using General Procedure D. LRMS (ESI) C30H31N5O4S found [M+H]: 558.2.
  • (S)—N-(3-(3-Cyanophenyl)-1-oxo-1-(4-phenylpiperazin-1-yl)propan-2-yl)naphthalene-2-sulfonamide. Prepared from (S)-3-(2-amino-3-oxo-3-(4-phenylpiperazin-1-yl)propyl)benzonitrile (0.121 g, 0.327 mmol) using General Procedure C. Purified by MPLC (0-75% EtOAc/Hexanes). Yield (0.133 g, 79.5%). LRMS (ESI) C30H28N4O3S found [M+H]: 525.2.
  • (S)-3-(2-Amino-3-oxo-3-(4-phenylpiperazin-1-yl)propyl)benzonitrile. Prepared from tert-butyl [(2S)-3-(3-cyanophenyl)-1-oxo-1-(4-phenylpiperidin-1-yl)propan-2-yl]carbamate (0.347 g, 0.80 mmol) using General Procedure B. Purified product obtained by trituration in ether followed by filtration and drying. Yield (0.29 g, 97%). LRMS (ESI) C20H22N4O found [M+H]: 335.2.
  • tert-butyl (S)-(3-(3-Cyanophenyl)-1-oxo-1-(4-phenylpiperazin-1-yl)propan-2-yl)carbamate. Prepared from N-Boc-3-cyanophenylalanine (19) (0.24 g, 0.83 mmol) and N-phenylpiperazine (0.92 mmol) using General Procedure A. Purified by MPLC (0-75% EtOAc/Hexanes). Yield (0.35 g, 96%). LRMS (ESI) C25H30N4O3 found [M+H]: 435.2.
  • (S)-Benzyl 4-(3-(3-carbamimidoylphenyl)-2-(4-methylphenylsulfonamido)propanoyl)piperazine-1-carboxylate (25h). Prepared from benzyl (S)-4-(3-(3-(N-acetoxycarbamimidoyl)phenyl)-2-((4-methylphenyl)sulfonamido)propanoyl)piperazine-1-carboxylate (0.141 g, 0.228 mmol) using General Procedure F. Purified by reversed-phase HPLC (5-75% acetonitrile/water/0.05% TFA), Yield (0.058 g). 1H NMR (300 MHz, DMSO-d6) δ 9.39 (br. s., 2H), 9.29 (br. s., 2H), 8.15 (d, J=9.34 Hz, 1H), 7.63-7.82 (m, 2H), 7.22-7.62 (m, 10H), 5.07 (s, 2H), 4.37-4.63 (m, 1H), 3.44-3.71 (m, 2H), 3.10-3.29 (m, 3H), 2.84-3.10 (m, 3H), 2.60-2.84 (m, 2H), 2.32 (s, 3H). LRMS (ESI) C29H33N5O5S found [M+H]: 564.2.
  • Benzyl (S)-4-(3-(3-(N-acetoxycarbamimidoyl)phenyl)-2-((4-methylphenyl)sulfonamido)propanoyl)piperazine-1-carboxylate. Prepared from benzyl (S)-4-(3-(3-(N-hydroxycarbamimidoyl)phenyl)-2-((4-methylphenyl)sulfonamido)propanoyl)piperazine-1-carboxylate (0.132 g, 0.228 mmol) using General Procedure E. LRMS (ESI) C31H35N5O7S found [M+H]: 622.2.
  • Benzyl (S)-4-(3-(3-(N-hydroxycarbamimidoyl)phenyl)-2-((4-methylphenyl)sulfonamido)propanoyl)piperazine-1-carboxylate. Prepared from benzyl (S)-4-(3-(3-cyanophenyl)-2-((4-methylphenyl)sulfonamido)propanoyl)piperazine-1-carboxylate (0.24 g, 0.228 mmol) using General Procedure D. LRMS (ESI) C29H33N5O6S found [M+H]: 580.2.
  • Benzyl (S)-4-(3-(3-cyanophenyl)-2-((4-methylphenyl)sulfonamido)propanoyl)piperazine-1-carboxylate. Prepared from benzyl (S)-4-(2-amino-3-(3-cyanophenyl)propanoyl)piperazine-1-carboxylate (0.243 g, 0.522 mmol) using General Procedure C. Purified by MPLC (0-75% EtOAc/Hexanes). Yield (0.124 g, 45.6%). LRMS (ESI) C29H30N4O5S found [M+H]: 547.2.
  • Benzyl (S)-4-(2-amino-3-(3-cyanophenyl)propanoyl)piperazine-1-carboxylate. Prepared from benzyl (S)-4-(2-((tert-butoxycarbonyl)amino)-3-(3-cyanophenyl)propanoyl)piperazine-1-carboxylate (0.257 g, 0.522 mmol) using General Procedure B. LRMS (ESI) C22H24N4O3 found [M+H]: 393.2.
  • Benzyl (S)-4-(2-((tert-butoxycarbonyl)amino)-3-(3-cyanophenyl)propanoyl)piperazine-1-carboxylate. Prepared from N-Boc-3-cyanophenylalanine (19) (1.02 g, 3.51 mmol) and N-carboxybenzyl piperazine (3.89 mmol) using General Procedure A. Purified by MPLC (0-80% EtOAc/Hexanes). Yield (0.257 g). LRMS (ESI) C27H32N4O5 found [M+H]: 493.2.
  • (S)-3-(3-Cyanophenyl)-2-(naphthalene-2-sulfonamido)propanoic acid (20B). Prepared from methyl (S)-2-amino-3-(3-cyanophenyl)propanoate (19B) (4.1 g, 20.1 mmol) using General Procedure C to give methyl (S)-3-(3-cyanophenyl)-2-(naphthalene-2-sulfonamido)propanoate. Yield (8.19 g). LRMS (ESI) C21H18N2O4S found [M+H]: 395.1. A solution of the crude ester in 1M HCl/AcOH (2:1) was refluxed for ˜8 hours until no starting material was remaining by LCMS. After cooling to room temperature, the precipitate was filtered to give the title compound, Yield (8.0 g). LRMS (ESI) C20H16N2O4S found [M+H]: 381.1.
  • (S)—N-(3-(3-Cyanophenyl)-1-oxo-1-(piperazin-1-yl)propan-2-yl)naphthalene-2-sulfonamide (21B). Using General Procedure A, the crude 20B (2.0 g, 5.26 mmol) and N-tert-butoxycarbonyl-piperazine (0.98 g, 5.26 mmol) were combined to give tert-butyl (S)-4-(3-(3-cyanophenyl)-2-(naphthalene-2-sulfonamido)propanoyl)piperazine-1-carboxylate after MPLC (0-75% EtOAc/hexanes), Yield (2.15 g). LRMS (ESI) C29H32N4O5S found [M+H]: 549.2. To a solution of the product in 1,4-dioxane was added HCl and stirred at room temperature overnight. After concentrating in vacuo, the residue was dissolved in MeOH and then concentrated to dryness. Purification by MPLC (0-10% MeOH/DCM gave the title product, Yield (0.8 g). 1H NMR (300 MHz, dmso-d6) δ 2.30-2.47 (m, 2H) 2.71 (dd, J=13.46, 9.07 Hz, 2H) 2.87 (dd, J=13.46, 5.77 Hz, 2H) 3.09-3.21 (m, 1H) 3.31-3.43 (m, 3H) 4.51 (dd, J=8.65, 6.46 Hz, 1H) 7.33 (t, J=7.83 Hz, 1H) 7.49 (d, J=7.69 Hz, 2H) 7.57-7.74 (m, 5H) 7.93-8.10 (m, 3H) 8.24 (s, 1H) ppm. LRMS (ESI) C24H24N4O3S found [M+H]: 449.2.
  • (S)—N-Benzyl-4-(3-(3-carbamimidoylphenyl)-2-(naphthalene-2-sulfonamido)propanoyl)piperazine-1-carboxamide (17a). Prepared from (S)-4-(3-(3-(N-acetoxycarbamimidoyl)phenyl)-2-(naphthalene-2-sulfonamido)propanoyl)-N-benzylpiperazine-1-carboxamide using General Procedure F. Purification by reverse phase HPLC (10-60% acetonitrile/water/0.05% TFA). Yield: 24.2 mg (44%). 1H NMR (300 MHz, dmso-d6) 6 ppm 2.56-2.83 (m, 3H) 2.86-3.10 (m, 3H) 3.18 (br. s., 2H) 3.79-4.02 (m, 1H) 4.17 (m, 2H) 4.56 (m, 2H) 6.96 (s, 1H) 7.02-7.08 (m, 2H) 7.13-7.22-7.31 (m, 3H) 7.43 (m, 2H) 7.51-7.77 (m, 4H) 7.97 (br. s., 1H) 8.00-8.21 (m, 2H) 8.22-8.49 (m, 2H) 8.92 (m, 2H) 8.63 (br. S. 1H) 9.29 (br s, 1H). LRMS (ESI) C32H34N6O4S found [M+H]: 599.2.
  • (S)-4-(3-(3-(N-Acetoxycarbamimidoyl)phenyl)-2-(naphthalene-2-sulfonamido)propanoyl)-N-benzylpiperazine-1-carboxamide. Prepared from (S)—N-benzyl-4-(3-(3-(N-hydroxycarbamimidoyl)phenyl)-2-(naphthalene-2-sulfonamido)propanoyl)piperazine-1-carboxamide using General Procedure E. LRMS (ESI) C34H36N6O6S found [M+H]: 657.2.
  • (S)—N-Benzyl-4-(3-(3-(N-hydroxycarbamimidoyl)phenyl)-2-(naphthalene-2-sulfonamido)propanoyl)piperazine-1-carboxamide. Prepared from (S)—N-benzyl-4-(3-(3-cyanophenyl)-2-(naphthalene-2-sulfonamido)propanoyl)piperazine-1-carboxamide (54.4 mg, 0.094 mmol) using General Procedure D. LRMS (ESI) C34H36N6O6S found [M+H]: 615.2.
  • (S)—N-Benzyl-4-(3-(3-cyanophenyl)-2-(naphthalene-2-sulfonamido)propanoyl)piperazine-1-carboxamide. To a solution of 21B (50 mg, 0.119 mmol) in THF (1 mL) under a nitrogen atmosphere was added benzyl isocyanate (41 uL, 0.335 mmol). The reaction mixture was stirred overnight at room temperature. The reaction was concentrated in vacuo and the residue purified by MPLC (10-75% EtOAc/hexanes) to give the title compound. Yield (54.4 mg). LRMS (ESI) C32H31N5O4S found [M+H]: 582.2.
  • (S)—N-(4-Bromobenzyl)-4-(3-(3-carbamimidoylphenyl)-2-(naphthalene-2-sulfonamido)propanoyl)piperazine-1-carboxamide (25a). Prepared from (S)-4-(3-(3-(N-acetoxycarbamimidoyl)phenyl)-2-(naphthalene-2-sulfonamido)propanoyl)-N-(4-bromobenzyl)piperazine-1-carboxamide using General Procedure F. Purification by reverse phase HPLC (25-75% acetonitrile/water/0.05% TFA). Yield: 9.8 mg (12%). 1H NMR (300 MHz, dmso-d6) δ ppm 2.56-2.83 (m, 3H) 2.83-3.00 (m, 2H) 3.04 (d, J=9.39 Hz, 1H) 3.11-3.28 (m, 2H) 3.39-3.51 (m, 1H) 3.57-3.76 (m, 1H) 4.11 (d, J=5.48 Hz, 1H) 4.42-4.61 (m, 1H) 6.99-7.27 (m, 3H) 7.27-7.52 (m, 4H) 7.52-7.74 (m, 4H) 7.82 (s, 1H) 7.89-8.17 (m, 3H) 8.17-8.43 (m, 2H) 9.09 (s, 2H) 9.32 (s, 2H). LRMS (ESI) C32H33BrN6O4S found [M+H]: 677.1/679.1.
  • (S)-4-(3-(3-(N-Acetoxycarbamimidoyl)phenyl)-2-(naphthalene-2-sulfonamido)propanol)-N-(4-bromobenzyl)piperazine-1-carboxamide. Prepared from (S)—N-(4-bromobenzyl)-4-(3-(3-(N-hydroxycarbamimidoyl)phenyl)-2-(naphthalene-2-sulfonamido)propanoyl)piperazine-1-carboxamide using General Procedure E. LRMS (ESI) C34H35BrN6O6S found [M+H]: 635.1/637.1.
  • (S)—N-(4-Bromobenzyl)-4-(3-(3-(N-hydroxycarbamimidoyl)phenyl)-2-(naphthalene-2-sulfonamido)propanoyl)piperazine-1-carboxamide. Prepared from (S)—N-(4-bromobenzyl)-4-(3-(3-cyanophenyl)-2-(naphthalene-2-sulfonamido)propanoyl)piperazine-1-carboxamide (78 mg, 0.112 mmol) using General Procedure D. LRMS (ESI) C32H33BrN6O5S found [M+H]: 693.1/695.1.
  • (S)—N-(4-Bromobenzyl)-4-(3-(3-cyanophenyl)-2-(naphthalene-2-sulfonamido)propanoyl)piperazine-1-carboxamide. To a solution of 21B (50 mg, 0.115 mmol) in THF (1 mL) under a nitrogen atmosphere was added 4-bromobenzyl isocyanate (32 μL, 0.23-0 mmol). The reaction mixture was stirred overnight at room temperature. The reaction was concentrated in vacuo and the triturated with THF, filtered, and dried to give the title compound. Yield (78 mg). LRMS (ESI) C32H30BrN5O4S found [M+H]: 660.1/662.1.
  • (S)-4-(3-(3-Carbamimidoylphenyl)-2-(naphthalene-2-sulfonamido)propanoyl)-N-hexylpiperazine-1-carboxamide (25d). Prepared from (S)-4-(3-(3-(N-acetoxycarbamimidoyl)phenyl)-2-(naphthalene-2-sulfonamido)propanoyl)-N-hexylpiperazine-1-carboxamide using General Procedure F. The crude product was purified using MPLC (0-10% MeOH/DCM) to the give the title compound. Yield: 20 mg (50%). 1H NMR (300 MHz, dmso-d6) 6 ppm 0.75-0.93 (m, 3H) 1.12-1.31 (m, 5H) 1.72 (s, 3H) 2.54 (s, 4H) 2.62-2.74 (m, 2H) 2.86 (d, J=7.43 Hz, 1H) 2.93 (d, J=7.04 Hz, 2H) 3.00 (s, 1H) 3.50 (s, 1H) 4.28 (br. s., 1H) 4.45 (br. s., 1H) 4.56 (d, J=7.43 Hz, 1H) 6.41 (br. s., 2H) 6.54-6.79 (m, 2H) 6.95 (d, J=8.61 Hz, 1H) 7.14 (d, J=7.04 Hz, 1H) 7.23 (br. s., 1H) 7.34 (br. s., 1H) 7.54 (br. s., 1H) 7.57-7.75 (m, 2H) 7.89-8.13 (m, 2H) 8.22-8.38 (m, 1H) 8.49 (s, 1H). LRMS (ESI) C31H40N6O4S found [M+H]: 593.3.
  • (S)-4-(3-(3-(N-Acetoxycarbamimidoyl)phenyl)-2-(naphthalene-2-sulfonamido)propanoyl)-N-hexylpiperazine-1-carboxamide. Prepared from (S)—N-hexyl-4-(3-(3-(N-hydroxycarbamimidoyl)phenyl)-2-(naphthalene-2-sulfonamido)propanoyl)piperazine-1-carboxamide using General Procedure E. LRMS (ESI) C33H42N6O6S found [M+H]: 651.3.
  • (S)—N-Hexyl-4-(3-(3-(N-hydroxycarbamimidoyl)phenyl)-2-(naphthalene-2-sulfonamido)propanoyl)piperazine-1-carboxamide. Prepared from (S)-4-(3-(3-cyanophenyl)-2-(naphthalene-2-sulfonamido)propanoyl)-N-hexylpiperazine-1-carboxamide (40 mg, 0.069 mmol) using General Procedure D. LRMS (ESI) C31H40N6O5S found [M+H]: 609.3.
  • (S)-4-(3-(3-Cyanophenyl)-2-(naphthalene-2-sulfonamido)propanoyl)-N-hexylpiperazine-1-carboxamide. To a solution of 21B (50 mg, 0.115 mmol) in THF (1 mL) under a nitrogen atmosphere was added hexyl isocyanate (49 uL, 0.335 mmol). The reaction mixture was stirred overnight at room temperature. The reaction was concentrated in vacuo and the residue purified by MPLC (10-70% EtOAc/hexanes) to give the title compound. Yield (40 mg). LRMS (ESI) C31H37N5O4S found [M+H]: 576.3.
  • (S)-3-(3-(4-(Benzo[b]thiophene-3-carbonyl)piperazin-1-yl)-2-(naphthalene-2-sulfonamido)-3-oxopropyl)benzimidamide (25e). Prepared from (S)—N-acetoxy-3-(3-(4-(benzo[b]thiophene-3-carbonyl)piperazin-1-yl)-2-(naphthalene-2-sulfonamido)-3-oxopropyl)benzimidamide using General Procedure F. Purification by reverse phase HPLC (5-60% acetonitrile/water/0.05% TFA). Yield: 11 mg (21%). 1H NMR (300 MHz, dmso-d6) δ ppm 2.71 (br. s., 1H) 2.74-2.86 (m, 1H) 2.87-2.96 (m, 1H) 3.00 (br. s., 1H) 3.15 (d, J=19.17 Hz, 2H) 3.92 (s, 2H) 4.54 (s, 2H) 6.57 (s, 2H) 7.04-7.20 (m, 1H) 7.20-7.34 (m, 1H) 7.34-7.54 (m, 2H) 7.59 (br. s., 1H) 7.63-7.77 (m, 2H) 7.87 (s, 2H) 7.97-8.22 (m, 3H) 8.33 (br. s., 1H) 8.39 (m, 1H) 8.60 (m, 1H) 8.90 (m, 2H) 9.25 (m, 2H). LRMS (ESI) C33H31N5O4S2 found [M+H]: 626.2.
  • (S)—N-Acetoxy-3-(3-(4-(benzo[b]thiophene-3-carbonyl)piperazin-1-yl)-2-(naphthalene-2-sulfonamido)-3-oxopropyl)benzimidamide. Prepared from (S)-1-(3-(4-(benzo[b]thiophene-3-carbonyl)piperazin-1-yl)-2-(naphthalene-2-sulfonamido)-3-oxopropyl)-N-hydroxy-1l4-pyran-3-carboximidamide using General Procedure E. LRMS (ESI) C35H33N5O6S2, found [M+H]: 684.2.
  • (S)-1-(3-(4-(Benzo[b]thiophene-3-carbonyl)piperazin-1-yl)-2-(naphthalene-2-sulfonamido)-3-oxopropyl)-N-hydroxy-1l4-pyran-3-carboximidamide. Prepared from (S)—N-(1-(4-(benzo[b]thiophene-3-carbonyl)piperazin-1-yl)-3-(3-cyanophenyl)-1-oxopropan-2-yl)naphthalene-2-sulfonamide (51 mg, 0.0139 mmol) using General Procedure D. LRMS (ESI) C33H31N5O5S2, found [M+H]: 642.2.
  • (S)—N-(1-(4-(Benzo[b]thiophene-3-carbonyl)piperazin-1-yl)-3-(3-cyanophenyl)-1-oxopropan-2-yl)naphthalene-2-sulfonamide. To a solution of 3-carboxy benzothiophene (18 mg, 0.101 mmol), HBTU (42 mg, 0.115 mmol), and DIPEA (88 uL, 0.506 mmol) in THF (1.5 mL) under a nitrogen atmosphere, was added 21B (50 mg, 0.115 mmol). The reaction mixture was stirred overnight at room temperature. The reaction was concentrated in vacuo and the residue purified by MPLC (10-70% EtOAc/hexanes) to give the title compound. Yield (51 mg). LRMS (ESI) C33H28N4O4S2 found [M+H]: 609.2.
  • (S)-3-(3-Oxo-3-(4-phenylpiperazin-1-yl)-2-((2,4,6-triisopropylphenyl)sulfonamido)propyl)benzimidamide (27). Prepared from (S)—N-acetoxy-3-(3-oxo-3-(4-phenylpiperazin-1-yl)-2-((2,4,6-triisopropylphenyl)sulfonamido)propyl)benzimidamide using General Procedure F. Purified by reversed-phase HPLC (5-80% acetonitrile/water/0.05% TFA), Yield (0.166g, 42.8%). 1H NMR (300 MHz, DMSO-d6) δ 9.08-9.47 (m, 4H), 8.15-7.91 (d, 1H), 7.57-7.74 (m, 2H), 7.39-7.56 (m, 2H), 7.07-7.29 (m, 4H), 6.71-6.91 (m, 3H), 4.41-4.64 (m, 1H), 3.93-4.20 (m, 2H), 3.27-3.52 (m, 2H), 3.15-3.27 (m, 2H), 2.99-3.15 (m, 2H), 2.78-2.99 (m, 4H), 2.59-2.78 (m, 2H), 0.98-1.31 (m, 18H). LRMS (ESI), C35H47N5O3S, [M+H]: 618.3.
  • (S)—N-Acetoxy-3-(3-oxo-3-(4-phenylpiperazin-1-yl)-2-((2,4,6-triisopropylphenyl)sulfonamido)propyl)benzimidamide. Prepared from (S)—N-hydroxy-3-(3-oxo-3-(4-phenylpiperazin-1-yl)-2-((2,4,6-triisopropylphenyl)sulfonamido)propyl)benzimidamide using General Procedure E. LRMS (ESI), C37H49N5O5S, [M+H]: 676.3.
  • (S)—N-Hydroxy-3-(3-oxo-3-(4-phenylpiperazin-1-yl)-2-((2,4,6-triisopropylphenyl)sulfonamido)propyl)benzimidamide. Prepared from (S)—N-(3-(3-cyanophenyl)-1-oxo-1-(4-phenylpiperazin-1-yl)propan-2-yl)-2,4,6-triisopropylbenzenesulfonamide using General Procedure D. LRMS (ESI), C35H47N5O4S, [M+H]: 634.3
  • (S)—N-(3-(3-Cyanophenyl)-1-oxo-1-(4-phenylpiperazin-1-yl)propan-2-yl)-2,4,6-triisopropylbenzenesulfonamide. Prepared from (S)-3-(3-cyanophenyl)-2-((2,4,6-triisopropylphenyl)sulfonamido)propanoic acid (0.36 g, 0.96 mmol)35 and 4-phenyl piperazine (1.19 mmol) using General Procedure A. Purification by MPLC (0-50% EtOAc/hexanes), Yield (0.34 g, 72%). LRMS (ESI), C35H44N4O3S, [M+H]: 601.3
  • (S)-3-(2-(4-Methylphenylsulfonamido)-3-oxo-3-(4-phenylpiperidin-1-yl)propyl)benzimidamide (25b). Prepared from using General Procedure F. Yield (0.13 g, 55%). 1H NMR (300 MHz, DMSO-d6) δ 9.32 (s, 2H), 9.37 (s, 2H), 8.00-8.36 (m, 1H), 7.63-8.00 (m, 2H), 7.40-7.63 (m, 4H), 7.06-7.40 (m, 5H), 7.00 (d, J=7.42 Hz, 1H), 4.41-4.73 (m, 1H), 4.21-4.39 (m, 1H), 3.92 (t, J=9.75 Hz, 1H), 3.63-3.81 (m, 1H), 2.90-3.02 (m, 1H), 2.49-2.88 (m, 4H), 2.36 (s, 2H), 1.95-2.33 (m, 1H), 1.65 (d, J=11.81 Hz, 1H), 1.39-1.60 (m, 1H), 1.08-1.39 (m, 1H), 0.78-1.08 (m, 1H). LRMS (ESI), C28H32N4O3S, [M+H]: 505.2.
  • (S)—N-Acetoxy-3-(2-((4-methylphenyl)sulfonamido)-3-oxo-3-(4-phenylpiperidin-1-yl)propyl)benzimidamide. Prepared from (S)—N-hydroxy-3-(2-((4-methylphenyl)sulfonamido)-3-oxo-3-(4-phenylpiperidin-1-yl)propyl)benzimidamide using General Procedure E. Purification by MPLC (0-90% EtOAc/hexanes). Yield (0.24 g, 89%). LRMS (ESI), C30H34N4O5S, [M+H]: 563.2.
  • (S)—N-Hydroxy-3-(2-((4-methylphenyl)sulfonamido)-3-oxo-3-(4-phenylpiperidin-1-yl)propyl)benzimidamide. Prepared from (S)—N-(3-(3-cyanophenyl)-1-oxo-1-(4-phenylpiperidin-1-yl)propan-2-yl)-4-methylbenzenesulfonamide using General Procedure D. LRMS (ESI), C28H32N4O4S, [M+H]: 521.2.
  • (S)—N-(3-(3-Cyanophenyl)-1-oxo-1-(4-phenylpiperidin-1-yl)propan-2-yl)-4-methylbenzenesulfonamide. Prepared from 3-[(2S)-2-amino-3-oxo-3-(4-phenylpiperidin-1-yl)propyl]benzonitrile (0.256 g, 0.69 mmol) using General Procedure C. Yield (0.23 g, 68%). LRMS (ESI), C28H29N3O3S, [M+H]: 488.2.
  • Benzyl (S)-1-((S)-3-(3-carbamimidoylphenyl)-2-(4-methylphenylsulfonamido)propanoyl)piperidin-3-ylcarbamate (18). Prepared from benzyl ((S)-1-((S)-3-(3-(N-acetoxycarbamimidoyl)phenyl)-2-((4-methylphenyl)sulfonamido)propanoyl)piperidin-3-yl)carbamate using General Procedure F. Yield (0.14 g, 44%). 1H NMR (300 MHz, DMSO-d6) δ 9.13-9.47 (m, 4H), 7.60-7.77 (m, 2H), 7.40-7.59 (m, 4H), 7.12-7.40 (m, 7H), 5.00 (s, 1H), 4.29-4.60 (m, 1H), 3.95-4.15 (m, 1H), 3.62-3.85 (m, 2H), 3.56 (d, J=1.10 Hz, 1H), 3.29-3.46 (m, 2H), 2.64-2.99 (m, 3H), 2.53-2.63 (m, 1H), 2.34 (s, 3H), 1.69-1.98 (m, 1H), 1.56-1.69 (m, 1H), 1.26-1.49 (m, 1H), 1.08-1.24 (m, 1H). LRMS (ESI), C30H35N5O5S, [M+H]: 578.2.
  • Benzyl ((S)-1-((S)-3-(3-(N-acetoxycarbamimidoyl)phenyl)-2-((4-methylphenyl)sulfonamido)propanoyl)piperidin-3-yl)carbamate. Prepared from benzyl ((S)-1-((S)-3-(3-(N-hydroxycarbamimidoyl)phenyl)-2-((4-methylphenyl)sulfonamido)propanoyl)piperidin-3-yl)carbamate using General Procedure E. LRMS (ESI), C32H37N5O7S, [M+H]: 636.2.
  • Benzyl ((S)-1-((S)-3-(3-(N-hydroxycarbamimidoyl)phenyl)-2-((4-methylphenyl)sulfonamido)propanoyl)piperidin-3-yl)carbamate. Prepared from benzyl ((S)-1-((S)-3-(3-cyanophenyl)-2-((4-methylphenyl)sulfonamido)propanoyl)piperidin-3-yl)carbamate using General Procedure D. LRMS (ESI), C30H35N5O6S, [M+H]: 594.2.
  • Benzyl ((S)-1-((S)-3-(3-cyanophenyl)-2-((4-methylphenyl)sulfonamido)propanoyl)piperidin-3-yl)carbamate. Prepared from benzyl ((S)-1-((S)-2-amino-3-(3-cyanophenyl)propanoyl)piperidin-3-yl)carbamate using General Procedure C. Purification by MPLC (0-75% EtOAc/hexanes). Yield (0.27 g, 69%). LRMS (ESI), C30H32N4O5S, [M+H]: 561.2.
  • Benzyl ((S)-1-((S)-2-amino-3-(3-cyanophenyl)propanoyl)piperidin-3-yl)carbamate. Prepared from benzyl ((S)-1-((S)-2-((tert-butoxycarbonyl)amino)-3-(3-cyanophenyl)propanoyl)piperidin-3-yl)carbamate using General Procedure B. LRMS (ESI), C23H26N4O3, [M+H]: 407.2.
  • Benzyl ((S)-1-((S)-2-((tert-butoxycarbonyl)amino)-3-(3-cyanophenyl)propanoyl)piperidin-3-yl)carbamate. Prepared from 19 (0.46 g, 1.59 mmol) and benzyl (S)-piperidin-3-ylcarbamate (0.48 g, 2.04 mmol) using General Procedure A. LRMS (ESI), C28H34N4O5, [M+H]: 507.2.
  • Benzyl (R)-1-((S)-3-(3-carbamimidoylphenyl)-2-(naphthalene-2-sulfonamido)propanoyl)piperidin-3-ylcarbamate (25f). Prepared from benzyl ((R)-1-((S)-3-(3-(N-acetoxycarbamimidoyl)phenyl)-2-(naphthalene-2-sulfonamido)propanoyl)piperidin-3-yl)carbamate using General Procedure F. Yield (0.136 g, 53%). 1H NMR (300 MHz, DMSO-d6) δ 9.20-9.48 (m, 3H), 9.15 (br. s., 1H), 8.15-8.43 (m, 2H), 7.85-8.15 (m, 3H), 7.77 (br. s., 1H), 7.55-7.69 (m, 3H), 7.29-7.53 (m, 8H), 4.86-5.23 (m, 3H), 4.35-4.68 (m, 1H), 3.87-4.17 (m, 1H), 3.57-3.87 (m, 1H), 2.81-3.09 (m, 2H), 2.52-2.81 (m, 3H), 1.74-1.94 (m, 1H), 1.58-1.74 (m, 1H), 1.34-1.58 (m, 1H), 0.90-1.29 (m, 2H). LRMS (ESI), C33H35N5O5S, [M+H]: 614.2.
  • Benzyl ((R)-1-((S)-3-(3-(N-acetoxycarbamimidoyl)phenyl)-2-(naphthalene-2-sulfonamido)propanoyl)piperidin-3-yl)carbamate. Prepared from benzyl ((R)-1-((S)-3-(3-(N-hydroxycarbamimidoyl)phenyl)-2-(naphthalene-2-sulfonamido)propanoyl)piperidin-3-yl)carbamate using General Procedure E. LRMS (ESI), C35H37N5O7S, [M+H]: 672.2.
  • Benzyl ((R)-1-((S)-3-(3-(N-hydroxycarbamimidoyl)phenyl)-2-(naphthalene-2-sulfonamido)propanoyl)piperidin-3-yl)carbamate. Prepared from benzyl ((R)-1-((S)-3-(3-cyanophenyl)-2-(naphthalene-2-sulfonamido)propanoyl)piperidin-3-yl)carbamate using General Procedure D. LRMS (ESI), C33H35N5O6S, [M+H]: 630.2.
  • Benzyl ((R)-1-((S)-3-(3-cyanophenyl)-2-(naphthalene-2-sulfonamido)propanoyl)piperidin-3-yl)carbamate. Prepared from benzyl ((R)-1-((S)-2-amino-3-(3-cyanophenyl)propanoyl)piperidin-3-yl)carbamate using General Procedure C. Purification by MPLC (0-85% EtOAc/hexanes). Yield (0.22 g, 57%). LRMS (ESI), C33H32N4O5S, [M+H]: 597.2.
  • Benzyl ((R)-1-((S)-2-amino-3-(3-cyanophenyl)propanoyl)piperidin-3-yl)carbamate. Prepared from benzyl ((R)-1-((S)-2-((tert-butoxycarbonyl)amino)-3-(3-cyanophenyl)propanoyl)piperidin-3-yl)carbamate using General Procedure B. Yield (0.29 g). LRMS (ESI), C23H26N4O3, [M+H]: 407.2.
  • Benzyl ((R)-1-((S)-2-((tert-butoxycarbonyl)amino)-3-(3-cyanophenyl)propanoyl)piperidin-3-yl)carbamate. Prepared from 19 (0.42 g, 1.46 mmol) and benzyl (R)-piperidin-3-ylcarbamate (0.48 g, 2.04 mmol) using General Procedure A. Purification by MPLC (5-80% EtOAc/hexanes), Yield (0.346 g, 47%). LRMS (ESI), C28H34N4O5, [M+H]: 507.2.
  • 1-((S)-3-(3-Carbamimidoylphenyl)-2-(4-methylphenylsulfonamido)propanoyl)-N-phenethylpiperidine-3-carboxamide (25c). Prepared from 1-((S)-3-(3-(N-acetoxycarbamimidoyl)phenyl)-2-((4-methylphenyl)sulfonamido)propanoyl)-N-phenethylpiperidine-3-carboxamide using General Procedure F. Yield (0.28 g, 39%). 1H NMR (300 MHz, DMSO-d6) δ 9.52-9.78 (m, 2H), 9.30-9.52 (m, 2H), 8.03-8.40 (m, 2H), 7.76-7.98 (m, 2H), 7.49-7.76 (m, 4H), 7.24-7.49 (m, 7H), 4.51-4.78 (m, 1H), 3.90-4.36 (m, 1H), 3.78-3.90 (m, 1H), 3.59-3.68 (m, 1H), 3.29-3.46 (m, 2H), 3.00-3.19 (m, 1H), 2.69-3.00 (m, 4H), 2.56-2.69 (m, 1H), 2.01-2.25 (m, 1H), 1.80-2.01 (m, 1H), 1.23-1.80 (m, 3H), 0.30-1.21 (m, 1H). LRMS (ESI), C31H37N5O4S, [M+H]: 576.3.
  • 1-((S)-3-(3-(N-Acetoxycarbamimidoyl)phenyl)-2-((4-methylphenyl)sulfonamido)propanoyl)-N-phenethylpiperidine-3-carboxamide. Prepared from 1-((S)-3-(3-(N-hydroxycarbamimidoyl)phenyl)-2-((4-methylphenyl)sulfonamido)propanoyl)-N-phenethylpiperidine-3-carboxamide using General Procedure E. LRMS (ESI), C33H39N5O6S, [M+H]: 634.3.
  • 1-((S)-3-(3-(N-Hydroxycarbamimidoyl)phenyl)-2-((4-methylphenyl)sulfonamido)propanoyl)-N-phenethylpiperidine-3-carboxamide. Prepared from 1-((S)-3-(3-cyanophenyl)-2-((4-methylphenyl)sulfonamido)propanoyl)-N-phenethylpiperidine-3-carboxamide using General Procedure D. LRMS (ESI), C31H37N5O5S, [M+H]: 592.3.
  • 1-((S)-3-(3-Cyanophenyl)-2-((4-methylphenyl)sulfonamido)propanoyl)-N-phenethylpiperidine-3-carboxamide. Prepared from (S)-3-(3-cyanophenyl)-2-((4-methylphenyl)sulfonamido)propanoic acid (0.67 g, 1.95 mmol) and N-phenethylpiperidine-3-carboxamide (0.68 g, 2.53 mmol) using General Procedure A. Yield (0.96 g, 88%). LRMS (ESI), C31H34N4O4S, [M+H]: 559.2.
  • (S)-3-(3-Cyanophenyl)-2-((4-methylphenyl)sulfonamido)propanoic acid. To a solution of methyl (S)-3-(3-cyanophenyl)-2-((4-methylphenyl)sulfonamido)propanoate (1.85g, 5.17 mmol) in THF (30 mL) was added LiOH (0.80 g) in water (10 mL). The reaction was stirred at room temperature for 2 h. The organic layer was extracted with water and the combined aqueous fractions were adjusted to pH 3 with conc. HCl and then extracted with EtOAc. The combined organic layers were dried over MgSO4, filtered and the filtrate concentrated in vacuo to give the title compound. Yield (1.68 g, 95%). LRMS (ESI), C17H16N2O4S, [M+H]: 345.1.
  • Methyl (S)-3-(3-cyanophenyl)-2-((4-methylphenyl)sulfonamido)propanoate. Prepared from 19B (1.53 g, 6.36 mmol) using General Procedure C. Yield (1.85 g, 81%). LRMS (ESI), C18H18N2O4S, [M+H]: 359.1.
    • Example 9 Inhibition Studies with Benzamidine Compounds
  • Fluorescent inhibitor and chromogenic proteolytic assays were performed in general accordance with the procedures described in Example 4 for compounds prepared in Example 8.
  • The results for these studies are presented in Tables 9.1, 9.2, and 9.3 and FIGS. 10-17.
  • The results for selective studies are presented in Table 9.4.
  • TABLE 9.1
    Figure US20220169676A1-20220602-C00186
    Fluorogenic Assay
    HGFA Matriptase Hepsin
    Compound Ki Ki Ki
    No. R1 R2 W (μM) (μM) (μM)
    16 (DEJ-1-69- 002)
    Figure US20220169676A1-20220602-C00187
    Figure US20220169676A1-20220602-C00188
         		C 10.1 0.3 3.28
    17a (FMF-1- 279-003)
    Figure US20220169676A1-20220602-C00189
    Figure US20220169676A1-20220602-C00190
         		N 14.0 2.06 1.0
    25a (FMF-1- 236-003)
    Figure US20220169676A1-20220602-C00191
    Figure US20220169676A1-20220602-C00192
         		N 16.2 4.2 0.048
    25b (DEJ-1-65- 001)
    Figure US20220169676A1-20220602-C00193
    Figure US20220169676A1-20220602-C00194
         		C 19.85 0.57 4.8
    25d (FMF-1- 278-003)
    Figure US20220169676A1-20220602-C00195
    Figure US20220169676A1-20220602-C00196
         		N >50 14.9 1.3
    25e (FMF-1- 281-003)
    Figure US20220169676A1-20220602-C00197
    Figure US20220169676A1-20220602-C00198
         		N >50 1.2 3.75
    25g (DEJ-1-63- 001)
    Figure US20220169676A1-20220602-C00199
    Figure US20220169676A1-20220602-C00200
         		N 18.3 1.8 7.0
    25h (DEJ-1- 112-004)
    Figure US20220169676A1-20220602-C00201
    Figure US20220169676A1-20220602-C00202
         		N >50 0.43 2.4
    26 (JJ-I-134- 2)
    Figure US20220169676A1-20220602-C00203
    Figure US20220169676A1-20220602-C00204
         		N 5.5 0.12 8.14
    JWJ-I-135
    Figure US20220169676A1-20220602-C00205
    Figure US20220169676A1-20220602-C00206
         		N 17.84 0.0043 1.58
    JJ-I-134-2
    Figure US20220169676A1-20220602-C00207
    Figure US20220169676A1-20220602-C00208
         		N 5.45 0.12 8.13
    27 (DEJ-1- 173-004)
    Figure US20220169676A1-20220602-C00209
    Figure US20220169676A1-20220602-C00210
         		N 22.2 0.76 7.4
    28 (FMF-1- 238-003)
    Figure US20220169676A1-20220602-C00211
    Figure US20220169676A1-20220602-C00212
         		N 2.286-002
    29 (FMF-1- 276-003)
    Figure US20220169676A1-20220602-C00213
    Figure US20220169676A1-20220602-C00214
         		N >20 >20
    30 (FMF-1- 277-004)
    Figure US20220169676A1-20220602-C00215
    Figure US20220169676A1-20220602-C00216
         		N 12.4 4.9
    31 (FMF-1- 280-003)
    Figure US20220169676A1-20220602-C00217
    Figure US20220169676A1-20220602-C00218
         		N 4.4 1.7
    32 (FMF-1- 237-003)
    Figure US20220169676A1-20220602-C00219
    Figure US20220169676A1-20220602-C00220
         		N 2.8 1.0
    FMF-1- 275-004
    Figure US20220169676A1-20220602-C00221
    Figure US20220169676A1-20220602-C00222
         		N 2.78 39.5
    FMF-1- 279-003
    Figure US20220169676A1-20220602-C00223
    Figure US20220169676A1-20220602-C00224
         		N 14.03 2.56 1.04
    FMF-1- 278-003
    Figure US20220169676A1-20220602-C00225
    Figure US20220169676A1-20220602-C00226
         		N >50 14.87 1.28
  • TABLE 9.2
    Figure US20220169676A1-20220602-C00227
    Fluorogenic Assay
    HGFA Matriptase Hepsin
    Compound Ki Ki Ki
    No. R1 R2 (μM) (μM) (μM)
    25f* (DEJ-1-86- 002)
    Figure US20220169676A1-20220602-C00228
    Figure US20220169676A1-20220602-C00229
         		>50 4.9 2.8
    18* (DEJ-1-85- 002)
    Figure US20220169676A1-20220602-C00230
    Figure US20220169676A1-20220602-C00231
         		>50 1 2.3
    25c* (DEJ-1-194- 002)
    Figure US20220169676A1-20220602-C00232
    Figure US20220169676A1-20220602-C00233
         		>50 1.3 0.67
  • TABLE 9.3
    Figure US20220169676A1-20220602-C00234
    Fluorogenic Assay
    HGFA Matriptase Hepsin
    Compound Ki Ki Ki
    No. R1 R2 W (μM) (μM) (μM)
    (FMF-1- 254-004)
    Figure US20220169676A1-20220602-C00235
    Figure US20220169676A1-20220602-C00236
         		N >50 >10 >10
  • TABLE 9.4
    Compound Thrombin Factor Xa Trypsin
    No. Ki (nM) Ki (nM) Ki (nM)
    FMF-1-236-003 3106.0 4564.0 2.20
    JWJ-1-135 >2000 — 1.93
    • Example 10. Tumor Microenvironment and Drug Sensitivity
  • The microenvironment of solid tumors is characterized by the presence of activated stromal cells, which produce an abundance of inflammatory mediators and growth factors that have been shown to play a critical role in tumor progression. Macrophages and myofibroblasts are two major components of the tumor microenvironment. HGF and other factors produced by macrophages and myofibroblasts that modulate oncogenic signaling pathways in tumor cells, include MET were investigated. An objective of this example is to understand the nature of tumor-derived factors that are responsible for activation of stromal cells and determine how the presence of genetic alterations in tumor cells alters communication of tumor cells with the stroma. In addition to their effect on tumor growth, HGF or MSP from the tumor microenvironment are also important regulators of responsiveness of cancer cells to antineoplastic therapies.
  • RON phosphorylation and migration and invasion assays of breast cancer cells: RON receptor tyrosine kinase activation confers resistance to tamoxifen in the MCF7 and T47D breast cancer cell lines. MDA-MB-231 express RON but we have not been able to detect phosphorylated RON (pRON) following MSP stimulation.
  • Detection and quantification of pRON in T47D cells was performed using a sandwich ELISA assy. RON capture antibody (R&D Systems, AF691) was immobilized on high protein binding 96-well plates. Next, cell lysates are added to wells, followed by incubation with an anti-phosphotyrosine-HRP antibody and then addition of a TMB substrate. Optical density of wells was determined by reading plates at 450 nm in a plate reader.
  • It can been seen in FIG. 18 that RON phosphorylation in T47D cells following active MSP stimulation, or HGFA-mediated pro-MSP stimulation, results in similar levels of RON phosphorylation. Inhibition with the triplex HGFA, matriptase, hepsin inhibitor Nafamostat, reduces pRON to background levels.
  • Triple-negative MDA-MB-231 breast cancer cells co-express MET, hepsin and HGFA but lower levels of RON and matriptase while T47D cells have good expression of RON.
  • MRC5 fibroblasts were plated in the bottom well of a Boyden chamber, and incubated overnight to condition the attractant media. The following day, MDA-MB-231 or T47D cells +/− inhibitors were plated above on Matrigel coated inserts (8.0 μm membrane inserts, 12-well; Corning 3422) and incubated in FBS media overnight. Inhibitors were added to fresh media and then cells were plated above on the inserts. The cells were fixed and stained at the 24 hour time point. The inserts were then removed and mounted on glass plates where the number of migrated cells were imaged and counted at 4 fields per membrane using a light microscope at 20×.
  • It can be seen in FIG. 19 that the two triplex inhibitors of HGFA, matriptase, and hepsin, 7115 and 7054 (1 μM) abrogate the MRC5-mediated migration and invasion of MDA-MB-231 cells through Matrigel by blocking active HGF production. The inhibitors tested are as effective as HAI-1, an endogenous inhibitor of matriptase, hepsin, and HGFA.
    • Example 11. PS-SCL and MSP-MS Substrate Screening of Natural and Unnatural Amino Acids
  • Characterization of hepsin and HGFA P4-P2 substrate specificity using HyCoSuL.: Each of the P4, P3, and P2 sublibraries were screened at the 100 μM concentration with hepsin either HGFA in a 100 μL final volume per well (99 μL of protease in buffer+1 μL of 10 mM substrates mixture). The total time of the assay was 30 minutes, however only linear portions of the progress curve (5-15 minutes) were used for velocity (RFU/s) calculations. Each sublibrary screening was repeated at least 3-times and the average value calculated from each measurement was used to create the substrate specificity matrix—the best recognized amino acid in each position was set to 100%, and other amino acids were adjusted accordingly.
  • Recombinant human hepsin (10 μg in 20 uL, 4776-SE-010, R&D Systems) was added to the 100 μL of activation buffer (0.1 M Tris, 0.15 M NaCl, 0.01 M CaCl2), 0.05% TRITON-X, pH=8.0) and incubated at 37° C. for 24 hours (hepsin concentration in activation buffer 2 μM). Once activated hepsin was diluted in assay buffer (0.05 M Tris, pH=9.0) to the final concentration of 4 nM and incubated at 37° C. for 15 minutes before added to a substrate.
  • HFGA enzyme was diluted in the assay buffer (0.15 M NaCl, 0.025 M Tris, 0.005 M CaCl2), pH=8.0) to the final concentration of 10-20 nM (depending of sublibrary) and incubated at 25° C. for 30 minutes before added to a substrate.
  • Characterization of hepsin and HGFA P1 substrate specificity using Ac-Ala-Arg-Leu-P1-ACC individual substrate library: The 142-membered Ac-Ala-Arg-Leu-P1-ACC fluorogenic substrate library containing 19 natural (except cysteine) and 123 unnatural amino acids was used to determine hepsin and HGFA preferences in P1 position. The protocol for both enzymes activation and incubation are as the same as in HyCoSuL screening. The P1 individual substrate library was used at the final concentration of 5 μM. The total time of the assay was 30 min, however only linear portions of the progress curve (5-15 minutes) were used for velocity (RFU/s) calculations. Each screening for hepsin either HGFA was repeated 3-times and the average value for each measurement was used to create the substrate specificity matrix.
  • The detailed protocol for the use of ACC-labeled combinatorial peptide libraries in protease substrate specificity screening can be found in: Poreba M, Szalek A, Kasperkiewicz P, Drag M., Methods Mol Biol. 2014, 1133, 41-59, which is incorporated herein by reference.
  • Results for MSP-MS profiling for HGFA substrate cleavage and specificity can be seen in FIG. 20 and Tables 11.1-11.4. IceLogo graphs can be seen in FIGS. 21A and 21B.
  • TABLE 11.1
    P4-P4′-Cleaved
    P4-P4′-All by HGFA (4 hr)
    ADARKYWN AMFRKYPI
    AGKRRDWX ASMRIYIE
    AMFRKYPI EIFRKWHX
    AMWRLDII ESARDXXX
    ASHRMGKN EYFRMIRW
    ASMRIYIE FLVRTWKM
    DAQRWKNI FRIRSGTX
    DEPRGHMY FTQRAGIL
    DQVRRMNX IDLRWMAY
    DSIRHQGP KLFRFNWX
    EIFRKWHX NFLRGPXX
    EKQRFHPX NQMRGFXX
    ELGRSANA PQRRGMXX
    ESARDXXX RMIRWAVL
    EVARPLGX SLYRMIRQ
    EYFRMIRW SYMRWPXX
    EYPRPQEW TYFRAWXX
    FDNRVGKW VQHRLFTY
    FHWRIMQG WAFRSRYH
    FLVRTWKM WPQRRGMX
    FPVRPTEX XKARSAFA
    FRIRSGTX YAFRSTMV
  • TABLE 11.2
    P1 position
    % activity
    Amino Acid Hepsin HGFA
    L-Ala (A) 0.49 0.00
    L-Arg (R) 100.00 100.00
    L-Asn (N) 0.00 0.00
    L-Asp (D) 0.00 0.00
    L-Gln (Q) 0.00 0.00
    L-Glu (E) 0.13 0.00
    Gly (G) 0.07 0.00
    L-His (H) 0.17 0.00
    L-Ile (I) 0.08 0.00
    L-Leu (L) 0.03 0.00
    L-Lys (K) 2.34 0.99
    L-Nle 0.07 0.00
    L-Phe (F) 0.12 0.00
    L-Pro (P) 0.04 0.00
    L-Ser (S) 0.20 0.00
    L-Thr (T) 0.45 0.00
    L-Trp (W) 0.70 0.73
    L-Tyr (Y) 0.30 0.00
    L-Val (V) 0.00 0.00
    L-MeAla 0.09 0.00
    B-Ala 0.00 0.00
    dhPro 2/2 0.00 0.00
    L-Oic 0.00 2.10
    L-Hyp 0.00 0.00
    L-Hyp(Bzl) 0.00 0.30
    L-Gla 0.00 0.00
    L-Asp(Me) 2.77 3.11
    L-Asp(Oall) 2.34 0.00
    L-Asp(Bzl) 0.93 12.28
    L-Glu(Me) 0.41 0.00
    L-Glu(All) 1.26 0.00
    L-Glu(Ochx) 0.17 0.00
    L-Glu(Bzl) 0.09 0.00
    L-Aad 0.00 0.00
    L-Api 0.00 0.00
    L-Dap 0.03 0.00
    L-Orn 0.00 0.00
    L-Cit 0.42 0.00
    L-hCit 0.13 0.00
    L-Lys(Ac) 0.00 0.00
    L-Lys(tfa) 0.00 0.00
    L-Lys(2-Cl-Z) 0.09 0.00
    His(Bzl) 0.12 0.00
    Arg(Me) 0.00 0.00
    Arg(Me)2 1/2 sym 0.00 0.00
    L-hArg 0.24 0.00
    L-3-Pal 0.00 0.00
    L-4-Pal 0.00 0.00
    L-Phe(4-NH2) 0.08 0.00
    L-Phe(2-F) 0.04 0.00
    L-Phe(3-F) 0.01 0.00
    L-Phe(4-F) 0.08 0.00
    L-Phe(3,4-F2) 0.25 0.00
    L-Phe(F5) 0.00 0.00
    L-Phe(2-Cl) 0.04 0.00
    L-Phe(3-Cl) 0.21 0.00
    L-Phe(4-Cl) 0.07 0.00
    L-Phe(3,4-Cl2) 0.02 0.00
    L-Phe(3-I) 0.00 0.00
    L-Phe(4-I) 0.34 0.00
    L-Phe(4-Br) 0.10 0.00
    L-Phe(NO2) 0.39 1.37
    L-Phe(guan) 9.45 0.00
    L-Phe(4-Me) 0.00 0.00
    L-hPhe 0.16 0.00
    L-Ala(2th) 0.28 0.42
    L-Ser(Bzl) 0.30 0.00
    L-Hse(Bzl) 0.06 0.00
    L-Thr(Bzl) 0.04 0.00
    L-Cys(Bzl) 0.00 0.00
    L-Cys(Me-Bzl) 0.13 0.00
    L-Cys(4-MeOBzl) 0.25 0.00
    L-Tyr(Bzl) 0.45 0.00
    L-Dht 0.00 0.00
    L-Trp(Me) 0.13 0.48
    L-Tyr(Me) 0.14 0.00
    L-hTyr(Me) 0.00 0.56
    L-Tyr(2,6-Cl-Bzl) 0.41 0.00
    L-Abu(Bth) 0.00 0.00
    L-Bip 0.13 0.00
    L-Bpa 0.56 1.57
    Nle(Obzl) 0.15 0.00
    L-1-Nal 0.20 0.00
    L-2-Na1 0.61 0.00
    L-Hse 0.00 0.00
    L-Hnv 1.55 0.00
    L-Met (M) 0.00 0.00
    L-Met(O) 0.00 0.00
    L-Met(O2) 0.00 0.00
    L-2-Abu 0.00 0.00
    L-Nva 0.14 0.00
    L-Tle 0.42 0.00
    L-hLeu 0.00 0.00
    L-2-Aoc 2.82 0.00
    AC5C 0.15 6.43
    L-Chg 0.00 0.00
    L-Cha 0.00 0.00
    L-hCha 0.21 0.00
    L-Thyr 0.28 0.00
    L-Inp 0.07 0.00
    D-Ala 0.00 0.00
    D-Asn 0.00 0.00
    D-Asp 0.05 0.00
    D-Gln 0.00 0.00
    D-Glu 0.00 0.00
    D-Leu 0.00 0.00
    D-Lys 0.23 0.00
    D-Phe 0.38 0.00
    D-Pro 1.08 0.00
    D-Phe 0.09 0.00
    D-Ser 0.02 0.00
    D-Thr 0.24 0.00
    D-Trp 0.50 0.00
    D-Tyr 0.23 0.00
    D-Pip 0.42 5.57
    D-Tic 0.14 1.12
    D-Gla 0.00 0.00
    D-Chg 0.60 0.65
    D-Cha 0.13 0.00
    D-Phg 0.09 0.00
    D-3-Pal 0.00 0.00
    D-4-Pal 0.00 0.00
    D-Phe(4-Me) 0.48 0.00
    D-Phe(2-F) 0.00 0.00
    D-Phe(3-F) 0.44 0.00
    D-Phe(4-F) 0.00 0.00
    D-Phe(3,4-F2) 0.31 0.00
    D-Phe(F5) 0.34 0.00
    D-Phe(2-Cl) 0.66 0.00
    D-Phe(3-Cl) 0.12 0.00
    D-Phe(4-Cl) 0.00 0.00
    D-Phe(3,4-Cl2) 0.07 0.00
    D-Phe(4-I) 0.32 0.00
    D-Phe(4-Br) 0.11 4.00
    D-Phe(4-NO2) 1.45 0.74
    D-Ser(Bzl) 0.00 0.00
    D-Thr(Bzl) 0.00 0.00
    D-hPhe 0.04 0.00
    D-Bip 0.30 0.00
    D-Bpa 0.34 0.00
    D-1-Nal 0.23 0.49
    D-2-Nal 0.11 0.00
  • TABLE 11.3
    P4 Position P3 Position P2 Position
    % Activity % Activity % Activity
    Amino Acid Hepsin HGFA Hepsin HGFA Hepsin HGFA
    L-Ala (A) 41.30 6.68 28.07 8.97 17.85 2.37
    L-Arg (R) 80.32 23.62 70.75 43.98 57.23 2.08
    L-Asn (N) 25.25 8.20 24.47 6.12 63.72 4.79
    L-Asp (D) 0.22 1.90 3.89 2.81 0.33 1.21
    L-Gln (Q) 29.82 9.01 58.69 15.98 12.19 3.35
    L-Glu (E) 0.76 1.96 16.72 3.47 0.00 0.89
    Gly (G) 29.19 10.84 26.14 10.42 0.00 1.14
    L-His (H) 25.35 8.90 43.05 11.93 31.24 4.00
    L-Ile (I) 47.02 14.09 11.37 9.06 45.68 4.94
    L-Leu (L) 33.10 10.18 19.51 13.71 100.00 100.00
    L-Lys (K) 75.43 18.29 80.71 44.63 46.70 1.04
    L-Nle 40.93 11.76 24.09 19.15 62.04 45.52
    L-Phe (F) 30.80 9.42 2.91 13.51 25.22 16.60
    L-Pro (P) 56.00 10.30 2.09 2.04 13.10 2.21
    L-Ser (S) 31.63 7.04 38.70 14.57 18.40 3.24
    L-Thr (T) 29.29 7.67 35.34 14.51 70.75 8.87
    L-Trp (W) 6.82 8.78 0.00 17.50 6.00 4.04
    L-Tyr (Y) 22.39 16.47 7.75 11.59 22.79 3.17
    L-Val (V) 43.08 11.66 16.77 9.51 51.85 8.33
    D-Ala 18.44 7.11 48.09 9.84 0.00 0.00
    D-Arg 44.37 23.20 66.08 29.10 0.00 0.00
    D-Asn 18.48 7.38 38.75 15.16 0.00 0.00
    D-Asp 1.98 2.25 17.18 5.37 0.00 0.00
    D-Gln 20.13 8.03 97.80 13.84 0.00 0.00
    D-Glu 2.98 2.62 34.55 3.61 0.00 0.00
    D-His 19.33 7.79 40.09 11.09 0.00 0.00
    D-Leu 24.76 10.56 20.14 7.08 0.00 0.00
    D-Lys 49.84 17.66 64.56 21.11 0.00 0.00
    D-Phe 13.15 8.13 24.92 15.22 0.00 0.00
    D-Pro 20.45 10.30 38.88 4.96 0.00 0.00
    D-Ser 21.84 7.94 54.84 10.86 11.55 0.00
    D-Phg 22.48 9.06 57.07 40.01 13.53 4.40
    D-Thr 25.74 8.61 36.69 6.45 0.00 0.00
    D-Trp 1.48 7.65 24.90 87.59 0.00 0.00
    D-Tyr 12.66 10.09 29.94 17.32 0.00 0.00
    D-Val 22.58 8.25 27.04 5.76 0.00 0.00
    β-Ala 30.74 10.07 22.78 15.95 0.00 0.24
    L-Hyp 37.81 10.66 4.70 2.18 38.67 3.95
    L-Hyp(Bzl) 33.33 8.91 1.29 4.34 32.68 4.39
    L-Thz 45.46 12.65 9.93 7.76 6.16 2.80
    L-Oic 53.72 16.76 2.92 2.78 0.67 20.71
    L-Idc 0.00 32.64 0.00 6.43 0.00 0.96
    L-Pip 34.68 9.25 1.64 0.83 10.66 1.75
    L-Tic 13.31 10.84 8.10 25.13 2.45 3.58
    dhAbu 44.51 24.45 7.29 9.44 7.72 14.12
    dhLeu 52.44 42.50 5.85 11.02 0.00 0.48
    L-Dap 35.65 13.31 48.71 24.27 10.01 1.49
    L-Dab 47.53 16.76 48.55 29.40 13.49 0.50
    L-Dab(Z) 96.34 16.55 31.58 21.38 20.86 4.84
    L-Cit 36.68 6.44 29.53 13.41 32.27 6.32
    L-hCit 40.51 10.53 27.31 19.71 36.25 7.59
    L-Orn 84.52 20.23 79.70 54.04 78.48 0.00
    L-Lys(TFA) 50.71 11.66 35.84 21.11 38.29 5.16
    L-Lys(Ac) 35.02 8.71 29.15 16.02 23.04 7.36
    L-Lys(2-ClZ) 41.91 47.56 2.55 14.21 21.20 29.53
    L-Agp 98.08 80.01 97.35 74.18 35.36 11.83
    L-Agb 37.96 11.59 26.80 19.62 3.53 1.05
    L-Arg(NO2) 82.11 8.33 41.82 16.01 17.44 2.76
    L-Arg(Z)2 61.73 16.44 50.93 33.31 52.91 4.93
    L-hArg 56.24 22.07 47.00 100.00 57.96 5.83
    L-His(3-Bom) 38.40 100.00 15.18 13.20 0.00 0.43
    L-Phe(NH2) 24.64 9.11 11.65 17.32 30.51 2.45
    L-Phe(guan) 35.43 20.91 9.10 42.11 34.36 11.74
    L-Trp(Me) 0.00 2.49 0.00 18.14 7.81 1.12
    L-Dht 1.56 10.19 0.00 58.65 13.91 20.10
    L-Asp(Me) 18.55 9.31 13.81 10.52 0.00 0.75
    L-Asp(Chx) 27.32 10.34 19.99 22.46 0.79 2.16
    L-Asp(Bzl) 19.34 9.60 7.29 6.92 0.00 1.35
    L-Glu(Me) 36.79 9.13 64.70 32.95 13.49 6.65
    L-Glu(Chx) 45.93 11.19 43.91 30.08 14.72 6.42
    L-Glu(Bzl) 60.31 13.89 50.15 33.35 36.33 6.88
    L-Phe(2-F) 24.33 10.49 7.80 13.39 1.78 5.98
    L-Phe(3-F) 24.03 10.21 10.43 15.12 30.55 11.72
    L-Phe(4-F) 27.78 11.22 5.16 15.01 32.86 4.84
    L-Phe(3,4-F2) 19.65 8.79 0.71 15.06 38.16 3.73
    L-Phe(F5) 26.60 12.25 5.13 22.36 0.36 1.55
    L-Phe(2-Cl) 14.92 10.91 0.98 10.78 2.71 11.87
    L-Phe(3-Cl) 9.26 10.25 0.35 21.45 33.86 12.49
    L-Phe(4-Cl) 26.01 12.60 0.31 13.32 2.85 1.74
    L-Phe(3,4-Cl2) 2.40 9.92 0.00 16.15 0.00 2.22
    L-Phe(4-Br) 5.08 13.65 0.00 13.96 2.42 2.41
    L-Phe(4-Me) 15.51 11.98 2.39 16.82 6.44 0.97
    L-3-Pal 31.27 7.69 28.37 11.00 17.32 4.29
    L-4-Pal 33.68 9.27 21.91 14.57 0.11 4.34
    L-Ala(2th) 35.30 11.16 11.54 20.51 10.54 11.48
    L-Ala(Bth) 14.64 10.26 20.97 23.90 6.52 2.16
    L-Bta 13.63 9.79 0.13 24.11 0.00 3.71
    L-Abu 38.68 9.87 28.98 15.31 0.00 1.81
    L-Abu(Bth) 38.68 11.84 4.21 21.63 0.64 14.29
    L-Ser(Ac) 37.96 7.56 42.09 21.69 6.73 1.67
    L-Ser(Bzl) 21.57 14.49 11.56 19.45 20.43 5.27
    L-hSer 26.55 7.34 33.48 16.59 31.76 2.12
    L-hSer(Bzl) 40.00 12.03 21.24 20.03 46.09 17.39
    L-Thr(Bzl) 40.13 13.14 16.36 21.72 36.14 7.19
    L-Cys(Bzl) 23.44 16.89 3.06 25.14 1.50 7.46
    L-Cys(MeBzl) 15.53 13.63 0.87 17.21 3.49 6.24
    L-Cys(4- 12.84 13.88 0.10 16.76 7.07 9.44
    MeOBzl)
    L-Nle(O-Bzl) 91.83 16.90 82.17 30.67 0.00 0.00
    L-Phg 34.01 11.24 28.27 23.25 48.33 14.18
    L-hPhe 44.79 11.14 10.63 61.77 4.71 32.14
    L-Chg 46.64 25.12 6.60 18.69 10.88 27.27
    L-Cha 25.44 13.42 3.64 22.61 74.49 6.03
    L-hCha 5.44 12.92 0.13 73.74 0.00 2.90
    L-Igl 25.47 10.62 0.00 52.15 2.20 19.79
    L-1-Nal 5.18 6.36 0.00 23.07 3.00 4.19
    L-2-Nal 1.34 11.72 0.00 12.75 0.00 5.10
    L-Bpa 0.86 12.77 0.00 8.16 0.00 1.57
    L-2-Aoc 19.98 12.15 12.74 33.06 8.90 14.37
    L-hLeu 41.61 14.86 13.84 23.44 14.44 72.69
    L-NptGly 27.66 8.34 9.92 12.95 37.46 53.86
    L-Hnv 33.75 7.92 33.40 15.07 34.62 5.49
    L-Tle 38.05 9.71 7.48 6.70 0.00 0.00
    L-Tyr(Me) 31.38 9.54 4.55 17.41 10.89 1.79
    L-Tyr(2,6Cl2-Z) 0.08 9.94 0.09 4.47 0.00 2.83
    L-Tyr(Bzl) 3.10 9.39 0.00 14.03 0.28 3.71
    L-Tyr(2-Br-Z) 22.51 12.67 8.05 17.09 7.72 2.39
    L-hTyr 31.56 13.69 7.46 73.59 0.00 42.92
    L-hTyr(Me) 36.30 10.62 10.00 25.48 0.00 23.13
    L-Nva 41.99 11.78 25.85 17.60 58.40 39.80
    L-Met(O) 22.86 6.64 68.16 16.63 11.40 1.68
  • TABLE 11.4
    Ac-Ala- NH2-Leu- Ac-His(3Bom)-
    Arg-Leu- DTrp-Nle- Agp-hLeu- Ac-Agp-hArg-
    Arg-ACC Arg-ACC Arg-ACC Leu-Arg-ACC
    KM 107.2 73.4 52.1 37.8
    kcat 0.337 1.30 1.47 1.56
    kcat/KM 3,144 17,662 28,140 41,254
  • When introducing elements of the present invention or the preferred embodiments(s) thereof, the articles “a”, “an”, “the” and “said” are intended to mean that there are one or more of the elements. The terms “comprising”, “including” and “having” are intended to be inclusive and mean that there may be additional elements other than the listed elements.
  • In view of the above, it will be seen that the several objects of the invention are achieved and other advantageous results attained.
  • As various changes could be made in the above compositions and methods without departing from the scope of the invention, it is intended that all matter contained in the above description and shown in the accompanying figures shall be interpreted as illustrative and not in a limiting sense.

Claims (22)

1.-26. (canceled)
27. A compound of Formula (I), as a single stereoisomer or as a mixture thereof:
Figure US20220169676A1-20220602-C00237
wherein R1 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
B1 is selected from the group consisting of:
Figure US20220169676A1-20220602-C00238
C1 is a group selected from the group consisting of:
Figure US20220169676A1-20220602-C00239
W is CH, CH2, N, or NH;
R2, R3, R4, R5, R6, R7, and R8 are each independently hydrogen, substituted or unsubstituted alkyl or cycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted aryl or heteroaryl, with the proviso that when R2 is methyl, then R3 cannot also be methyl and vice versa; and
m is 0 to 5, or a pharmaceutically acceptable salt thereof.
28. The compound of claim 27 wherein R1 is substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl, or a substituted or unsubstituted nitrogen-containing aromatic ring.
29. The compound of claim 28 wherein R1 is substituted or unsubstituted phenyl or substituted or unsubstituted naphthyl.
30. The compound of claim 27 wherein the substituted C1-C6 alkyl, substituted C3-C6 cycloalkyl, substituted phenyl, substituted naphthyl, or substituted nitrogen-containing aromatic ring comprise one or more substituents comprising halo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, halo-substituted C1-C4 alkyl, or amino.
31. The compound of claim 27 wherein R1 is a group selected from the group consisting of:
Figure US20220169676A1-20220602-C00240
32. The compound of claim 27 wherein C1 is a group selected from the group consisting of:
Figure US20220169676A1-20220602-C00241
W is CH or N;
R2, R3, R4, R5, R6, R7, and R8 are each independently hydrogen, substituted or unsubstituted alkyl or cycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted aryl or heteroaryl, with the proviso that when R2 is methyl, then R3 cannot also be methyl and vice versa; and
m is 0 to 5, or a pharmaceutically acceptable salt thereof.
33. The compound of claim 27 wherein C1 is a group selected from the group consisting of:
Figure US20220169676A1-20220602-C00242
Figure US20220169676A1-20220602-C00243
R2, R3, R4, R5, R6, R7, and R8 are each independently hydrogen, substituted or unsubstituted alkyl or cycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted aryl or heteroaryl, with the proviso that when R2 is methyl, then R3 cannot also be methyl and vice versa; and
m is 0 to 5, or a pharmaceutically acceptable salt thereof.
34. The compound of claim 27 wherein R2, R3, R4, R5, R6, R7, and R8 are each independently hydrogen, substituted or unsubstituted C1-C10 alkyl or cycloalkyl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
35. The compound of claim 27 wherein:
R2 is hydrogen;
R3 is hydrogen, C1-C6 alkyl, benzyl, or halo-substituted benzyl;
R4 and R5 are each independently hydrogen, C1-C6 alkyl, halo- or alkoxy-substituted C1-C6 alkyl, phenyl, phenethyl, benzyl, halo- or alkoxy-substituted benzyl; substituted or unsubstituted 3-benzothiophenyl, or substituted or unsubstituted 1-morpholinyl;
R6 is hydrogen, C1-C4 alkoxy; and/or
R7 and R8 are each independently hydrogen or C1-C6 alkyl.
36. The compound of claim 27 wherein C1 is
Figure US20220169676A1-20220602-C00244
R2 is hydrogen; and
R3 is hydrogen, C1-C6 alkyl, benzyl, halo-substituted benzyl, aryl, cycloalkyl, alkylaryl, or hetercyclo.
37.-41. (canceled)
42. A method of inhibiting tumor progression comprising administering to the subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 27.
43. A method of treating a malignancy, a pre-malignant condition, or cancer in a subject comprising administering to the subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 27.
44. The method of claim 43, wherein the cancer is selected from the group consisting of breast, ovarian, prostate, endometrial, colon, pancreatic, head and neck, gastric, renal, brain, liver, bladder, kidney, lung, esophageal, leukemias, multiple myeloma, lymphoma, and melanoma.
45.-52. (canceled)
53. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 27.
54. An imaging composition comprising a fluorescent compound of Formula (I) or (II) of claim 27, wherein the labeled compound comprises a fluorophore selected from the group consisting of Cy3, Cy3.5, Cy5, Cy5.5, Cy7, and Cy7.5.
55. A method of detecting cancer comprising:
(i) administering to a subject an imaging composition of claim 54;
(ii) employing a fluorescence imaging technique for monitoring or visualizing a distribution of the fluorescent compound within the body or within a portion thereof; and
(iii) correlating the distribution of the fluorescent compound to the existence of cancer.
56. An imaging composition comprising a radiolabeled compound of Formula (I) or (II) of claim 27, wherein the labeled compound comprises a radioisotope selected from the group consisting of 11C, 13N, 15O, 18F, 75Br, 124I, 125I, and 131I.
57. A method of detecting cancer comprising:
(iv) administering to a subject an imaging composition of claim 56;
(v) employing a nuclear imaging technique for monitoring or visualizing a distribution of the radiolabeled compound within the body or within a portion thereof; and
(vi) correlating the distribution of the radiolabeled compound to the existence of cancer.
58. The method of claim 57, wherein the nuclear imaging technique is positron emission tomography (PET) or photon emission computed tomography (SPECT).
US17/475,290 2015-03-09 2021-09-14 Inhibitors of growth factor activation enzymes Abandoned US20220169676A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/475,290 US20220169676A1 (en) 2015-03-09 2021-09-14 Inhibitors of growth factor activation enzymes

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562130117P 2015-03-09 2015-03-09
US201562220998P 2015-09-19 2015-09-19
PCT/US2016/020516 WO2016144654A1 (en) 2015-03-09 2016-03-02 Inhibitors of growth factor activation enzymes
US201715556804A 2017-09-08 2017-09-08
US17/475,290 US20220169676A1 (en) 2015-03-09 2021-09-14 Inhibitors of growth factor activation enzymes

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US15/556,804 Continuation US11130780B2 (en) 2015-03-09 2016-03-02 Inhibitors of growth factor activation enzymes
PCT/US2016/020516 Continuation WO2016144654A1 (en) 2015-03-09 2016-03-02 Inhibitors of growth factor activation enzymes

Publications (1)

Publication Number Publication Date
US20220169676A1 true US20220169676A1 (en) 2022-06-02

Family

ID=56879255

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/556,804 Active US11130780B2 (en) 2015-03-09 2016-03-02 Inhibitors of growth factor activation enzymes
US17/475,290 Abandoned US20220169676A1 (en) 2015-03-09 2021-09-14 Inhibitors of growth factor activation enzymes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US15/556,804 Active US11130780B2 (en) 2015-03-09 2016-03-02 Inhibitors of growth factor activation enzymes

Country Status (2)

Country Link
US (2) US11130780B2 (en)
WO (1) WO2016144654A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018118838A1 (en) * 2016-12-20 2018-06-28 Biomarin Pharmaceutical Inc. Ceramide galactosyltransferase inhibitors for the treatment of disease
WO2020264187A1 (en) * 2019-06-25 2020-12-30 James Janetka Compounds and methods for treating cancer, viral infections, and allergic conditions
EP3925667A1 (en) * 2020-06-17 2021-12-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Selective tmprss2 inhibitors and medical use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05503300A (en) 1990-11-15 1993-06-03 ペンタファルム　アクチェンゲゼルシャフト Meta-substituted phenylalanine derivatives
WO1994018185A1 (en) 1993-02-10 1994-08-18 Pentapharm Ag Piperazides of substituted phenylalanine derivates as thrombin inhibitors
ES2188003T3 (en) 1998-09-18 2003-06-16 Pentapharm Ag UROQUINASE INHIBITORS.
WO2000044733A1 (en) * 1999-01-27 2000-08-03 Ortho-Mcneil Pharmaceutical, Inc. Peptidyl heterocyclic ketones useful as tryptase inhibitors
US6495358B1 (en) 2000-04-19 2002-12-17 Wichita State University Sulfamide and bis-sulfamide amino acid derivatives as inhibitors of proteolytic enzymes
US6677377B2 (en) 2000-06-21 2004-01-13 Georgetown University School Of Medicine Structure based discovery of inhibitors of matriptase for the treatment of cancer and other conditions
WO2003045977A2 (en) 2001-11-26 2003-06-05 Trustees Of Tufts College Peptidomimetic Inhibitors of Post-Proline Cleaving Enzymes
AU2003225540A1 (en) 2002-01-31 2003-09-02 Irm, Llc Hepsin substrates and prodrugs
WO2003070229A2 (en) 2002-02-22 2003-08-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Use of proteinase inhibitors in the treatment of autoimmune diseases
US7019019B2 (en) 2002-12-23 2006-03-28 Dendreon Corporation Matriptase inhibitors and methods of use
DE10322191B4 (en) 2003-05-16 2014-02-27 The Medicines Company (Leipzig) Gmbh N-sulfonylated amino acid derivatives, process for their preparation and their use
WO2005076886A2 (en) 2004-02-05 2005-08-25 Irm Llc Prostasin substrates and inhibitors
WO2006014928A1 (en) 2004-07-26 2006-02-09 Genentech, Inc. Methods and compositions for modulating hepatocyte growth factor activation
US7741096B2 (en) 2004-12-10 2010-06-22 Genentech, Inc. Crystal structure of hepatocyte growth factor activator complexed with Kunitz domain inhibitor
AR055395A1 (en) 2005-08-26 2007-08-22 Vertex Pharma INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS
DE102007010815B3 (en) 2007-03-06 2008-07-31 Curacyte Discovery Gmbh New N-phenylsulfonyl-3-amidino-phenylalanine piperidide derivatives useful as antitumor agents
US8450334B2 (en) 2008-06-11 2013-05-28 Fred Hutchinson Cancer Research Center Hepsin inhibitors
US20110206704A1 (en) 2009-10-19 2011-08-25 Genentech, Inc. Methods and compositions for modulating hepatocyte growth factor activator
WO2011050270A2 (en) 2009-10-23 2011-04-28 Tranzyme Pharma, Inc. Macrocyclic inhibitors of serine protease enzymes
ES2676412T3 (en) 2011-06-02 2018-07-19 Socpra Sciences Santé Et Humaines S.E.C. Matriptase inhibitors and their uses against orthomyxovirus infections

Also Published As

Publication number Publication date
US11130780B2 (en) 2021-09-28
US20180066015A1 (en) 2018-03-08
WO2016144654A1 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
US20220169676A1 (en) Inhibitors of growth factor activation enzymes
JP5419468B2 (en) Compounds that bind to the BIR domain of IAP
US7109172B2 (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
EP0915700B1 (en) Use of beta-sheet mimetics as protease and kinase inhibitors and as inhibitors of transcription factors
AU712581B2 (en) Beta-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins
US10975119B2 (en) Selective cysteine protease inhibitors and uses thereof
JPH09511501A (en) 26S proteolytic complex and 20S proteasome inhibitor contained therein
BRPI0711591A2 (en) iap bir domain binding compound
US6831196B2 (en) Urokinase inhibitors
US6372744B1 (en) β-sheet mimetics and methods relating to the use thereof
US7374898B2 (en) Peptide inhibitors against seprase
Richy et al. Structure-based design of human immuno-and constitutive proteasomes inhibitors
US20220380407A1 (en) Compounds and methods for treating cancer, viral infections, and allergic conditions
JP4898091B2 (en) Inhibitors of urokinase, their production and use
KR20010040939A (en) β-sheet mimetics and methods relating to the use thereof
US20050267127A1 (en) Guanidino phenylalanin compounds used as urokinase inhibitors
US7511039B2 (en) β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins
JP2009001494A (en) Atypical proline-rich sequence binding inhibitor
US20030191109A1 (en) Beta-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins
EP1661566A2 (en) Use of beta-sheet mimetics as protease and kinase inhibitors and as inhibitors of transcription factors
AU5421301A (en) Use of beta-sheet mimetics as protease and kinase inhibitors and as inhibitors of transcription factors

Legal Events

Date Code Title Description
AS Assignment

Owner name: WASHINGTON UNIVERSITY, MISSOURI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JANETKA, JAMES W.;HAN, ZHENFU;HARRIS, PETER;AND OTHERS;SIGNING DATES FROM 20170912 TO 20170919;REEL/FRAME:057503/0738

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION